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Abstract 
 
The work described in this thesis focuses on two main topics: i) the study of the 
dynamic behaviour of metallo-supramolecular cylinders, that are known for their 
major groove DNA binding properties, and ii) the synthesis and DNA binding studies 
of the cylinders conjugated to short peptides and amino acids. In Chapter 1 an 
overview of the DNA molecular recognition by synthetic agents and biomolecules is 
presented, with a section dedicated to the selective recognition of DNA. 
In Chapter 2 the study of the dynamic behaviour of the Fe(II) supramolecular 
cylinder is explored. The behaviour of the complex at variable temperature 
conditions was analysed by NMR, UV-Vis and CD. Thermal experiments with the 
complex in the presence of DNA are also presented.  
In Chapter 3 a versatile procedure for the conjugation of short amino acids and 
peptides to Fe(II), Cu(I) and Ag(I) cylinders has been established and the influence  
of the attached peptides on the chirality of the resulting hybrids has been 
investigated. 
In Chapter 4 the DNA binding properties of the conjugated cylinders are explored 
by CD, LD and gel electrophoresis experiments and the cytotoxic activity of the 
Fe(II) conjugates against cancer cell lines was investigated by MTT tests. 
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CHAPTER 1 
 
DNA RECOGNITION. 
 
During the last 50 years, following the initial studies that established DNA and 
RNA structures1-5, great efforts in the scientific world have been focused on 
achieving a greater knowledge about ‘how’ the information in DNA encodes all the 
biological events in any living organism. Such knowledge requires understanding of 
the structures, functions, interactions, and evolutions of all the genes composing a 
genome. New branches of molecular biology, such as genomics, proteomics and 
genetic engineering, have been introduced and have exponentially developed such 
that in just a few decades big scientific aims, such as the “Human Genome Project”, 
have been solved. In this context, the parallel and rapid expansion of informatic 
technologies has been crucial, giving origin to new methodologies such as 
bioinformatics, which is one of the major tools used in analysing and processing data 
from genomics and proteomics.  
Now, in the post genomic environment, the goal is to understand the processing of 
the genetic code and ‘how’ to stimulate, manipulate or prevent this processing. In 
this context the study of DNA recognition is an interesting and widely explored 
approach, because it offers potential for controlling gene expression, creating new 
therapeutic and diagnostic devices, and investigating molecular recognition in 
general.  
 
1.1 Structural properties of DNA. 
 
DNA is composed of polymers whose monomeric units are called nucleotides. 
Each nucleotide is composed of a five-carbon sugar (2'-deoxyribose), one phosphate 
group attached to the 5' position of the sugar and one nitrogenous base, of purine or 
pyrimidine nature, attached to the 1' position of the sugar (Figure 1.1.a)). Only four 
bases are part of the nucleotides of the DNA: adenine (A) and guanine (B) (the 
purine bases), cytosine (C) and thymine (T) (the pyridine bases). Usually, each 
nucleotide is identified by the base that is attached to it. The nucleotides are joined 
together to form a chain by formation of phosphodiester bonds between the third and 
3 
 
 
 
Figure 1.1. a) Composition of the nucleotides with the IUPAC numbering 
system given for the sugar and bases6. b) A chain of polymeric DNA.  
 
 
fifth carbon atoms of adjacent sugar rings (Figure 1.1.b)). One chain of DNA with a 
given sequence of nucleotides is the primary structure of the DNA. In living 
organisms, DNA rarely exists as single strands, but it is organised in double stranded 
or “duplex” secondary structures. In these structures the two strands wrap around 
each other forming a double helix with the phosphate groups directed to the external 
hydrophilic environment. The bases are directed to the heart of the helix and a 
specific pattern of hydrogen bonds between base pairs is formed. This is also known 
as complementary or Watson-Crick base pairing, in which A interact with T and G 
with C (Figure 1.2). The base pairs are approximately perpendicular to the axis of the 
double helix and they are stacked parallel to each other, forming face-face π−π 
interactions. Grooves are traced between the two twisting strands of the helix, but the 
two strands are not directly opposite to each other along the hydrogen bonds vector 
so that the two grooves have different sizes. In fact they are known as the
 
a)                                                                       b) 
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Figure 1.2. The Watson-Crick hydrogen bond patterns between base pairs (left) 
and the three known structures of double helix, A, B and Z-DNA (right). Figure 
adapted from ref. 7). 
 
 
 
Structural Characteristic 
DNA form 
A B Z 
Helical sense Right-handed Right-handed Left-handed 
Diameter 25.5 Å 23.7 Å 18.4 Å 
Repeating unit 1 bp 1 bp 2 bp 
Rotation per repeating unit (tg) 32.7° 35.9° -60° 
bp* per turn (mean) 10.7 10.5 12 
Tilt of bp relative to helical axis +19° -1° -9° 
Rise/bp along axis  2.56 Å 3.38 Å 3.71 Å 
Pitch/turn of helix 28.2 Å 35.5 Å 44.6 Å 
Mean propeller twist +18° +16° 0° 
Minor groove Wide and shallow Narrow and deep Narrow and deep 
Major groove Deep and narrow Deep and wide Shallow 
 
Table 1.1. Structural parameters of the three principal conformation of DNA 
(adapted from reference 8). 
* base pairs 
 
 
major and minor groove. 
There are three types of DNA double helix that have been crystallised, known as 
A, B and Z-DNA (right of Figure 1.2). A and B-DNA are right-handed helices whilst 
Z-DNA is left-handed. Some of the structural parameters that differentiate the three 
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structures are reported in Table 1.1. 90% of the DNA in living organisms is in B 
conformation and molecules of water and different cations (especially K+ and Na+) 
are also involved in this structure. Z-DNA has also been observed in living cells,9-12 
whilst it seems that the DNA can assume the A conformation at low levels of 
hydration, as during a crystallographic experiment, or when forming certain hybrids 
with RNA.13 
Alternative conformations of DNA also exist and in some cases have important 
biological roles. Quadruplex DNA or G quadruplexes are four stranded structures 
formed by G rich strands of DNA. These structures are stabilized by sets of 
Hoogsteen hydrogen bonds between guanines and the interaction with positive 
cations (especially K+) located at the heart of the tetrads (Figure 1.3).14-20 Great 
interest is now focused on G quadruplex since they have been found in telomeric 
DNA at the end of the chromosomes and involved in DNA replication.  DNA Triple-
helix formation is possible between a homopyrimidine-homopurine Watson-Crick 
duplex and a third strand of DNA, either pyrimidine or purine rich, that lays in the 
major groove of the former duplex. The third strand forms Hoogsteen or reverse 
Hoogsteen hydrogen bonds if it is pyrimidine or purine rich respectively (Figure 
1.4.a)). A possible biological role of triplex DNA has emerged in the area of gene 
regeneration.21,22 Several branched DNA structures are also possible and play 
important biological functions.23-25 The simplest example involves only three strands 
of DNA and it is known as DNA three way junction or Y-shaped junction (Figure 
1.4.b).25,26 This conformation is possible when the two strands of a fragment of 
duplex DNA present frayed ends  (non complementary sequences) so that the pairing 
between bases cannot occur. But a third strand that is complementary to the frayed 
ends of the duplex can stabilise the formation of a three way junction structure. 
These assemblies are formed transiently during DNA replication (replication 
fork)27,28 and they are very common RNA structures;29-31 they are also associated 
with some human genetic diseases, such as myotonic dystrophy type 1 and 
Huntington’s disease;32 they are present in the inverted terminal repeats of certain 
viral genomes and are intermediates during phage genetic recombination.33-35  Four 
way junctions, also known as Holliday junctions (Figure 1.4.c)) are the key 
intermediates in nearly all recombination process,36,37 whilst higher levels of 
branched DNA are not so common in cells but they are widely employed in
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Figure 1.5. Crystallographic structures a) including a A-C base pair mismatch 
(structure taken from ref. 40); b) of the tridecamer d(CGCAGAATTCGCG)2 
showing the extra adenosine looped out (structure taken from ref. 41); c) of the 
hairpin conformation of the hexadecanucleotide CGCGCGTTTTCGCGCG 
(structure taken from ref. 42). 
 
 
Bulged double helixes are stretches of extra bases, within the double helix, that do 
not have the complementary stretch in the opposite strand so that are looped out of 
the duplex (Figure 1.5.b)).41 Formation of hairpin loops can occur upon DNA 
intermolecular base pairing, although this is a very common characteristic of RNA 
(Figure 1.5.c).42 
 
1.2 DNA recognition in biological systems. 
 
All the necessary information for the life, functions and death of a living cell is 
mainly included in fragments of B-DNA (genes), inside the cell itself. Each gene 
contains specific instructions in the form of a “code” made of sequences of base 
pairs. The processing of an instruction occurs upon specific recognition events and 
“reading” of the corresponding code. DNA recognition is not only the basis for gene 
expression, but also the way in which possible genetic errors are identified and 
repaired. For this reason the understanding of the molecular recognition of DNA with 
other molecules, both biomolecules and synthetic agents, is the base for the 
discovery of new approaches to mimic such recognition or interfere with it.  
Within biological systems, sequence specific code recognition is generally
  
a)                                          b)                                        c) 
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 achieved by particular surface motifs of proteins; the most important structures are 
the helix-turn-helix motifs, the zinc-fingers, the zipper motifs, the β-sheets and the β-
hairpins.43 More rarely, other biomolecules can recognise DNA, including 
oligonucleotides which can bind in the major groove forming DNA triplexes, as 
explained above. Since the ‘reading’ of the DNA involves a large number of non 
specific and specific DNA-binding proteins, DNA-protein interactions have been the 
objective of many studies.44-48 Structural information is now available on over 400 
distinct DNA-protein complexes, from a wide range of eukaryotic and prokaryotic 
sources, but this is a relatively small number compared to the total protein encoded 
by individual genomes. The determination of the human genome sequence in 200149 
has led to estimate that of the ca. 30000 proteins in total, ca. 2300 are involved in 
nucleic acid binding, of which 6% are expected to be transcription factors.  
The wide diversity of functions of DNA-binding proteins is in contrast with the 
relatively few ways that they use to interact with the DNA itself. Principally DNA-
protein recognition occurs by non-covalent contacts, such as hydrogen-bonding, Van 
der Waals, hydrophobic and electrostatic interactions. Usually proteins bind DNA in 
the major groove, because it contains a higher number of possible H-bond interacting 
sites and more variety in the bases sequence, and because its dimensions are well-
matched to hosting protein structural motifs. Nonetheless, the minor groove is also 
an important target for some regulatory and structural proteins. Indirect readout can 
also occur via the sugar-phosphate backbone or solely the phosphate group. Indeed, 
even when the phosphate groups do not participate directly in the binding with 
proteins, they provide DNA with an anionic nature which makes the whole structure 
a target for basic side chains, and the resulting electrostatic interactions are 
significant contributors to overall protein-DNA binding. Van der Waals interactions 
and water-mediated hydrogen bonds are recurrent themes in protein-DNA contacts, 
but usually they are not involved in any selective recognition event although they 
display an important role in stabilising the complexes.50,51  
Although a very complicated combination of factors contributes in each gene 
recognition event, the direct DNA-protein contacts occur mainly through hydrogen 
bonds between amino acids side chains and the edges of the base pairs, involving 
their pattern of donor acceptors molecules.52 The majority of interactions involve the 
O6 and/or N7 atoms of guanine bases forming hydrogen bonds with the charged ends  
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 Guanine Cytosine Adenine Thymine 
Arginine 98 8 19 24 
Lysine 30 6 4 9 
Serine 12 2 1 3 
Asparagine 7 10 18 7 
Glutamine 6 2 16 2 
Glutamate 1 10 1 0 
 
Table 1.2 Distribution of amino acid-base interactions observed from the 
analysis of a data set of 129 structures of protein-DNA complexes. For example 
98 contacts between arginine and guanine have been observed (table adapted 
from ref. 52). 
 
                     
 
             
 
 
Figure 1.6.  Examples of hydrogen-bonding patterns which can be observed in 
amino acid-base pairs interactions.52 
G·C G·C G·C 
G·C A·T A·T
Arg Lys Gln
Gln
GlnSer
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of long flexible side chains from the basic residues arginine or lysine, the amide 
residues glutamine and asparagines or the hydroxyl group of a serine.48,50,53-55 
Table1.2 shows the distribution of amino acid-base interactions and Figure 1.6 some  
examples of observed patterns of hydrogen-bonding interactions.52 Although table 
1.2 shows that just few amino acids are the most recurrent in DNA-protein contacts, 
there is not a one-to-one correspondence between specific amino acid residues and a 
base pairs, and in addition to the simple mono or bidentate interactions as the type 
showed in Figure 1.6, many other type of interactions are also possible.  
From the many DNA-protein complexes investigated, a few general 
characteristics have been understood concerning the nature of the interactions that 
can occur and the structures of the most recurrent DNA-protein complexes. But it is 
also understood that each gene recognition event involves a very complex 
combination of numerous factors: amino acid sequences, DNA base sequences, their 
reciprocal positions (that depend on DNA and protein motifs folding), the position of 
amino acids side chains in respect of the sugar backbone, molecules of water and 
different ions. All these are variables whose combination in space and time 
contributes to the uniqueness of each recognition event and any attempt of mimic or 
reproduce these systems is extremely difficult. 
 
1.3 DNA-drug recognition. 
 
Synthetic molecules that can act on the DNA and can modulate DNA processing 
have a great potential especially for the development of new drugs. The activity of a 
large number of clinically important drugs and antibiotics is based on the interaction 
with DNA and the subsequent inhibition of its template function. Since the 1960s it 
is known that there are essentially five distinct ways in which existing synthetic 
agents can bind the DNA:7,56,57  
1. Binding covalently or through coordination bonds to DNA. 
2. Interacting with DNA by a process termed intercalation.  
3. Binding in the major groove, often with the formation of hydrogen bonds to 
the bases.  
4. Binding in the minor groove, via hydrogen bonds with the bases. 
5. Binding to the sugar-phosphate backbone. 
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Using any of these modes, the drug disturbs the natural interactions present in the 
Watson-Crick double helix (such as the hydrogen bonding of the base pair or the 
regular arrangement of the sugar-phosphate back bone), causing abnormal uncoiling 
or irregular bending and coiling in the DNA. As a result replication and/or 
transcription can be affected.  
The modes of DNA binding described above concern mainly B-DNA, which is 
the most abundant conformation in cells. However, much interest now focuses on 
drugs able to target other DNA structures, such as quadruplex, triplex and junctions. 
These synthetic agents are potentially very selective since these structures occur only 
in specific times and/or parts of the genome in a cell.  
 
1.3.1 Covalent bonding drugs. 
 
Several drugs inhibit DNA replication and transcription forming covalent bonds 
or coordination bonds with DNA bases, usually involving nitrogen atoms of the 
bases. Pt(II) based drugs use this kind of interaction and they are among the most 
important antitumor compounds. Particularly, cis-platin was introduced in the clinic 
in 1978 and today it is still one of the leading compounds in cancer treatment.58-64  
Out of thousands of synthesized and evaluated Pt(II) complexes, only cis-platin and 
two other cis-platin derivatives, carboplatin and oxaliplatin, have been approved for 
worldwide clinical practice. Other cis-platin derivatives have been clinically 
approved as anticancer agents only in Japan (nedaplatin), China (lobaplatin) and 
South Korea (heptaplatin) (Figure 1.7). 
             
          
 
 
Figure 1.7. Cis-platin and its derivatives. 
    Cis-platin                                  Carboplatin                                      Oxaliplatin 
   Nedaplatin                                        Heptaplatin                                        Lobaplatin  
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Figure 1.8. Bending of the DNA upon interaction with cis-platin (left, PBD ref. 
1AIO, figure taken from ref. 63) and DNA (green)-cis-platin (red) adduct 
recognised by the HMG ptotein (pink) in the major groove (right, PBD ref. 
1CKT, figure taken from ref. 64) 
 
 
When cis-platin binds to DNA, the two chlorides are displaced and the Pt(II) 
centre forms metal-coordination bonds with the  N7 of two adjacent purine DNA 
bases (with a strong preference of G over A) on the same strand. This binding cause 
a bend of DNA of ~45 degree that affects the DNA functionality and that is 
recognised by the HMG proteins which bind the lesion and “protect” it from repair 
mechanisms (Figure 1.8). In general, many metallo-drugs that are today under 
clinical investigation (especially Pt and Ru based compounds) base their action on 
the formation of coordination bonds with purine bases upon displacement of one or 
two of the ligands of the first coordination sphere (ref. 59 and references therein).  
Among organic compounds, chlorambucil65,66 (Figure 1.9.a)) is a chemotherapy 
drug used for the treatment of lymphocytic leukemia, ovarian and breast carcinomas 
and Hodgkin’s disease, often in combination with other drugs. It belongs to nitrogen 
mustards compounds67 also known as DNA ‘alkylating agents’ because they cause 
alkylation of the nitrogen bases. Chlorambucil causes alkylation of the N7 of guanine 
bases. Other important examples of alkylating agents are the (+)CC1065 (whose 
clinical use in chemotherapy was abandoned due to its side effects) and its 
derivatives. The pyrrolidine ring subunit of (+)CC1065 forms a covalent bond with
13 
 
                      
 
 
 
 
 
 
 
 
 
Figure 1.9. a) Chlorambucil. b) Structures of CC1065 and its adenine adduct. 
The natural drug assumes the (+) conformation at the C4a chiral centre. The 
synthetic enantiomer, (-)-CC1065, has different biological activity. The 
cyclopropane ring in subunit A opens on adduct formation, according to the 
mechanism indicated by the arrows (figure adapted from ref. 7). 
 
         
 
Figure 1.10. Structures of anthramycin (left), tomaymicin (centre) and 
ecteinascidins (right). Red arrows indicate the carbon atoms involved in the 
alkylation of the guanine residues. 
       
                 
 
Figure 1.11. Structures of mitomycin C (MC) (left) and a monoalkylation 
adduct of MC with guanine (figure adapted from ref. 68). 
a)                                                                        b) 
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the adenine N3 upon opening the cyclopropane ring (Figure 1.9.b)).69,70 
Anthramycin, tomaymycin (belonging to the family of chemicals classified as 
pyrrolo[1,4]-benzodiazepines)71 and ecteinascidins (Ets)72 are anticancer drugs that 
form covalent bonds with the N2 (amine) of guanine residues in the minor groove 
(Figure 1.10). Mitomycins are a class of antitumor antibiotics currently in clinical 
use and over 1000 analogous have been studied (mitomycin C (MC) is shown in 
Figure 1.11). These compounds also bind the N2 of guanines, but unlike other drugs, 
they are reductive alkylating agents. Thus, a one-electron reduction produces a 
mono- functional adduct, whereas a two-electron reduction yields a bifunctional 
adduct with DNA (Figure 1.11).68,73-75 
 
1.3.2 Intercalators. 
 
The concept of intercalation was pioneered by Lerman during the 1960s.76 During 
those years it was observed that polycyclic aromatic ring molecules, such as acridine 
dyes, can be sandwiched (intercalated) in the gap between two base pairs of the DNA 
double helix, forming face-face π−π interactions with the heterocyclic rings (above 
and below) of the base residues.  Positive charges, usually present on intercalators, 
reinforce the binding with the DNA by ionic interaction with negatively charged 
sugar-phosphate backbone (Figure 1.12). The insertion of the drug between two 
bases causes an opening up of the gap and an unwinding effect of the twisted helix. 
Usually the maximum loading of an intercalator is one per two gaps of the helix, thus 
the free gap between the two loaded gaps ensures the necessary space for the 
elongation and the unwinding of the helix. Intercalating compounds are very popular 
as antibacterial and anticancer drugs. Together with the acridine dyes cited above, 
daunomycin, doxorubicin, and thalidomide are also very important organic 
intercalators employed in cancer therapy 77-79 and ethidium bromide is one of the 
most common fluorescent tag (nucleic acid stain) that are used in molecular 
biology80 (Figure 1.13). With a similar principle of interaction, organic intercalators 
such as dibenzophenanthrolines and diazoniapolycycles (Figure 1.13) have been 
recently employed to selectively stabilise other DNA structures such as triplex-
DNA.81,82  
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Figure 1.14. Examples of metallo-intercalators.  
 
 
The idea of combining the properties of intercalating drugs with the use of 
transition metal complexes has led to the development of the class of metallo-
intercalator agents. These compounds are stable, inert and water-soluble, and contain 
spectroscopically active metal centres. In this way, the positive charge imparted by 
the metal facilitates the interaction with the negative DNA backbone and the 
presence of the metal can provide the compound with additional properties. .84-88 For 
example the luminescence of Ru(II) and Rh(III) based intercalators makes these 
compounds useful as probes of biological systems, whilst metal centres with 
oxidising properties (photo induced as in rhodium or chemically induced as in 
copper) impart DNA cleavage activity. Numerous synthetic intercalators based on 
metallo-complexes have been investigated and few representative examples are 
shown in Figure 1.14.89-94 The terpyridine-Pt(II) complex [Pt(tpy)(SCH2CH2OH)]+          
was the first metallo-intercalator reported by Lippard.95,96 Particularly intense has 
been the activity of Barton and co-workers in this field, especially concerning the 
study of Rh(III) and Ru(II) intercalators (Figure 1.15 a)).89 Interestingly, Barton and 
co-workers demonstrated that is possible to design the size and the shape of the 
ligand in a way to exclude intercalation in the Watson-Crick duplex and target 
alternative structures. For example [Rh(bipy)2(chrysi)]3+ and [Rh(bipy)2(phzi)]3+ are  
 
 
 
 
 
[Pt(tpy)(SCH2CH2OH)]+                   Δ-α-[Rh{(R,R)-Me2trien}(phi)3+ 
Λ-[Rh(phen)3]3+ 
Δ-[Ru(phen)2(dppz)]2+
[Rh(bipy)2(chrysi)]3+ 
[Rh(bipy)2(phzi)]3+ 
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Figure 1.15.a) Crystal structure of Δ−α−[Rh{(R,R)-Me2trien}(phi)]3+ bound to 
its target sequence 5'-TGCA-3' (PDB ref. 454D, figure taken from ref. 89) b) 
Crystal structure of two Δ-Rh(bpy)2(chrysi)3+ molecules (red) are inserted, one 
in each AA mismatch of oligonucleotide 5'-CGGAAATTACCG-3' (green). The 
ejected adenosines are coloured blue (PDB ref. 3GSK, figure taken from ref 97).  
 
 
 
 
 
 
Figure 1.16. a) Pikramenou’s and b) Lowe’s bis-intercalators. c) Lincoln’s 
threading intercalator.  
              
a) 
b) 
c) 
a)                                                     b) 
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too big to be inserted in the gap of a Watson-Crick duplex but they fit in the gaps of a 
bulged helix originating from base pair mismatches.94,97-99 
Due to the importance of metallo-intercalators among DNA binding agents, more 
sophisticated variations of these compounds have been proposed such as bis-
intercalators and threading intercalators.84,100-102 For example Pikramenou and co-
workers have studied a Ln-Pt2 complex bearing two Pt(terpy) groups as intercalating 
units folded in a hairpin fashion by a neodymium  aminocarboxylate centre (Figure 
1.16.a)103.  The two intercalating Pt(terpy) units are oriented in a way to intercalate 
the same DNA double strand and allowing a gap to be left between them. These 
caused an increase of DNA stiffening compared to mono-intercalators.  The rigid 
tetracationic bis-intercalator based on Pt(terpy) in Figure 1.16.b) was designed by 
Lowe and co-worker to obtain DNA intramolecular cross-linking.104-106 The bis-
intercalator  [Δ,Δ−μ−(bidppz)-(phen)4Ru2]4 proposed by Lincoln and Nordén (Figure 
1.14.c))56,107 is different from the others because the two dppz intercalating units are 
not exposed but linked inside the drug, so that the intercalation occurs after that part 
of the molecule threads through DNA. 
 
1.3.3 Major and minor groove binders. 
 
Groove-binding drugs are molecules that can fit within DNA grooves forming non 
covalent interactions (hydrogen bonds, π−π interactions, Van der Waals forces) 
mainly with the base pairs of the duplex. Most of the known and clinically used 
groove-binding drugs are long and flexible organic molecules and they usually bind 
the minor groove. Goodsell and Dickerson demonstrated that minor groove binders 
tend to have a characteristic structure containing between two and five aromatic 
heterocycles linked by amide or vinyl groups and flanked at each end by cationic 
groups.108 Baraldi et al. reported a selection concerning all the most important DNA-
minor groove binders which, in some case, show a good level of sequence specificity 
and several biological activities, especially with antiprotozoal, antiviral and 
antibacterial properties.109-114 Natural compounds netropsin and distamycine (Figure 
1.17)115-119 are the most studied natural antibiotics that bind the AT-rich minor 
grooves of B-DNA. The binding includes hydrogen bonds formation between the 
amide NH of the drugs and the N3 of adenines and O2 of thymines, van de Waals
19 
 
  
 
 
Figure 1.17 Conceptual drawing of minor groove binding, and structures of 
distamycin and netropsin (Figure adapted from ref. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18. AT rich-minor groove binders and the structure of Berenil (pink) 
in a DNA minor groove (PDB ref. 1D63, figures taken from ref. 7,56).   
 
 
and electrostatic interactions. At least four base pairs within the minor groove are 
involved in the binding with the drug. Particularly important in this field was the 
contribution of Dervan and co-workers for the understanding of how distamycine- 
type compounds can recognise different AT rich sequences.7,120,121 
In Figure 1.18 other well known synthetic minor groove binders are shown. DAPI 
and Hoechst 33258 are used mainly as fluorescent dyes. Berenil is used in veterinary  
Distamycine                                     Netropsin 
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Figure 1.19. GC rich-minor groove binders.7,56  
 
 
medicine for the treatment of the trypanosomiasis class of parasitic diseases (e.g. 
sleeping sickness). Pentamidine is also a diarylamidine anti-parasitic agent and it is 
used in the clinic to treat sleeping sickness and also pneumonia, particularly in HIV-
positive patients. All these compounds bind AT rich minor grooves because the 
absence of the amino group of the guanine residues makes the groove slightly 
narrower than GC rich minor grooves. This allow a better fit of the drug inside the 
groove without causing particularly changes to the width of the groove.56 
The two natural compounds chromomycin A3 and mithramycin (Figure 1.19) are 
antitumor antibiotics and consist of an aglycon ring (chromophore) to which the 
disaccharide (A-B), the trisaccharide (C-D-E) and a hydrophilic side chain are 
attached. Unlike the AT-groove-binding drugs, chromomycin (A3) and mithramycin 
bind to the GC-rich region causing conformational changes of the B-DNA structure: 
the resulting minor groove is wider and shallower so that these drugs tend to convert 
B-DNA in A-DNA.113,122-126 
Most of the organic drugs (either synthetic of natural) that interact non covalently 
with DNA, target the minor groove. This occurs because the major groove is too 
wide to provide the right contacts with relatively small organic molecules. Most of 
the attempts of targeting the major groove are based on the use of synthetic 
biomolecules (such as oligonucleotides, peptides, synthetic protein motifs), agents 
that mimic biomolecules (peptide nucleic acids, PNA) or minor groove binders
21 
 
 
 
Figure 1.20. Schematic representation of the three 6 zinc finger peptides 
designed by Imanishi and co-workers. Each of them contain a linker with a 
different amino acid sequence (Figure taken from ref. 127). 
 
 
conjugated with other elements that allow the binding in the major groove. As it has 
been described in section 1.2, the major groove is the main target in the natural 
recognition of DNA. However, the reproduction of that combination of factors that 
determines the specific DNA recognition, typical of protein motifs, is very 
complicated. Libraries of peptides may be prepared, with rounds of selection and 
amplification used to identify the best binder for a given sequence. Particular 
successes have been achieved with synthetic peptides containing zinc finger motifs.51  
Some useful result can be obtained by modifying the residues of an established 
protein unit to affect its specificity55 or by connecting multiple protein motifs in 
tandem. For example Imanishi and co-workers designed artificial peptides containing 
6 zinc fingers units. The three zinc fingers units indicated as SP1ZF3 in Figure 1.20 
correspond to the DNA binding domain of a transcription factor so that the whole 
system contain two DNA binding domains connected by a α-helix linker peptide. 
Three 6 zinc fingers peptides with three different linkers were studied. The amino 
acid sequence of the linkers determines the reciprocal position of the two DNA 
binding domains and each 6 zinc finger peptide recognise differently discontinue 
DNA binding sites.127 
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can form both Watson-Crick and Hoogsten hydrogen bonds and in fact they bind 
DNA duplex in the major groove forming (DNA)2(PNA) triplexes. However this is 
not the most stable structure, thus DNA double helix is opened up by PNA strands 
forming more stable (DNA)(PNA)2 triple helixes (Figure 1.21, bottom). The use of 
both oligonucleotides and PNAs for medical and biotechnological purposes has been 
widely explored in the last decades, not only as major groove binders. This will be 
further discussed in section 1.4. 
 
1.3.4 Sugar-backbone binding. 
 
The sugar-backbone of DNA offers a hard oxygen-rich polyanion surface that can 
be involved in both electrostatic interactions and hydrogen bonds with either drugs or 
natural proteins. The most representative example of backbone binding drug is a 
class of multinuclear complexes of Pt(II) developed by Farrell.135,136 In these 
compounds Pt(II) centres are coordinated by inert amine ligands, so that formation of  
 
 
 
 
  
 
Figure 1.22. Chemical structure of the trinuclear platinum(II) compound, 
TriplatinNC (top) and Backbone Tracking (bottom). Hydrogen bonds between 
TriplatinNCa and DNA are indicated by dashed lines. Two Phosphate Clamps 
are shown. View perpendicular (A) and along (B) the helical axis (PDB ref. 
2DYW, figure adapted from ref 137).  
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Pt-DNA covalent bonds (as it occurs in Pt-Cl based drugs) is excluded and the 
compounds can only form hydrogen bonds and electrostatic interactions. The 
structure of the adduct that the tri-nuclear platinum compound TriplatinumNC forms 
with DNA was analysed by Komeda137  and is shown in Figure 1.22. The amino 
groups of the Pt(II) compound forms bidentate complexes with the oxygen of the 
phosphate groups (NH···O···HN) that have been named ‘phosphate clamps’ and this 
way of binding the DNA along the sugar-backbone is known as ‘back-bone 
tracking’. 
 
1.4 Selective DNA recognition. 
 
The recognition of specific DNA regions is one of the main issues that allow a 
DNA binding agent to find application as a successful drug. Thousands of 
compounds that can bind DNA and affect its functionality, do not have a future at 
clinical level, because they are unable to discriminate those parts of DNA and or/type 
of cells that are involved in a given disease. For example, all the agents used in 
chemotherapy are known for their grave side effects and this originates from the 
inability of these compounds to act exclusively against cancer cells. Thus, DNA 
selective recognition is still a subject of major interest and in the last decades many 
strategies have been explored in this area. 
 
1.4.1 Sequence selectivity. 
 
 In section 1.2 it has been highlighted that, in Nature, protein motifs are the main 
molecules that selectively recognise DNA, but also that the de novo design of those 
motifs, including all the pattern of factors that are involved in each recognition event, 
is extremely complex. Something analogous occurs for oligonucleotides or PNAs. In 
theory, a certain bases sequence of DNA could be recognised by a complementary 
synthetic oligonucleotide, as mentioned in section 1.3.3, and for this reason 
oligonucleotides are considered a very significant tool in therapeutics design. They 
can be employed according to three different strategies: the antisense strategy, in 
which the oligonucleotide targets a single strand of nucleic acid, most commonly of 
mRNA, thus to affect the transcription of the related protein; the antigene strategy 
25 
 
aims to use oligonucleotides to target DNA double helices to form triple helices as 
described above; the aptamer strategy is based on the design of oligonucleotides that 
are recognised by DNA binding proteins, such as transcription factors, thus to 
obstruct the gene recognition activity of the proteins. However, the use of ‘naked’ 
oligonucleotides fails often for several reasons: their poor cellular uptake, their lack 
of stability in intracellular fluid (due to the high possibility of being recognised and 
modified by nuclease proteins) and their low binding affinity to the target (in part 
due to their negative charge). The use of PNAs can surely obviate the problems 
concerning the charge and these artificial polymers are not hydrolysed by nuclease 
enzymes. But the low cell uptake is an issue for PNAs as well as the fact that the 
DNA is organised in complex coiled structures (chromosomes) and the target 
sequence could be not easily available for the recognition. 
On the other hand, DNA binding agents, either organic, inorganic or metallo-organic 
compounds, can bind the DNA more efficiently, causing more effective 
modifications, such as coiling, unwinding, bending, rupture of the DNA, but they 
lack sequence selectivity most of the time. For this reason, one of the most explored 
strategies for the achievement of selective DNA recognition aims to combine the 
efficiency of DNA binding agents, with the selective DNA recognition potential of 
either peptides, oligonucleotides or PNAs. This has led to a wide production and 
analysis of a huge number of bioconjugates. Barton and co-workers demonstrated 
that Rh(III) based intercalators conjugated to peptides exhibited a DNA recognition 
selectivity that depended on the amino acids sequence of the conjugated peptide. For 
example the intercalator [Rh(phi)2(phen')]3+ was conjugated to a 13 residues peptide 
in α-helix conformation and the resulting peptide-intercalator system showed DNA 
site recognition to the sequence 5'-CCA-3' that depended on the presence of the 
glutamate at the position 10 (Figure 1.23 a)).138 The DNA sequence selectivity of this 
peptide-complex system involved different DNA sequences by single amino acid 
modification of the peptide sequence.139-141 With a similar approach a de novo 
designed Zn(II) metallo-peptide, known as the active site of metal containing 
hydrolase enzymes, was conjugated to the intercalator [Rh(phi)2bpy'] and this system 
showed selective DNA nuclease activity.142 
Most recently the same strategy has been investigated for Ru(II) and Pt(II) 
complexes, due the large importance of this compounds especially in
26 
 
  
 
 
 
Figure 1.23. Barton’s peptide metallo-intercalator. a) Peptide 
[Rh(phi)2(phen')]3+ conjugate as example of glutamate switch (figure taken from 
ref.138) b) Peptide-[Rh(phi)2(bpy')]3+ as artificial selective DNA nuclease (figure 
taken from ref 142). 
 
 
chemotherapy.143 In Reedijk laboratories mono and di-nuclear cisplatin based 
complexes have been conjugated to peptides for the first time via solid phase 
synthesis144,145 and in Hadjiliadis group a similar synthetic approach led to the 
development of Ru(II) complexes conjugated with peptide and amino acids, whose 
DNA binding affinity depended on the type of amino acid appended.146-148 
Obviously, the idea of assembling DNA binders with DNA recognition motifs does 
not concern metal complexes only. Mascareñas and co-workers demonstrated that 
DNA sequence-selective binding can be achieved with the rational design of minor 
grove binder-peptide hybrids.149 They chose a minimal DNA binding domain of a 
zinc transcription factor from Drosophila melanogaster. This domain is a zinc finger 
unit that binds its consensus DNA sequence (GAGAG) by means of a trivalent 
interaction involving a classical zinc-finger module and two basic regions, that are 
indicated as BR1 and BR2 in figure 1.24.a). The 65 amino acids minimal domain 
alone does not bind the DNA. Two different distamycin-like tripyrrole units were 
anchored at the Arg44 of the zinc finger, in a position in which the folding of the 
zinc finger conformation was not compromised and aiming to a major-minor groove 
binding combination (Figure 1.24.b) and c)). DNA binding studies showed that both 
hybrids bind the DNA, involving also the zinc finger unit, and the hybrid 2a showed  
 
a) 
b) 
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Figure 1.24 Mascareñas design of zinc finger-tripyrrole hybrid a) Sequence of 
the minimal DNA binding domain of the GAGA factor, showing the location of 
the two basic regions (BR1 and BR2) as well as the secondary-structure 
elements. b) Two tripyrrole-peptide hybrids investigated (1 and 2a). c) 
Representation of the designed bipartite major-minor groove recognition 
(Figure adapted from ref. 149). 
 
 
selective binding for a GAG sequence adjacent to an A-rich minor groove.149 It has 
been demonstrated that the approach of conjugating is effective also using 
oligonucleotides150-154 and PNA.155-160 
 
1.4.2 Structure specificity. 
 
The design of synthetic agents that target tertiary structures of DNA, rather than 
specific sequences along the B-DNA, is a valid alternative to achieve selective DNA 
recognition. DNA structures such as G-quadruplex, DNA junctions or triplexes, 
occur only in specific moments or are located only in few regions of the entire 
genome, so their recognition would affect the genetic event in which they are 
involved. For example, the binding of G-quadruplex structures has been deeply 
 
a) 
b) 
c) 
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investigated in the last decades, since they have been found in telomeric DNA. 
Telomeres are stretches of DNA, located at the ends of the chromosomes, which are 
not replicated with the rest of the genome. The telomerase enzyme (not normally 
present in cells) is responsible for the synthesis of telomeres and can maintain their 
integrity and prevent their shortening. The telomerase enzyme is particularly active 
in cancer cells and because it can keep replicating telomeric DNA, the cell cannot 
reach crisis points of senescence and apoptosis.161 It has been discovered that if the 
G-rich telomeric DNA folds in G-quadruplex structures, these are able to inhibit the 
telomerase.162 Consequently synthetic agents that can induce the formation of G-
quadruplex structures and stabilise them are considered very useful for applications 
in cancer therapy. Many organic and metallo-based compounds, that are known DNA 
duplex intercalators or groove binders, exhibit the ability of stabilising G-
quadruplex.163-165 An example is shown in Figure 1.25: the complex of daunomycin 
(known intercalator) with d(TGGGGT) has  been crystallised showing that the 
daunomycin does not intercalate within stacked bases of the tetraplex; rather two 
layers of daunomycine molecules fill the interface between two quadruplex forming 
π−π interactions.165  
 
           
 
 
Figure 1.25. Structure of daunomycin (left) and crystal structure of the 
daunomycin-d(TGGGGT) complex, showing the arrangement in the crystal 
lattice of two quadruplexes, in van der Waals space-filling mode, and stacked 
end-to-end. The daunomycin molecules are shown in green ball-and-stick 
representation (PDB ref. 10OK, figure adapted from ref. 165).  
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therapeutic and diagnostic agents.  However there is still a lot to be discovered about 
the possibility of targeting specific structures of nucleic acids or specific genes. 
Chapter 2 will be dedicated to the description of a class of metallo-supramolecular 
helicates developed in Hannon laboratories and whose DNA binding properties have 
been explored in the last decade. These di-nuclear complexes bind the major groove 
of the DNA and this makes them particularly interesting, as most of the synthetic 
DNA binders are intercalators, minor groove binders or alkylating agents. Most 
interestingly, they bind the heart of DNA three way junctions. Studies concerning the 
dynamic behaviour of the most representative of these helicates will be discussed in 
the same chapter. As it has been highlighted above, the conjugation of DNA binders 
to DNA recognition motifs can provide several advantages, especially concerning the 
selective recognition of DNA. Thus the synthesis and characterisation of these 
helicates conjugated with short peptides and amino acids will be presented in 
Chapter 3 and Chapter 4 will be dedicated to the study of the DNA binding 
properties and cytotoxic activity of the conjugates.    
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CHAPTER 2 
 
 METALLO-SUPRAMOLECULAR CYLINDERS: A 
NEW APPROACH FOR DNA MAJOR GROOVE 
RECOGNITION. 
 
2.1 Non covalent DNA recognition and supramolecular chemistry.  
 
Non covalent interactions (hydrogen bonding, metal coordination, hydrophobic 
and van der Waals forces, π−π interactions and electrostatic effects)  play a major 
role in biological systems both regarding the multi dimensional assembly of 
biomolecules (such as proteins, RNA and DNA) and in the modes in which they 
“communicate” with their external environment and consequently the way their 
functions are processed and regulated.1,2 Because of the key role of the non covalent 
bond in DNA recognition, this field is closely related to supramolecular chemistry, 
which is a branch of modern chemistry whose features and importance started to be 
understood during the 1980s thanks to the intense activity of Donald J. Cram, Jean-
Marie Lehn and Charles J. Pedersen (Nobel Prizes, 1987). Supramolecular chemistry 
is known as the “chemistry beyond the molecule”3 to distinguish it from the 
traditional molecular chemistry. The latter is mainly focused on making and breaking 
covalent bonds between atoms, while supramolecular chemistry concerns 
intermolecular interactions of non covalent nature to enforce the spontaneous but 
controlled generation of well-defined architectures4.  
The synthesis of a supramolecular compound does not have to be particularly 
intricate because the final molecule is the result of a natural self-assembly of smaller 
components. However the supramolecular chemist has to be particularly able in 
designing the right components capable of promoting the desired assembly and 
precluding the formation of unwanted structures. If this is achieved, it is possible to 
make slight modifications to these components or combine them in different ways to 
obtain a large number of final molecules to examine.  
During the 1980-90’s supramolecular chemistry was mainly focused on the 
design, construction and understanding of fascinating architectures, with the aim of 
establishing the general principles to create different supramolecular assemblies. 
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During this period a myriad of beautiful structures such as squares, triangles, boxes, 
grids, knots, helicates and many others, were designed and fully described5. 
However, during the mid 90s, it became evident that supramolecular chemistry was 
not only a way to create molecular constructions with nice forms, definite features 
and functions based on the “bottom up” approach, but also a method to understand 
and describe many physical, chemical and biological events5. Today supramolecular 
chemistry is a highly interdisciplinary field of science with applications in a very 
wide range of areas from material technologies to catalysis, from medicine to 
nanotechnologies.6-8 For example a protein motif that recognises a specific sequence 
of DNA with consequent switching on or off a particular biological process, or a 
drug that interacts with its target producing a specific effect, or molecules that are 
able to be transferred throughout protein membranes, are all examples of events 
based on molecular recognition, which is one of the key concepts in supramolecular 
chemistry.  
The study of synthetic molecules that recognise DNA via non covalent 
interactions, forming specific host-guest complexes that produce modifications of 
natural events, is the area of supramolecular chemistry on which this thesis focus. 
 
2.2 Design of “cylinders”: where metallo-supramolecular chemistry meets 
bioinorganic chemisty.   
 
Starting from the end of 1990s, a key focus of the research in the Hannon group 
has been the design and synthesis of agents that probe DNA for potential applications 
in drug discovery and biotechnologies.  
In natural systems the processing of DNA principally occurs by non covalent 
molecular recognition of the major groove of B-DNA by specific protein motifs. In 
Chapter 1 it has been explained that many sophisticated and complex factors, of a 
supramolecular nature, are involved in such recognition, not all of them completely 
explained and it is very difficult to replicate these systems by de novo design 
approach. However, it is known that “shapes” of protein motifs have a relevant role 
in the recognition.  
The approach used by Hannon and co-workers was based on the idea to “mimic” 
the action of protein motifs by reproducing their shapes and dimensions rather than 
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their compositions. A further important aspect was the idea of employing a synthetic 
methodology which allowed a large number of synthetic agents to be prepared with 
the smallest possible synthetic effort, which could be an advantage in terms of costs 
and time. Metallo-supramolecular chemistry, which is a combination between 
coordination chemistry and supramolecular chemistry, was used as the key synthetic 
method. This method involves the use of ligand-metal ion interactions for the self 
assembly of the supramolecular product of desired architecture. The directionality 
inherent in the geometry of different metal ions, which can be controlled by changing 
the nature or the oxidation state of the metal, plays a crucial role in the spatial 
orientations of large organic molecules in the final supramolecular structure.  
Helicates are among the most studied architectures in metallo-supramolecular 
chemistry. The term helicate, first introduced by J.M. Lehn in 1987, indicates helical 
architectures where one or more strands of organic ligands wrap around two or more 
metal ions, which are located along the axis of the helix itself9. The organic ligands 
must possess several binding sites that are able of coordinating to the metal ions, and 
they have to include appropriate rigid spacers between the binding domains to 
prevent two binding sites from the same ligand coordinating to the same metal centre 
(see schematic representation in Figure 2.1).  
The most recurrent protein motifs that recognise the DNA major groove in natural 
systems have a typical cylindrical shape which promotes the formation of a perfect 
“host-guest” complex based, most of the time, on non covalent interactions. 
Examples are shown in Figure 2.2, all of which employ α-helix protein motifs for the  
 
 
 
 
Figure 2.1. Schematic representation of the design of a poly nuclear double 
stranded helicate.  
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Figure 2.2. Examples of protein motifs that recognise DNA major groove: a) 
zinc finger, b) leucine zipper and c) helix-turn-helix (figures taken from ref. 10, 
11 and 12 respectively). 
 
 
recognition. Supramolecular helicates architectures can mimic, in terms of shape and 
dimensions, the cylindrical shape of those protein motifs. As potential DNA binders, 
the presence of the metal centres is particularly helpful, not only for their structural 
role, but also because the presence of cationic charges can energetically contribute to 
the interaction with the negatively charged DNA and they can eventually provide the 
potential drug with useful physical and/or chemical properties (depending on the 
metal). The wide range of metal ion coordination geometries available and the vast 
number of possible ligands, allows the identification of different “blocks” that could 
be combined in different ways to obtain a large set of helicate structures with 
different features.  
Many studies, reported by Hannon et co-workers over the last decade, have 
demonstrated the ability of some of these helicates to recognise the DNA major 
groove by non covalent interactions,13-22 opening new routes for the development of 
potential metallo-based drugs which are now receiving major attention in 
bioinorganic chemistry.23 Because of their distinctive shape and the modality in 
which they recognise the DNA, these helicates have been termed “cylinders”. 
Interestingly, this approach makes use of metallo-supramolecular chemistry twice: 
as key method to design and synthesise a large array of different “cylinders” and as 
the discipline whose principles (in this particular case referred to the non covalent 
molecular recognition concept) are the base to design and understand the interaction 
between potential metallo-based drugs and their target binding site (DNA).  
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2.2.1 Triple stranded helicates-based “parent cylinders”. DNA recognition 
and biological activity studies. 
 
Ligands containing pyridine rings units, such as poly 2,2'-bipyridine-based 
ligands,9 where the pyridine nitrogen is one of the coordinating sites, are the most 
common helicating ligands known in supramolecular chemistry. However, the 
preparation of poly-pyridyl ligands often requires long multistep organic synthesis 
from relatively expensive starting materials. A valid alternative is the use of poly-
pyridylimine based ligands, whose characteristics can still ensure the formation of 
helicate architectures, but can be easily and inexpensively synthesised (one step 
reaction) by mixing pyridine aldehyde containing units and amino-based spacers to 
obtain Schiff bases. 
One of the most important “cylinders”, whose structure was first reported in 
1997,24 is based on the bispyridylimine ligand L1 showed in Figure 2.3 a). Reactions 
of this ligand with octahedral metal ions (such as Fe(II), Ni(II), Co(II), Zn(II), 
Ru(II)) led to the formation of dinuclear triple helicates of general formula [M2L13]4+ 
in which three strands of ligand wrap around the 2 metal centres (Figure 2.3 
b)).13,24,25  
 
 
 
 
Figure 2.3. a) Scheme of synthesis of bispyridylimine based ligand L1, from 
which b) a triple stranded helicate (“cylinder”) is obtained upon reaction with 
octahedral metals. 
 
Ligand L1 
Octahedral M 
X-ray structure 
EtOH 
rt, 2 h 
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From a structural point of view the formation of these triple helicate complexes 
does not depend on the nature of the octahedral metal M (it forms with all the ones 
that have been investigated) and each N imine and N pyridine of the ligand are 
involved in the coordination of the metal centres. These new systems satisfy the 
design requirements to target the major groove of  DNA via non covalent 
interactions: firstly they have the right dimensions (~2 nm length and ~1 nm 
diameter from X-ray studies) and shape (cylindrical, like the DNA-binding protein 
motifs) to exclude either binding in the minor groove or intercalation; secondly, they 
are saturated triple helicates (the metal centres are fully coordinated by the helical 
ligands26 excluding metal coordination to the DNA bases) and the exposed surface, 
made of ligand strands, can easily form π-stacking (face to face or edge to face) 
interactions with the DNA. 
Cylinders based on saturated triple stranded helicates of ligand L1 were the first to 
be investigated for binding to DNA in the Hannon group, and for this reason we refer 
to them as the “parent cylinders”. Extensive DNA binding and biological studies 
have been carried out and are currently ongoing, in order to verify the potential of 
this new class of synthetic agents as potential drugs, with particular attention given to 
the triple stranded Fe(II) cylinder ([Fe2(L1)3]4+)13,15,18,22,27-30 and Ru(II) cylinder, 
([Ru2(L1)3]4+).31,32 The Fe(II) cylinder is very easy to synthesise, purify and 
characterise. Its characteristics and its DNA binding properties are considered 
representative for all the “parent cylinders” in general.  
Spectroscopic methodologies, such us UV-vis, Circular Dichroism (CD), Linear 
Dichroism (LD) and 1D and 2D NMR were the first techniques to study DNA 
binding activities of Fe(II) cylinder at molecular level. All the results demonstrated 
that this agent binds B-DNA (both long DNA from calf thymus and smaller 
oligonucleotides) in a single binding mode up to DNA:complex ratio of 5:1. At this 
concentration, the binding occurs via the major groove although at higher loading of 
complex other kinds of interactions cannot be excluded.13,15,28 
LD experiments confirm that the binding starts at very low concentration of Fe(II) 
cylinder (100:1=DNA:complex), with the consequent effect of loss of initial 
orientation of B-DNA. Atomic Force Microscopy (AFM) experiments13 provided a 
molecular-level picture of the binding and showed that by increasing the 
concentration of Fe(II) cylinder in the presence of linear plasmid DNA, there is
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Figure 2.4 AFM images of linear plasmide DNA pBR322 in presence of a) 
several concentrations of [Fe2L3]4+ b) [Co(NH3)6]3+ and c) [Ru(phen)3]2+ (Figure 
adapted from ref. 13). 
 
 
bending followed by cooperative coiling of DNA around the complex (Figure 2.4-
a)). This behaviour was interesting as it is unusual if compared with other known 
related mononuclear metal complexes: condensation agents such as [Co(NH3)6]3+ and 
spermines cause aggregation of multiple DNA strands (Figure 2.4.b), and di-cationic 
[Ru(phen)3]2+ complex, whose structure can be seen as “half cylinder” produce 
simply bending of the DNA (Figure 4.c)).  
The synthesis of the Ru(II) cylinder is not as straightforward as for Fe(II) and the 
yield not completely satisfactory (~33% at the moment). However the study of this 
complex is particularly important: the presence of Ru(II) centres provides the 
cylinder with a considerably better stability compared with other triple stranded 
cylinders, especially at higher temperatures; this allows the use of some techniques 
(such as PCR) whose experimental conditions are not always suitable for other 
cylinders. Moreover, the properties of luminescence and photo cleavage of this 
Ru(II) system add useful functionalities to the cylinders. Indeed ruthenium based
a)       
b)       c)       
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Figure 2.5: X-ray structure of Ru (II) cylinder (figure taken from ref.21). 
 
 
drugs are among the most studied systems in the field of metallo-drugs in the last 
decade.33-36 The X-ray structure of the Ru(II) cylinder is very similar to its Fe(II) 
analogue (Figure 2.5) and, as expected, the binding activity of the two complexes is 
comparable. There is no reason to suppose a different type of activity since shapes 
and dimensions play a decisive role for this type of DNA recognition. The 
photoresponse of the Ru(II) cylinder to DNA is very interesting: successive additions 
of ct-DNA to this complex induce both an enhancement in the intensity of the 
emission from the complex and a blue shift (8 nm) in the emission maximum. This 
increase in the luminescence occurs very rapidly and at DNA bases:complex ratio of 
4:1 the intensity of the emission has almost doubled. At the moment different 
experiments are ongoing to convert this important property into useful applications, 
such as artificial DNA cleavage activity by photoactivation of ruthenium centres and 
the option of probing cylinder activity inside cells. 
Although the cylinders were initially designed to target at the major groove of 
DNA, it was later discovered that the Fe(II) cylinder binds at the heart of DNA three 
way junctions (Figure 2.6), formed either with palindromic18 or non palindromic37 
sequences of oligonucleotides. NMR and gel electrophoresis studies confirmed that 
this is not only a construct at the crystalline state, but a type of recognition that also 
occurs in solution and was also seen in other Y-shaped junction structures.22,37 This 
is an unprecedented mode of interaction between a synthetic agent and nucleic acids 
and it could open an alternative way to achieve specific recognition of DNA. Most 
recently the ability of Fe(II) cylinder of stabilising G-quadruplex DNA has also been 
observed38 and is currently under investigation in our lab. 
Once the DNA recognition of parent cylinders had been described at molecular 
level, the study of their action in biological systems was also investigated.30 IC50 
values (half maximal inhibitory concentration) of the Fe(II) parent cylinder against
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Figure 2.6: X-ray structure of Fe(II) cylinder binding at the heart of a three way 
junction formed by palindromic esanucleotides (Figure adapted from ref. 18).                          
 
                            
several cancer cell lines were evaluated using an MTT assay: a range of 
concentration of complex from 18 to 57 μM is needed to inhibit the mitochondrial 
activity (by 50%) in the cell cultures that have been tested and the Ru(II) cylinder 
exhibits a comparable cytotoxic activity. Such activity is approximately 5 times less 
than cisplatin activity, which is not surprising since a different molecular lever action 
is expected for these two agents. However, the cytotoxicity of parent cylinders is 
comparable with that exhibited by carboplatin, which is a cisplatin derivative that is 
alternatively employed in clinical treatments where there is resistance to cisplatin or 
drugs with lower toxicity are required.  
Further experiments indicate that that Fe(II) parent cylinder is not mutagenic, as 
proved by Ames bacterial mutagenicity test, and is not genotoxic, as it does not 
generate DNA strands breaks in comet assay in mammalian cell lines. This aspect is 
particularly significant in drug design if we consider that the high mutagenicity and 
genotoxicity of cisplatin causes very serious side effects in chemotherapy.  
Treatment of cultures of cancer cells with Fe(II) cylinder resulted in inhibitions of 
cellular proliferation and subsequent cell death by apoptosis, which is a further 
important requisite in drug action design: although cellular senescence and cell death 
by necrosis are also important, the ability of a drug to induce apoptosis is always 
preferred because it avoids nonselective necrotic mechanisms that produce adverse 
inflammatory responses.39 
 
 
Minor groove side Major groove side 
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2.2.2 Other “cylinders”. 
 
The design of different variations on the “parent” triple-helicate-based “cylinders” 
has been possible using supramolecular chemistry as synthetic tool. Thus, many 
different cylinders have been synthesised, in order to investigate the effect of 
changes in the type of ligand and/or in the nature of the metal centres and/or in 
dimensions and shape of the complex, both for chemical and physical studies of the 
complexes and to observe the influence on DNA binding activity. 
In Figure 2.7 there are three examples of ligands that have been employed to 
synthesise bulky Fe(II) cylinders.16,20,29 Although these larger complexes bind the 
DNA, the binding properties are less remarkable than those of the parent Fe cylinder, 
and in some cases the mode of binding appears random without an apparent 
orientation of the cylinders as result of the interaction with DNA. This suggests that 
both the bending/coiling efficiency and the major groove targeting modality are 
related to size and dimensions of cylinders.  
When reacted with tetrahedral metal ions such as silver(I) or copper(I), ligand L1 
(Figure 2.3) forms a dinuclear species of composition [M2L12]2+. The flexibility of 
this ligand, coupled to the lability of these metal ions, leads to the presence in 
solution of  two species in equilibrium40: a helicate (rac-isomer) in which each ligand 
strand wraps over and under the plane of metals ions, and a metallo-cyclophane 
(meso-isomer or box), in which one ligand lies above the plane of metal ions and the 
other lies below (Figure 2.8). To overcome the problem of the presence of two 
architectures in double stranded cylinders, ligand L5 (Figure 2.9) has been employed: 
 
 
     
 
 
Figure 2.7: Three examples of ligands (L216, L3 and L429) employed for the 
synthesis of bulky triple stranded Fe (II) cylinders. 
 
Ligand L2 
Ligand L3 
Ligand L4 
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                       Box (meso isomer)                                              Helix (rac isomer) 
 
Figure 2.8 Representation of cyclophane (box) and helix structures that are 
possible when ligand L1 is coordinated to tetrahedral metal ions.40  
 
 
it contains bulky substituents in the central spacer and its reaction with tetrahedral 
metal ions results in the exclusive formation of the double stranded helical isomer. 
The larger steric bulk of the spacer twists the ligand, making the formation of the box 
isomer energetically unfavourable; the helix conformation is also stabilised by 
CH···π interactions between the end of the ethyl chains of one ligand and the 
aromatic ring of the spacer of the second molecule. The result is a very stable di-
cationic Cu(I) double helicate complex, [Cu2L52]2+ which also binds ct-DNA but 
does not induce the same dramatic coiling and bending effect seen for the tetra-
cationic triple helicates.17 Since the copper(I) cylinder has very similar dimensions to 
the iron(II) cylinder and is only slightly different in shape (it appears a bit more like 
a “square” tube), the consistent difference in binding activity could in part depend on 
the lower positive charge of the copper system. These synthetic copper compounds 
 
 
 
 
 
 
 
 
 
Figure 2.9 Bispyridylimine Ligand L5 with ethyl groups in the spacer to induce 
the formation of di- Cu(I) double stranded cylinder with helicate architecture 
(structure taken from ref. 17). 
 
                    
                    Ligand L5                                                       Cu (I) double stranded cylinder 
CuA 
 
 
 
A=PF6 or Cl 
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can catalytically cleave DNA in presence of an oxidising agent,41-44 acting as 
artificial nuclease; in fact, gel electrophoresis experiments confirm that the Cu(I) 
cylinder chops up plasmid DNA in the presence of hydrogen peroxide and shows 
some tendency to perform a double strand cleavage at the same site, which may 
reflect its di-nuclear nature.  
A very important alternative to the di-Ru(II) “parent” cylinder described above is 
a set of double-stranded di-Ru(II) complexes which are based on the dinucleating 
bisazopyridine ligand (Ligand L6 in Figure 2.10).19 In contrast to the “saturated” 
triple stranded helicate based on the bispyridylimine ligand system L1, the metals in 
the double stranded systems based on the azo analogue ligand L6 are “unsaturated” 
and two chlorides are required to complete the coordination of each Ru(II) centre. 
According to the configuration of each metal centre, several isomers are expected, 
five of which were isolated and characterised by X-ray crystallography. These 
complexes exhibit very exciting cytotoxic activities in both breast and ovarian cancer 
cell lines which is comparable with and in some case higher than cis-platin 
cytotoxicity. The different isomers show different levels of cytoxicity which would 
suggest that the activity of the drug depends on its architecture. In general all the 
cytotoxic azo ligand based Ru cylinders have lower IC50 values than the saturated 
imine ligand based triple helicates (i.e. are more active); this could suggest that the 
unsaturated Ru centres in the double stranded complexes could be directly involved 
in the binding with the DNA (Ru-DNA covalent bonds are frequent in Ru- based  
 
 
 
Figure 2.10. Bispyridil azo Ligand L6 and X-ray structures of 5 isomers of di 
Ru (II) double stranded cylinders (figure adapted from ref 19). 
 
[Ru(dmso)4Cl2]
2L:2M(II) 
N N
N N
NN
Ligand L6 
5 isomers isolated and 
characterised 
(X-ray structures) 
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drugs), whilst saturated triple helicate systems recognise the DNA by non-covalent 
interactions only involving the ligand surface of the cylinder. 
 
2.3 Understanding dynamics in the Fe(II) cylinder. 
 
2.3.1 Circular Dichroism. 
 
In the following sections, as well as in Chapter 3 and 4, the chiralty of both 
helicates alone and helicate-DNA complexes will be object of analysis and 
discussion. Circular Dichroism (CD) is the most common spectroscopic technique 
for the study of chiral systems and is also widely employed to probe the interaction 
between DNA and other molecules, either biomolecules or synthetic agents.45,46 This 
technique is based on the interaction between matter and circularly polarized light, 
whose electric field vector has a constant length, but rotates about its propagation 
direction, such to form a helix in the space while propagating (Figure 2.11). The light 
is referred as left or right circularly polarized when the helix is left or right handed 
respectively. The electronic rearrangement of chiral molecules, which are molecules 
that cannot be superimposed to their own mirror image, have no reflection plane so 
that the electrons move in some kind of helix as well. These kinds of systems absorb 
differently the left and the right circularly polarized light, and this difference in 
absorbance (A) is detected as CD signal (CD = Al - Ar, where Al and Ar are the 
 
 
 
 
Figure 2.11. Representation of a) linearly and b) right circularly polarized 
electromagnetic radiation. In both cases k indicates the propagation direction of 
the radiation and arrows indicate the direction of electric field vector E which 
oscillates in the same plane of k in the linearly polarized light, whereas retains 
constant magnitude in time but traces out a helix about k if the light is circularly 
polarized.  
a)                                                              b) 
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absorbance of left and right circularly polarized light respectively, with a 
corresponding Δε=εl-εr, where εl and εr are the molar extinction coefficients for left 
and right circularly polarized light). Chiral systems could be either small organic 
molecules or coordination complexes (in fact the chirality of helicates will be 
analysed by CD in the following sections and in Chapter 3), but also large secondary 
or tertiary structures such as proteins, membranes or DNA (CD is one of the methods 
employed for DNA binding studies by helicates in Chapter 4).  
 
2.3.2 Structure and chirality of Fe(II) cylinder. 
 
To date the tetra cationic Fe(II) triple helicate, described in section 2.2.1, is 
considered as one of the most representative cylinders: it is easy and very 
inexpensive to synthesise; each Fe(II) centre, is low spin and the system is 
diamagnetic so that both characterisation and experiments via NMR are possible. By 
changing the counter anion it is possible to dissolve the complex in different solvents 
(the chloride salt is soluble in water and alcoholic solvents, hexafluorophosphate and 
hexafluoroborate salts are soluble in other organic solvents such as acetonitrile, 
acetone and nitomethane). This allows both the study of chemical and physical 
characteristics of the system in different conditions and the investigation of its 
suitability for biological applications in water soluble conditions.  
The molecular structure of Fe(II) parent cylinder has been determined by X-ray 
analysis (Figure 2.12. a)24: each Fe(II) centre is coordinated by three N imine-N 
pyridine bidentate units from three different strands of ligand L1 and the pseudo- 
octahedral geometry of each Fe(II) centre causes an intermolecular twisting at the 
level of the phenylene spacer units, with consequent formation of a triple helicate. In 
addition to metal ion-ligand interactions, there are six edge-face π-stacking 
interactions between the aryl rings of the spacer which contribute to stabilise the 
structure (Figure 2.12.b) and c)). 
As in any other helical structure, the triple helicate-based cylinder has a right or 
left handedness: when it is viewed down its helical axis, it is right-handed or P (plus) 
helicate if it rotates clockwise and left-handed or M (minus) if it rotates 
anticlockwise. Furthermore, the two octahedral metal centres in any ligand L1 based 
cylinders are homo configurational, since they present the same optical configuration  
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Figure 2.12. a) X-ray structure of Fe(II) parent cylinder. Highlighting the edge-
face interactions: b) balls and sticks and c) space filling between aryl rings. 
 
 
(ΔΔ or ΛΛ) in each enantiomer. Because of the geometry of theoctahedral metal ions 
and the symmetry of the ligand L1, the synthesis affords a racemic mixture of the 
two enantiomers of the triple stranded parent cylinders. However, the two 
enantiomers of Fe(II) cylinder can be separated on a cellulose column (or paper 
sheets, Figure 2.13.a)) eluted with 20 mM NaCl solution, and, as expected, they are 
perfectly equivalent by NMR and UV-Vis, but they present two distinct and opposite 
CD signals (Figure 2.13.b) ). The first enantiomer eluted from the column is the M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. a) separation of M and P enantiomer of Fe(II) parent cylinder on 
cellulose and b) the corresponding CD signals (Figure adapted from ref. 47). 
 
a) 
b) 
a) 
b) c)
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enantiomer (confirmed by X-ray). The configuration of the Fe(II) centres of the M 
enantiomer is ΛΛ although its CD signal (green line in figure) presents a Cotton 
effect whose sign is typical for tris-chelate mono nuclear complexes with Δ 
configuration.46,48 This confirms that the absolute configurations of metal centres in a 
polynuclear complex may be incorrectly assigned on the basis of CD data. In fact the 
CD sign and magnitude of these complexes not only depend on intranuclear exciton 
coupling between chromophores located on the same metal centre, but there is also 
the contribution of internuclear exciton coupling between chromophores located on 
two different metal centres, which is not present in mononuclear complexes. The CD 
signal is the result of which of these two contributions prevails in each specific 
polynuclear complex.49 
The chirality of these systems is a very significant issue for applications in new 
drug design. The chirality of biomelocules (DNA, RNA, proteins) is the proof that 
systems with a specific orientation have been selected in nature. In some cases, the 
chirality of the DNA itself can influence its interaction with different structural or 
stereo isomers of the same agent. Indeed, it has been demonstrated that the M 
enantiomer of the Fe(II) cylinder has higher affinity in binding the DNA than the P 
enantiomer, whilst the binding activity of the racemic mix is an average between the 
activities of the two enatiomers separately.27 
  
2.3.3 Characterisation and dynamic studies by 1H NMR spectroscopy. 
 
Part of the work presented in this thesis and described in this section and in the 
next section, concerns the study of the behaviour of the Fe(II) cylinder at different 
temperatures and in two different solvents (water and acetonitrile). This aims to 
achieve a better “chemical” knowledge of this system and understand whether there 
are remarkable changes of the molecule in certain conditions. The information 
obtained from these studies could also facilitate the understanding of DNA 
recognition studies and help the planning of the most appropriate biological tests. 
Some initial variable temperature (vt) NMR experiments of [Fe2L13](PF6)4 in 
acetonitrile and estimation of free energies activation were already described in C.L. 
Painting PhD thesis,50 but they are shown again in this section for the completeness 
of the discussion. Herein, the aim was to complete those vt-NMR studies with some 
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additional NMR experiments (also presented in this section) and perform a set of 
UV-Vis and CD thermal experiments (section 2.3.4) that combined with the NMR 
experiments would allow a better understanding of the dynamic behaviour of Fe(II) 
cylinder.  
The bispyridylimine ligand L1 was synthesised by mixing 4,4'-methylenedianiline 
(1 eq) and 2-pyridine carboxaldehyde (2 eq) at room temperature in ethanol to obtain 
Schiff base formation24. A deep purple solution was obtained by mixing 3 eq of L1 
with 2 eq of Fe(II) chloride, as cylinder [Fe2L13]Cl4 is formed. The counter anion can 
be exchanged from Cl- to PF6- by addition of saturated methanolic solution of 
ammonium hexafluorophosphate which causes the precipitation of purple 
[Fe2L13](PF6)4. In Figure 2.14 the 1H NMR spectrum of the complex in CD3CN at 
298 K is compared with the spectra of its building block components (spacer + 
carboxaldehyde=Ligand L1). The pyridyl and imine protons of the complex are 
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Figure 2.14. 1H NMR (300 MHz, CD3CN, 298K) of a) 4,4'-methylenedianiline, 
b) 2-pyridine carboxaldehyde, c) Ligand L1 and d) [Fe2L13](PF6)4. 
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Figure 2.15. 1H NMR (400 MHz) of [Fe2L13](PF6)4 in CD3CN at different 
temperatures (Figure taken from ref. 50) 
 
 
shifted (compared to the ligand L1 protons) and H6 and Hi present the most 
significant shifts as expected consequence of the coordination of N pyridine and N 
imine to Fe(II) ion. In the spacer and the ligand L1, protons Ha and c are equivalent, 
because of the symmetry of the phenylene group. In the same way Hb and d are 
equivalent. Consequently the phenylene protons appear as a set of 2 peaks, whose 
chemical shift and multiplicity depend on the substituent groups of the aryl ring 
(Figure 2.14 c)). However, when the complex is formed, the same protons appear as 
two broad signals at room temperature (Figure 2.14 d)). 
1H NMR variable temperature studies of the Fe(II) cylinder in acetonitrile, 
presented in C.L. Painting PhD thesis,50 showed that at low temperature, up to 253 K, 
there are 4 separate resonances corresponding to the 4 phenyl protons, Ha, b, c and d 
(Figure 2.15 a)). By increasing the temperature, two main features are observed: i) 
the signals corresponding to phenylene protons Ha and c (and Hb and d) initially 
start to broaden (at 273 K, Figure 2.15 b)), then they flatten out (Figure 2.15 c)) and 
they coalesce in one broad  band at room temperature until they become one single 
sharp doublet at 338 K (Figure 2.15 d)); ii) starting from ~300 K all the pyridine and
            Hi   H3H4          H5    H6/Hph       Hph           Hph         Hph 
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Figure 2.16. Chemical shifts (ppm) in function of the temperature (K) for each 
aromatic proton of [Fe2L13](PF6)4 in CD3CN. Hi and H6 (red and pink curves 
respectively) exhibits the higher shift effect starting from 300 K. 
 
 
imine proton peaks shift, but this effect is particularly significant for the Hi and H6 
protons, which are the closest protons to the two nitrogen responsible for the 
coordination. This is more evident in the graph in Figure 2.16 where chemical shifts 
versus temperature are reported for all the aromatic protons. In C.L. Painting PhD 
thesis, it was already suggested that these effects (the behaviour of the phenyl rings 
and the shift of Hi and H6) might have two distinct causes, although both temperature 
depending, and herein this is further confirmed with additional experiments. 
The behaviour of the phenylene protons is the result of a typical environmental 
exchange. Due to the involvement in face-edge π interactions (see X-ray structure 
Figure 2.12 b and c)), the two edges of the aryl rings are in two different 
environments (only one of two opposite edges point at the face of another ring). 
Consequently Ha and c and (Hb and d) are not each other equivalent as they are in 
the free ligand L1 or in the spacer. At low temperature the phenylene rings rotate 
very slowly and the rate constant for the exchange Ha-Hc from one environment to 
the other is lower than the frequency difference of the proton resonances in the 
separate environments and the two protons appear with two single signals. When the 
temperature increases, the phenylene rings start to rotate more freely and the two 
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protons Ha-Hc (and Hb-Hd) start to exchange with a higher rate constant comparable 
with their frequency difference; the two signals coalesce in one broadened signal at a 
coalescence temperature (Tc) of ~284 K. On further warming the speed of the 
phenylene rings increases and at a certain temperature Ha and c (and Hb and d) 
exchange so fast that their resonance appear as one sharp signal. 
In this system the barriers to the phenylene rings spinning freely are (i) the π-
stacking interactions must be broken and (ii) steric effects that probably force the 
rings to spin concertedly (if the phenylenes spin randomly within the triple helix the 
protons would clash). Free energy of activation and rate of spinning at the 
coalescence temperature where estimated in different solvents:50,51 in CD3CN 
ΔG‡288= 55.0±0.4 kJ/mol and ΔG‡285=55.2±0.4 kJ/mol, k288=630±20 s-1 and 
k285=450±20 s-1; in CD3NO2 the value of Tc is the same for both peaks and ΔG‡294= 
56.6±0.4 kJ/mol and k294=540±20 s-1; in CD3OD ΔG‡294= 55.4±0.4 and  k294=450±20 
s-1 (peaks overlap with solvent peak, thus only one set of value could be calculate). 
These values would be on the very high side if they just represent breaking of a 
single π-stacking interaction within the system52 and this would seem to confirm that 
steric effects are also involved leading to concerted spinning.  
Herein, it was possible to assign the two doublets at 338 K to the correspondent 
Ha/c or Hb/d protons by a combination of HSQC and HMBC experiments at 340 K . 
In the HSQC spectrum (Figure 2.17 a)) the cross peak correspondent to the CH2 
proton, confirms that the carbon at 40.1 (i) is the CH2 carbon C1. The same spectrum 
(enlargement in Figure 2.17 b)) shows that the two carbon at 123.9 (ii) and 131.2 (iii) 
can be either C3 or C4 of the phenylene ring because each of them is correlated to 
one of the two phenylene protons. In the HMBC spectrum there are only two cross 
peaks relative to CH2 protons (Figure 2.17 c), although this technique reveals long 
range heteronuclear couplings with proton observation up to 5 bonds. Consequently 
the carbon at δ 143.8 (iv), which is not correlated to any phenylene protons in the 
HSQC spectrum, is C2 and the signal at δ 131.2 (iii) necessary correspond to C3. 
Returning to the HSQC spectrum (Figure 2.17 b)), since the carbon at 131.2 (iii) 
corresponds to C3, then the carbon at 123.9 (ii) is C4 and from the correlations in the 
same spectrum we can confirm that the proton at 7.03 is Hb/d and the proton at 5.50 
is the Ha/c at 340 K.  
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Figure 2.17. 2D NMR (500 MHz, 343 K) of [Fe2L13](PF6)4 in CD3CN: a) 
HSQC, b) enlargement from the HSQC in a) and c) HMBC. Carbon resonances 
significant for the discussion are: δ 40.1 (i), 123.5 (ii), 131.2 (iii), 143.8 (iv). 
 
 
In order to exclude any effect of complex degradation in acetonitrile at 
temperature close to acetonitrile boiling point, the 1H NMR spectrum of the complex 
was compared with the 1H NMR spectra of  the starting components (ligand L1, 
spacer and carboxaldehyde) at 340 K (Figure 2.18). It was observed that at this 
temperature there is no proton of the complex (Figure 2.18 d)) whose chemical shift 
coincides with any chemical shift of the protons from the starting materials (Figure 
2.18 a), b) and c)).  
In Table 2.1 all the chemical shifts of the complex and starting materials at 298 
and 340 K are compared. The data were extracted from the NMR spectra shown in 
Figure 2.14 and 2.18 and are consistent with the results presented by C.L. Painting
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Figure 2.18. 1H NMR (300 MHz, CD3CN, 340K) of a) 4,4'-methylenedianiline, 
b) 2-pyridine carboxaldehyde, c) Ligand L1 and d) [Fe2L13](PF6)4. In spectrum 
c), peaks marked with a red cross correspond to protons of the compounds 
deriving from ligand degradation at high temperature (4,4'-methylenedianiline 
and 2-pyridine carboxaldehyde).  
 
 
in her PhD thesis. The table highlights that the effect of protons shifting, as a 
consequence of the variation of temperature, concerns only the protons of the 
complex, whilst temperature does not affect the chemical shift of the protons of the 
starting compounds. 1H NMR spectrum of ligand L1 (Figure 2.18 c)) presents, 
besides the protons of the ligand itself, also other peaks that correspond to both 4,4'-
methylenedianiline and 2-pyridine carboxaldehyde protons (marked with red crosses) 
as consequence of imine bonds of the ligand L1 breaking at high temperature. Also 
the presence of half ligand (where only one of the two imine bond is broken) cannot 
be excluded. The instability of ligand L1 at high temperature is expected, as well as 
the fact that it is significantly more stable when it is involved in the formation of the 
complex.  
These results (together with further UV-Vis thermal experiments described below  
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Compound 
(Temp. K) 
Hald 
(δ) 
Hi 
(δ) 
H3 
(δ) 
H4 
(δ) 
H5 
(δ) 
H6 
(δ) 
Hb/d 
(δ) 
Ha/d 
(δ) 
HCH2 
(δ) 
a) 
(298 K) 
      6.93 6.56 3.69 
a) 
(340 K) 
      6.92 6.57 3.70 
b) 
(298 K) 
10.03  8.80 7.95 
(overlapped)
7.63    
b) 
(340 K) 
10.05  8.80 7.95 
(overlapped)
7.61    
c) 
(298 K) 
 8.62 8.17 7.90 7.46 8.81 7.31 
(multiplet) 
4.06 
c) 
(340 K) 
 8.62 8.17 7.89 7.45 8.70 7.27 
(multiplet) 
4.07 
d) 
(298 K) 
 8.94 8.58 8.41 7.79 7.37 6.99 
(br) 
5.55 
(br) 
4.05 
d) 
(340 K) 
 9.90 8.83 8.38 8.04 7.96 7.00 5.50 4.18 
 
Table 2.1. Comparing chemical shifts of 1H NMR spectra (400 MHz, CD3CN) 
of a) 4,4'-methylenedianiline, b) 2-pyridine carboxaldehyde, c) Ligand L1 and 
d) [Fe2L13](PF6)4 at 298 K (blue) and 340 K (red). 
 
 
in section 2.3.4) suggest that in vt-NMR experiments (Figure 2.16) complex 
degradation is not involved and the behaviour of the phenylene protons is due to a 
typical environmental exchange, whose energetic barrier has been quantified. 
However, UV-Vis and CD experiments described below suggest that the 
temperature-depending shift of Hi and H6 is due to a distinct dynamic process that 
involves the two coordinating units of the helicate. 
 
2.3.4 UV-Vis and CD studies of [Fe2L13](PF6)4 in acetonitrile. 
 
The UV-vis spectrum of [Fe2L13](PF6)4 in acetonitrile (Figure 2.19) shows a band at 
572 nm due to MLCT transition and 3 more bands at 324, 277, 237 nm, due to 
electronic transitions in the ligand L1. Since the NMR thermal experiments evidence  
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Figure 2.19. UV-Vis spectrum [Fe2L13](PF6)4 in acetonitrile.  
 
 
that the increasing of the temperature affects the protons that are closest to the two 
coordinating sites, suggesting that alterations related to the metal centres and their 
coordination occur, we were particularly interested to observe the behaviour of the 
MLCT band in different temperatures. 
The thermal experiment in Figure 2.20 a) shows a linear decreasing of the 
absorbance at 572 nm of a 900 μM solution of the complex in acetonitrile, in 1 mm 
path length, when the temperature was raised from 5 to 78 °C in 1 °C/min rate (red 
circle). In the same experiment the temperature was then successively decreased 
from 78 to 5 °C with the same rate. The absorbance at 572 nm increases again, with 
exactly the same linearity, to reach exactly the same initial value at 5 °C. 
The concentration used in the experiment in Figure 2.20 a) is comparable with 
NMR experiment concentrations (around 1000 μM), but this behaviour is not 
concentration dependent, as showed in Figure 2.20 b), where the same experiment 
was carried out by using 50 μM complex solution in 1 cm path length and an 
analogous result was obtained. Individual scans of the complex in the whole UV-Vis 
region at different temperatures (Figure 2.21) confirm that upon increasing the 
temperature there are no new bands or other global spectral changes but only a linear 
decrease in magnitude of the absorbance at each maximum, and this process is 
reversible. This variation of the molar extinction coefficient ε at different
0
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Figure 2.20. UV-Vis thermal experiment of a) 900 μM (1 mm path length) and 
b) 50 μM  (1 cm path length) [Fe2L13](PF6)4 in acetonitrile. In both experiments 
the absorbance at 572 nm is monitored when temperature is raised from 5 to 78 
°C at 1 °C/min rate (red circle) and then decreased back to 5 °C at the same rate 
(blue square).  
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Figure 2.21. UV-Vis scans at 10 °C intervals of 75 μM [Fe2L13](PF6)4 in 
acetonitrile (1 cm path length) a) when temperature was increased from 5 to 75  
°C at 1 °C/min rate and b) decreased back to 5 °C at the same rate.  
 
 
 
temperatures seems more likely to be due to small dynamic variations inside the 
structure of the complex rather than destruction of the compound (because the 
variation is reversible) or changes of the spin state of the Fe (II) centres (since the 
NMR does not broaden as might be expected if high spin iron centres were resent). 
However, the process observed by UV-Vis spectroscopy is not necessary that leading  
a) 
b) 
a) b) 
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Figure 2.22. CD thermal experiments with 75 μM of M enantiomer of 
[Fe2L13](PF6)4 in acetonitrile (1 cm path length): a) temperature was increased 
from 5 to 75  °C at 1 °C/min rate and CD scans were recorded with intervals of 
10 °C; b) during the same experiment CD  absorbance at 596 nm was monitored 
when temperature was increasing (red circle) and decreased back to 5 °C at the 
same rate (blue square). 
 
 
to the chemical shifts in the NMR spectrum, since the linear variation in ε occurs 
between 5 at 70 °C, while the chemical shift effect only assets above 20 °C.  
One process that we thought possible and wished to investigate was an 
interchange between P and M configurations. To explore this circular dichroism 
(CD) spectroscopy has been employed. CD scans of a 75 μM solution of the M 
enantiomer of [Fe2L13](PF6)4 in acetonitrile at different temperatures (Figure 2.22 a)) 
show a loss of CD signal on increasing the temperature. The graph in Figure 2.22 b) 
(CD at 596 nm vs temperature) indicates an exponential type loss of signal and 
complete racemisation isobserved at 70 °C. The fact that the complex in acetonitrile 
racemises (as is evident from CD data) but it does not break apart (see UV-Vis and 
NMR experiments) suggests that it is thermodynamically stable but kinetically labile. 
To verify whether racemisation occurs only at highest temperatures, the CD signals 
of the M enantiomer of both PF6- and Cl- Fe(II) cylinders (in acetonitrile and water 
respectively) were monitored at room temperature over a 14 days period (Figure 
2.23). For each solution of complex in acetonitrile and water, both CD and UV-Vis 
spectra were recorded every 24-48 hours and the magnitude of CD absorbance at 596 
nm (which is the minimum of the band at higher wavelengths of the CD spectrum)
a) b) 
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Figure 2.23. CD absorbance at 596 nm (normalized from the corresponding 
UV-Vis absorbance at 572 nm) of [Fe2L13](PF6)4 (red circle) and [Fe2L13](Cl)4 
(blue triangle) in acetonitrile and water respectively as a function of the time.  
 
 
was divided by the magnitude of the corresponding UV-Vis absorbance at 572 nm 
(which is the maximum of the MLCT band) to normalise from any degradation 
effects. The graph in Figure 2.23 shows that the complex is enantiomerically stable 
in water at room temperature but in acetonitrile there is loss of ~50% of enantiomeric 
purity during the first 50 hours and then the CD signal remains approximately stable 
for the rest of the period over which it was observed. However, the thermal 
experiment described in Figure 2.22 is carried out over 2 hours (to go from 10 to 70 
°C), consequently contribution of kinetic instability in that experiment can be 
considered irrelevant. 
Interestingly, the loss of CD signal in Figure 2.22 becomes significant starting 
from ~40 °C and approximately at this temperature, in NMR experiments, the signals 
of Hi and H6 start significantly to shift to low fields (Figures 2.15 and 2.16). This 
might therefore be the same process observed in the NMR studies.     
Obviously, the racemisation of the triple helicate is a consequence of the inversion 
of the configuration of the two tris(chelate) Fe centres at higher temperatures. 
Several possible mechanisms that cause racemisation in mono nuclear tris(chelate) 
complexes have been described.53,54 One mechanism involves temporary but 
complete dissociation of one or more ligands, with formation of intermediate 
complexes where, in some case, the solvent is also involved. This type of mechanism 
occurs when the rate of dissociation of the complex is higher than the rate of 
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racemisation. Both NMR and UV-Vis thermal studies described above suggest that 
this is not occurring: if there is ligand exchange we would expect the chemical shifts 
of the phenyl protons at high temperature to be an average between their chemical 
shifts in the complex and the free ligand. Also there are no changes in the UV-Vis 
profile at high temperature (no new bands) and this does not support the possibility 
of ligand dissociation and/or formation of intermediates.  
Other mechanisms for mononuclear compounds are based on intramolecular 
pathways in which ligands interchange each other without bond rupture. At least four 
of these mechanisms, where the symmetry of the intermediates is allowed, have been 
identified (Figure 2.24 ).54  The “push through” and the “crossover” pathways are 
based on six coplanar ligands and four coplanar ligands transition states respectively. 
They both require large metal ligand bond stretches to relieve steric barriers and are 
energetically unfavourable. The other two mechanisms are known as Bailar twist55 
and Rây-Dutt56 twist and, since they require more modest bond stretches, they are 
believed to be the most frequent in intramolecular racemisation. The Rây-Dutt, also 
 
 
 
 
Figure 2.24. Four intramolecular mechanism for racemization of  a tris(chelate) 
octahedral compplex (R = reactant, T = transition state, P = product, figure 
taken from ref. 54). 
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known as the rhombic twist, involves rotating a trigonal face that is not associated 
with a threefold axis of the complex through a C2v transition state into its mirror 
image. With the Bailar twist pathway the complex twist about a threefold axis via the 
formation of a trigonal prismatic intermediate with D3h symmetry. Defining the bite b 
as the distance between donor atoms in the same chelating ligand and l as the 
distance between donor atoms on neighbouring chelate ligands, usually a rhombic 
twist is favoured when b is much greater the l; Bailar twist mostly occurs when b is 
smaller than l.  
The Fe(II) cylinder is a di-nuclear complex in which the metal centres of each 
enantiomer have specific configurations and reciprocal orientations defined by the 
rigidity and the orientation of each poly chelating ligand L1, and for this reason not 
all the intramolecular mechanisms are possible. Figure 2.25 a) shows the detail of the 
two tris(chelate) complex units (A and B) extracted from the X-ray structure of the 
M enatiomer. They both have Λ configuration and are in pseudo-parallel reciprocal 
orientation. Figure 2.25 b) shows the configuration of the two metal centres from the 
M enantiomer, and chelating units with their corresponding spacers are indicated 
with plain and dash lines respectively. Dash lines indicate how each spacer connects 
the imine nitrogens of two different chelating units that belong to the same ligand 
(for example dash green line represents the spacer that connect nitrogen 5 of complex 
A to nitrogen 2' of complex B). In the same way the P enantiomer is represented in 
Figure 2.25 d) (obviously the 2 metal centres have Δ configuration after 
racemisation). Because of the structure of the two enantiomer-helicates, the 
coordinating imine nitrogen 4, 5 and 6 of the metal centre A and the 1', 2' and 3' of 
metal centres B, must remain on the side of the metal centre that looks at the other 
metal centre. Only by Bailar twist mechanism this is possible in each phase of the 
racemisation event. Any other intramolecular mechanisms (among those described 
above) or a combination of them (supposing that the two complex units racemise 
with two different mechanisms) would require that one or more of the coordinating 
imine nitrogen ends pointing at the external edge of the cylinder, and this would be 
possible only with helicate rupture.  
Furthermore, comparing the Bailar twist and Rây-Dutt pathway for a single 
tris(chelate) units (Figure 2.26), only the former involves a rotation that is 
simultaneously equivalent for all the chelating units so that the racemisation process 
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Figure 2.25. a) two tris(chelate) Fe (II) centres (ΛΛ configuration) from the X-
ray structure of  the M enantiomer of the Fe(II) cylinder; in a), b), c) and d) the 
dash lines represent how each spacer connect each couple of chelating units 
(from the same ligand) between the two centres; b) representation of the 
configurations of the two metal centres of M enantiomer; c) possible transition 
state of the two metal centres in case of Bailar twist; d) representation of the 
configurations (ΔΔ) of the two metal centres of P enantiomer after Bailar twist 
racemization.  
 
 
influences equally all the protons neighbouring the coordinating nitrogens. This 
would be consistent with the mode in which Hi and H6 (next to N imine and N 
pyridine respectively) shift in vt NMR experiment. Thus an intramolecular 
racemisation of the helicate must likely proceed by a Bailar twist mechanism.
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Figure 2.26 Possible rcemisation of one tris(chelate) Fe centre by Bailar twist 
or Rây-Dutt twist are compared.  
 
 
2.3.5 UV-Vis and CD studies of [Fe2L13](Cl)4 in water. 
 
The previously described experiments investigated the stability of the compound 
in the coordinating solvent acetonitrile where temperatures below as well as above 
ambient can be explored. However, since the parent cylinders are designed for 
biological application we were interested to explore the perhaps more relevant 
stability and lability of the chloride salt of the Fe(II) cylinder, [Fe2L13](Cl)4, in 
water.  
An analogous thermal experiment is shown in Figure 2.27 a), carried out with 900 
μM [Fe2L13](Cl)4 in water with a 1 mm path length. As in acetonitrile, in this case 
the absorbance at 573 nm (this is the λmax of the complex in water for the MLCT 
band) decreases when the temperature is increased from 6 to 76 °C at 1°C/min rate 
(red circle) and returns to the same initial value when the temperature is decreased 
back to 6 °C (blue square), although this does not occur with the same linearity 
observed in the experiments in acetonitrile. In a different experiment (Figure 2.27 b)) 
if the temperature is raised up to 96 °C, then a dramatic decrease of the absorbance 
starts from ca 70 °C and, although the absorbance increases again when the sample is 
cooled down, it never reaches the same initial value. This suggests that, in these 
analogous concentration conditions, dynamic effects occur in water as in acetonitrile, 
but that degradation of the complex, most probably due to hydrolysis of imine bond
Bailar twist 
racemization 
Rây-Dutt twist 
racemization 
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Figure 2.27. UV-Vis thermal experiments with 900 μM (1 mm path length) 
[Fe2L13](Cl)4 in water. In both experiments the absorbance at 573 nm is 
monitored when temperature is a) increased from 6 to 76 °C and decreased from 
76 back to 6 °C at 1 °C/min rate and b) increased from 6 to 96 °C and decreased 
from 96 back to 6 °C at the same rate.  
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Figure 2.28. a) CD thermal experiments with 50 μM of M enatiomer 
[Fe2L13](Cl)4 in water (1 cm path length) temperature was increased from 10 to 
90  °C at 1 °C/min rate and CD scans were recorded with intervals of 10 °C. b) 
Plotting of CD magnitude at 596 nm (divided by the corresponding value of 
absorbance at λmax in MLCT band) as a function of temperature of M-
[Fe2L13](Cl)4 in water (from thermal experiment in Figure 2.28 a)) and M-
[Fe2L13](PF6)4 in acetonitrile (from thermal experiment in Figure 2.22 a)). 
 
 
a) b) 
a) b) 
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of the ligand, also occurs in water at high temperatures. 
CD scans of the M enantiomer of [Fe2L13](Cl)4 at different temperatures (Figure 
2.28.a)) confirm that the complex racemises in water when the temperature increases, 
whilst this does not occur if the complex is kept at room temperature (Figure 2.23). 
In Figure 2.28.b) the decrease magnitude of the CD signal at 596 nm as a function of 
the temperature for M-[Fe2L13](Cl)4 in water and M-[Fe2L13](PF6)4 in acetonitrile 
(from experiment shown in Figure 2.22 a)) are compared (CD values were 
normalised dividing by the corresponding values of absorbance at λmax in the MLCT 
band, to eliminate the effect of concentration and complex degradation). It seems that 
the complex racemises faster in acetonitrile than in water when temperature is 
increased, but also at room temperature, the complex in acetonitrile shows higher 
lability (Figure 2.23). This could be related to the solvent itself or to the counter 
anion or a combination of the two factors. At lower concentrations of complex in 
water, the effect of degradation increases; at 50 μM concentration all the complex is 
destroyed at high temperature (Figure 2.29 a).  
DNA binding properties of racemic (rac) [Fe2L13](Cl)4 (described above) have 
been already reported in several publications, and the better binding ability of M 
enantiomer over P enantiomer has been demonstrated, suggesting a role of the 
chirality of the triple helicates in their DNA binding properties. The ability of the 
complex to stabilise DNA by increasing DNA melting temperature (Tm) beyond 100 
°C has also been reported.57 It was interesting to verify whether (vice versa) ct-DNA 
also stabilises the complex in water from racemisation/degradation. Figure 2.29.b) 
shows the variation of UV-vis absorbance at λmax of the MLCT band as a function of 
the temperature for M, P and rac-[Fe2L13](Cl)4 (50 μM in 1 mM sodium cacodylate 
and 20 mM sodium chloride) in the presence of ct-DNA. A concentration of 5 bp of 
DNA per cylinder was selected as the cylinder can fit across ~5 base pairs. For all the 
DNA-complex adducts, the absorbance decreased when the temperature was raised 
from 6 to 96 °C (red empty circles) at 1 °C/min rate. But starting from 70 °C there is 
a dramatic drop in absorbance for the P-[Fe2L13](Cl)4-DNA adduct only. This effect 
is not so remarkable for the M-[Fe2L13](Cl)4-DNA adduct whose absorbance 
decreases the least at the end of the experiment. The rac-[Fe2L13](Cl)4-DNA adduct 
is half way in between the P and M values, indicating that is a sum of its P and M 
component effects. When the samples were cooled down at the same rate (blue plain 
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Figure 2.29. Uv-vis thermal experiments in 1 mM sodium cacodylate and 20 
mM sodium chloride in which absorbance at λmax of MLCT band (573 nm if 
only complex and 575 nm for complex-ct-DNA adduct) is monitored during 
increase of temperature from 6 to 96 °C (red markers) and decreasing from 96 
back to 6 °C (blue markers) at 1 °C/min rate. a) 50 μM rac-[Fe2L13](Cl)4 only; 
b) ct-DNA (5 times excess in bp) in the presence of M (circles), rac (triangles) 
and P (turbots) -[Fe2L13](Cl)4.  
 
 
markers), the absorbance of both rac and M-[Fe2L13](Cl)4-DNA adducts slightly re-
increased, although not reaching the initial values. The experiment suggests that the 
degradation is ~34% for M-[Fe2L13](Cl)4 and ~67% for the rac, whilst the 
absorbance of the P-[Fe2L13](Cl)4-DNA adduct is completely lost. These results, 
compared with the graph in Figure 2.29.a) suggest that the DNA can in part “protect” 
the M-Fe cylinder from degradation at high temperature, but not the P enantiomer, 
whilst for rac-cylinder there is an average result between M and P. This is consistent 
with the known higher DNA binding affinity of M enantiomer but may also point to 
different binding modes.  
The ability of ct-DNA to “protect” each enantiomer from racemisation has also 
been investigated. Figure 2.30.a) shows CD scans of M-[Fe2L13](Cl)4/ct-DNA (1/5) 
adducts at 10 °C intervals when temperature was raised from 10 to 90 °C in 1 °C/min 
rate (the graphs focus on the cylinder CD spectroscopy). The CD signal slightly 
decreases on increasing the temperature, but it is not completely lost as observed in
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Figure 2.30. CD thermal experiments with 250 mM ct-DNA in 1 mM sodium 
cacodylate and 20 mM sodium chloride of a) and b) 50 μM M enantiomer of 
[Fe2L13](Cl)4 in and c) and d) 50 μM M enantiomer of [Fe2L13](Cl)4. In a) and 
c) temperature was increased from 10 to 90 °C at 1 °C/min rate and CD scans 
were recorded at 10 °C intervals; b) and d) are referred to the same experiments 
when temperature was decreased back to 10 °C.  
 
 
the absence of DNA both in water and acetonitrile. At 90 °C the CD absorbance at 
598 nm decreased of ~35% and the CD signal remains constant when the 
temperature is decreased back to 10 °C (Figure 2.30.b)). In the same experiment UV-
Vis scans for each corresponding CD scan were recorded confirming a loss of ~34% 
of absorbance at 575 nm as in Figure 2.29.b) (data not shown). This indicates that the 
loss of CD signal in Figure 2.30.a) is due to complex decomposition rather than any 
configurational change into the M complex, suggesting that the binding to the DNA 
is such that the cylinder cannot freely racemise. As expected, the same experiment 
a) b) 
c) d) 
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with P-[Fe2L13](Cl)4/ct-DNA (1/5) adducts lead to complete loss of CD signal 
(Figure 2.30.c) and d), mainly due to the complete degradation of the complex, 
whose configuration is responsible of inferior binding affinity with DNA. 
 
2.4 Conclusions. 
 
The dynamic behaviour of Fe(II) parent cylinder has been investigated by NMR, 
CD and UV-Vis thermal experiments. The 1H NMR spectra at different temperatures 
of the PF6 complex in acetonitrile indicate that dynamic processes occur and these 
cause the coalescence of phenyl protons and the shifts of the protons (Hi and H6) that 
are adjacent to the two coordinating nitrogen atoms. Both the effects occur at ~35-40 
°C. The coalescence of phenyl protons is due to their reciprocal environmental 
exchange whilst the shift of Hi and H6 might be related to racemisation of the two 
tris(chelate) Fe(II) centres, as CD thermal experiments of the M enantiomer of the 
complex show that racemisation increases exponentially starting from ~40 °C. UV-
Vis and CD thermal experiments in acetonitrile, of the racemic complex and the M 
enantiomer, suggest that the complex is thermodynamically stable but kinetically 
labile, as there is not degradation (variations of temperature do not affect the UV-vis 
profile of the complex) but there is racemisation (the CD signal of the M enantiomer 
is lost as the temperature is increased). The complex is labile in acetonitrile also at 
room temperature. There is no evidence that the racemisation occurs with ligand 
dissociation or with the involvement of the solvent. An intramolecular mechanism of 
racemisation is implicit and the Bailar twist mechanism, involving both the metal 
centres, seems the only possible way in which the complex rearrangement can occur. 
UV-Vis and CD thermal experiments were performed also with the chloride 
complex in water. Similar dynamic behaviour, related to racemisation, was observed 
in water too, although the complex appears less labile in this solvent. However, a 
direct comparison concerning the influence of the two solvents is not possible since 
the complex is rather unstable in water at high temperatures. The CD and UV-Vis 
thermal experiments in water and in presence of ct-DNA show that DNA “protects” 
the complex from its degradation at high temperature and the M enantiomer from its 
racemisation. This protection effect is not as efficient for the P enantiomer, 
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confirming the different binding affinity and/or mode of the two enantiomers to the 
DNA. 
 
2.5 Experimental. 
 
2.5.1 Materials. 
 
All chemicals and solvents were purchased from Sigma-Aldrich, Fisher, Alfa 
Aesar, or Fluorochem and used as received. Deuterated solvents for NMR were 
supplied by Goss Scientific. Different solutions of rac, M and P- [Fe2L13](PF6)4 and 
[Fe2L13](Cl)4, in acetonitrile and water respectively, were prepared in the day of the 
experiment and the concentrations were measured spectroscopically by using the 
molar extinction coefficient of the complex at longer wavelength ε572=16900 mol-
1dm3cm-1. The ct-DNA (highly polymerised) was purchased from Sigma-Aldrich and 
it was dissolved in water (ultrapure 18.2 MΩ,  Fisher) without any further 
purification. Stock solutions of ct-DNA were kept frozen until the day of use. The 
DNA concentrations of those stocks were determined by UV-Vis measurements 
using the known molar extinction coefficient of ε259=6600 mol-1dm3cm-1 per DNA 
base pairs. Stock solutions of 1M NaCl and 100 mM sodium cacodylate buffer (pH 
6.8) were prepared and, together with ct-DNA and rac, M or P-[Fe2L13](Cl)4 stock 
solutions, were used to obtain final solutions of ct-DNA/complex at the required 
ratios, NaCl 10 mM and sodium cacodylate 1 mM.  
 
2.5.2 Synthesis of racemic Fe(II) cylinder. 
 
Ligand L1 and racemic [Fe2L13](Cl)4 and [Fe2L13](PF6)4 were synthesised 
according with the procedure previously described in literature24. Ligand L1 (3 eq) 
and iron (II) chloride (2 eq) were heated under reflux in methanol under dinitrogen 
for 2 hours. The resulting purple coloured solution was cooled and treated with 
saturated methanolic ammonium hexafluorophosphate. The purple precipitate of 
[Fe2L13](PF6)4 was isolated by filtration and abundantly washed with methanol.  
1NMR (CD3CN, 300 MHz, 298 K) δ 8.87 (1H, s, Hi), 8.51 (1H d, J=7.7 H3), 8.36 
(1H, t, J=7.7 Hz, H4), 7.72 (1H, t, J=7.7 Hz, H5) 7.31 (1H, d, J=4.8 Hz, H6), 6.90 
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(2H, br, Hb/d), 5.48 (2H, br, Ha/c),  3.99 (1H, s, HCH2). Mass spectrum (ESI): m/z 311 
[Fe2L13]4+ 100%, 421 [Fe2L3F]3+ 1%, [Fe2L3(PF6)]3+ 5%. 
 
Exchange of counter anion from PF6- to Cl- was obtained by treating 
[Fe2L13](PF6)4 with ion exchange resin (Dowex® 1X8 chloride form, 100-200 mesh, 
supplied by Sigma-Aldrich) in water. The resulting purple solution was freeze dried. 
1NMR (D2O, 300 MHz, 298 K) δ 8.89 (1H, s, Hi), 8.44 (1H d, J=7.7 H3), 8.27 (1H, t, 
J=7.72 Hz, H4), 7.58 (1H, t, J=6.66 Hz, H5) 7.27 (1H, d, J=5.5 Hz, H6), 7.1 (2H, br, 
Hb/d), 6.6 (2H, br, Ha/c),  3.89 (1H, s, HCH2). 
1NMR (CD3OH, 300 MHz, 298 K) δ 9.13 (1H, s, Hi), 8.67 (1H d, J=7.3 H3), 8.49 
(1H, td, J=1.1, 7.7 Hz, H4), 7.85 (1H, t, J=1.1, 7.3 Hz, H5) 7.43 (1H, d, J=5.2 Hz, H6), 
7.03 (2H, br, Hb/d), 5.58 (2H, br, Ha/c),  3.4.05 (1H, s, HCH2). 
 
2.5.3 Separation of enantiomers.  
 
Separation of M and P enantiomers of [Fe2L13](Cl)4 was obtained by using 
cellulose (20 mM from Aldrich) column eluted with 20 mM NaCl, as previously 
reported.47 After the first purple band (corresponding to M enantiomer) was 
collected, pressure was applied to the column to improve the elution of the second 
band. Both enantiomers were freeze dried and successively desalted by re-dissolving 
the complex in methanol and filtering off most of NaCl, followed by desalting with 
Sephadex G-10 (Aldrich) in water and further freeze drying. The UV-Vis and CD of 
each band were collected and since the CDmax/Absmax ratios (where CDmax and 
Absmax are the magnitudes of CD and UV-Vis absorbance respectively for each 
maximum in the spectra) corresponding to the two enantiomers are equal and 
opposites, the compounds were considered enantiomerically pure. M and P 
[Fe2L13](Cl)4 were dissolved in methanol and treated with saturated methanolic 
ammonium hexafluorophosphate, to exchange the counter anion, The precipitates 
were collected by filtration and, also in this case CD an UV-vis spectra in acetonitrile 
confirmed the presence of enantiomerically pure M and P- [Fe2L13](PF6)4.  
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2.5.4 Spectroscopy. 
 
NMR spectroscopy. 
300 and 500 MHz 1H NMR spectra were performed on Bruker AC 300 and DRX500 
spectrometers respectively. Coupling constants are given in Hz and multiplicities of 
the spectroscopic data are recorded as follows: s = singlet, d = doublet, dd = double 
doublet, t = triplet, q = quartet, dt= double triplet, br = broaden. 
 
UV-Vis spectroscopy. 
UV-Vis thermal experiments were run in a Varian Cary 5000 spectrophotometer with 
Cary temperature controller. 1 or 10 mm cuvettes were used depending on the 
concentration of the complex in each experiment. Variations of temperatures were 
always performed at 1 rate °C/min and adsorbance at the maximum wavelength 
(λmax) of the MLCT band (572 nm in acetonitrile, 573 and 575 nm in water, without 
and with ct-DNA respectively) of the complex was monitored. Before starting each 
thermal experiment, the samples were left 20 min in the machine at the starting 
temperature to allow the absorbance to stabilize. Cuvettes were always carefully 
sealed to avoid solvents evaporation at higher temperatures. 
  
Circular dichroism. 
CD thermal experiments were carried out in 10 mm pathlength cuvettes using a Jasco 
J-715 spectropolarimeter supported with Jasco PTC-423S temperature controller and 
RTE 111 bath circulator from Neslab. Variations of temperature were applied at 1 
°C/min rate and for each thermal experiment i) CD absorbance at 576 nm was read at 
2 °C intervals and ii) CD and UV-vis scans were collected simultaneously at 10 °C 
intervals. Holding time of 1 min was set up before each CD/UV-Vis scan. Final 
CD/UV-Vis scans were the results of 8 accumulation scans. Before starting each 
thermal experiment, the samples were left 20 min at the starting temperature to allow 
the absorbance to stabilize. Cuvettes were always carefully sealed to avoid solvents 
evaporation at higher temperatures. 
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CHAPTER 3 
 
END-FUNCTIONALISATION OF CYLINDERS: 
CONJUGATION WITH SHORT PEPTIDES AND 
AMINO ACIDS. 
 
3.1 Planning a second generation of metallo-supramolecular cylinders using 
bioconjugate chemistry technology.  
  
The technology of bioconjugate chemistry concerns the joining of two or more 
molecular entities with different functional and/or structural features, usually by 
linkages of covalent nature, to assembly hybrid systems for biological applications. 
In the last decades this has been a key approach in many fields of modern 
biotechnology and drug discovery because it allows the design and construction of 
systems with a combination of useful characteristics, to selectively interfere in 
biological events or to work as probes in organisms.  
Synthetic agents that exhibit the ability to interact with biomolecules and can 
potentially be employed as drugs, are not always able to circulate in biological 
systems and/or recognise specific targets. The diffusion and the delivery of drugs to 
specific targets is often achieved by conjugating the drug to appropriate carriers such 
as biomolecules (proteins1-3, glycoproteins, liposomes4), synthetic polymers (PNA5,6, 
dendrimers7,8) or biocompatible nano-materials (nanoparticles9,10, carbon 
nanotubes11,12). Dendrimers, well known highly branched synthetic polymers, are 
often used as scaffolds for the conjugation of a high number of molecules with a 
specific function. In the resulting system the function of the conjugated molecule is 
significantly amplified. For example, in the field of new vaccine design, the 
conjugation of antigenic peptides on the surface of dendritic structures allows a 
considerable increasing of the antigenic activity compared to that exhibited by 
systems in which the antigenic peptide is carried by proteins.13 
The technology of prodrugs is also widely investigated in medicinal chemistry 
and is based on the synthesis of substances that are administered in an inactive form. 
This inactive prodrug is delivered to the target and then metabolised in vivo (for 
example by selective enzymatic action) to release the active drug. The design and
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 synthesis of such systems is often achieved by conjugation methodologies. Beside 
drugs design, many other significant area of biotechnology, such as construction of  
biosensors14 and design of biomarkers for molecular imaging15, often depend on 
bioconjugate chemistry as strategy of assembling of the desired system. From a 
synthetic point of view, the conjugation is such to not compromise any of the 
chemical and/or biological and/or physical properties of the single elements that are 
intended to be joined.  
In the last decade this approach has also been employed in the field of DNA 
binding agents. In Chapter 1 the different modalities in which synthetic molecules 
interact with DNA have been described. Although many of these agents are 
particularly effective in interfering with the activity of DNA and in fact many drugs 
are based on this kind of action, there are not many examples of molecules that can 
recognise specific DNA sequences or genes. This is still a major issue in this field 
because many undesired side effects related to these drugs depend on their inability 
to target only those genes that are responsible for a certain disease, compromising the 
general functionality of the organism. Furthermore, the delivery of the drug-
molecules through the organism and the ability to penetrate cell membrane are also 
two aspects that, in some cases, limit the development of a DNA binder to an 
effective drug. The option of combining the action of known DNA binding agents 
with elements that can potentially discriminate different sequences of nucleic acids is 
very often investigated. Peptide sequences, oligonuclotides and most recently peptide 
nucleic acids are the synthetic motifs that are more frequently employed for this 
purpose, as it has been reviewed in Chapter 1.  
The remarkable results concerning metallo-supramolecular cylinders as potential 
anti-cancer drugs (widely described in Chapter 2), encouraged the idea of designing a 
second generation of cylinders based on their conjugation with elements that could 
somehow improve their characteristics and/or add new functions. Importantly, 
cylinders specifically recognise the DNA major groove and distinctive DNA 
structures such as three way junctions, but they do not present any significant 
binding affinity toward specific DNA base sequences as most of DNA binding 
agents. The conjugation of cylinders with DNA recognition motifs is one possible 
approach to improve their selectivity, as this method was successful for other DNA 
binding agents for different applications. 
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Figure 3.1. Parent bis-pyridylimine ligand L1 and L5. 
 
 
The work presented in this chapter and in Chapter 4, aimed to establish a versatile 
synthetic procedure, based on bioconjugate chemistry technology, to functionalise 
cylinders with amino acids and short peptides (as chosen DNA recognition motifs), 
investigate about the structural characteristics of the achieved compounds and verify 
whether the new hybrids retain the DNA binding properties and the cytotoxic activity 
of the unconjugated parent cylinders. In particular, the triple stranded Fe(II) cylinder 
[Fe2L13]4+ is the most exciting and well explained cylinder, for its unprecedented 
DNA binding properties and important biological activity,16-21 whilst the Cu(I) 
double stranded cylinder [Cu2L52]2+ exhibits interesting DNA cleavage activity22 
(ligands L1 and L5 in Figure 3.1) and this project focused on the end-
functionalisation of these two important types of bis-pyridylimine ligands based 
cylinders. 
 
3.2 First conjugated cylinders: design criteria and selection of amino acids. 
 
Two main aspects were considered for the design of the first conjugated cylinders: 
the choice of an appropriate site where the conjugating units could be attached to the 
cylinder with the most suitable synthetic procedure, and the selection of the amino 
acids to include in the conjugating units.   
Key features in the efficiency of cylinders as DNA binders are their specific shape 
and dimensions (which allow them to selectively target to DNA major groove and Y-
shaped junctions), the presence of aromatic rings on their surface (which form 
π−staking interactions with DNA bases) and the presence of positive charge (from 
the metals) that further promotes the binding with the negatively charged DNA. In 
addition, the Cu(I) centres are responsible of the artificial nuclease activity of double  
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1, table 1.2).27 Arginine is the amino acid involved most often in contacts both with 
DNA and RNA, because of the wide range of hydrogen bond patterns that it can 
form with nucleic acids. Moreover, the guanidinium group, the protonated form of 
guanidine side chain of arginine, is an excellent anion binding site because it remains 
protonated over an extremely wide pH range (pKa=13.5 for the parent CN3H6) and 
can participate in double hydrogen bonds with carboxylates, phosphate, sulphate 
etc.28 In fact, interactions between the ariginine guanidinium group and the 
phosphate backbone of nucleic acids are also very frequent; Frankel et al proposed a 
very interesting example known as “arginine fork”, to describe the mode in which 
the arginine-rich Tat protein from immune-deficiency virus (HIV) protein binds 
specifically to an RNA stem-loop structure named TAR (Figure 3.3).29,30 The 
proposed model suggested that the η and ε nitrogens from the same arginine residue 
of the Tat protein can form specific network of hydrogen bonds with different 
adjacent pairs of phosphates of the Tar region and that these arrangements are likely 
to occur near RNA loops and bulges and not within double-stranded A-form RNA. 
Thus, arginine side chains may be commonly used to recognise specific RNA 
structures. Arginine is also a very important amino acid in cellular uptake, since cell 
penetrating peptides (short peptides that facilitate the penetration of various 
molecular cargos inside cells) usually contain high abundance of positively charged 
  
 
                           
 
Figure 3.3. Model of “arginine fork” proposed by Frankel et al (A) possible hydrogen  
bonding configurations for arginines. There are five hydrogen bond donors on arginine 
and distances between possible acceptors positions are indicated. (B) One possible 
configuration of an “arginine fork” based on energy minimization calculation (Figure 
adapted from ref. 29). 
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lysine and arginine residues.31-35 This inspired the design of several drug molecules 
conjugated to arginine rich peptides to improve both cell uptake and water solubility. 
For example, Vásquez et al. demonstrated that distamycine tripyrrole analogues 
(which are well known AT reach minor groove binders) conjugated to an octa-
arginine peptide not only improve cell penetrating and nuclear localization but target 
A-rich DNA sites with high affinity in living HeLa cells.36 Serine is also one of the 
amino acids that are known to form interactions with DNA in natural system. It has a 
relative inert side chain that is desirable when designing the synthetic procedure to 
employ.  
On the basis of these observations three type of conjugating units to attach at the 
edges of the cylinder were chosen. The short tripeptide of sequence Gly-Gly-Ser was 
the first selected. The plan was to anchor the peptide via amide bond formation using 
its N-terminus, with the two glycine residues could provide a linker which would 
have minimal steric bulk between the cylinder core and the serine residue. 
Eventually, formation of hydrogen bonds between glycine residues, anchored to 
different ligands, could help to stabilise the final hybrid. The conjugation with single 
amino acids was also planned. The target was conjugating with serine residues, 
because studies comparing Gly-Gly-Ser-cylinder with Ser-cylinder conjugates could 
help to understand if the length of the conjugating unit had any influence on the 
stability and/or DNA binding activity of the hybrids. A further target was the 
conjugation with arginine residues, due to the importance of this amino acid both in 
natural DNA-protein contacts and in the design of synthetic drugs. 
 
3.3 Will the conjugation affect the chirality of cylinders? 
 
A further aspect in the designs of conjugated cylinders concerns the effect of the 
attachment of amino acids on the chirality of the hybrids. Achiral ligands that are 
employed for the assembly of helicates, usually yield a racemic mixture of 
complexes under equilibrium conditions. For example the symmetric pyridylimine 
based ligands L1 and L5 yield the mixture of left and right handed cylinder-helicates 
(Chapter 2 section 2.3.1). However, properly designed chiral polynucleating ligands, 
can stereospecifically form a single homochiral isomer complex. For example the 
incorporation of carbon stereocentres at the extremities of bis-bidentate ligands leads 
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Figure 3.4. L-valine substituted 5,5'-bipyridyl ligand 1 designed by Telfer et al. 
lead to diastereospecific formation of Δ-[M(1)3]n+ mono nuclear helicates with 
octahedral metals (Fe(II), Co(II), Co(III)). In the space filling structure 
representation chloride ions are shown in green and carboxylate oxigens in red 
(figure adapted from ref 37). 
 
 
to the exclusive (or partial) formation of one of the possible diastereoisomers of di-
nuclear double and triple stranded helicates, whose helicate handedness and metal 
configurations are enantiomerically pure. 
Telfer37 et al synthesised a valine 5,5'-substituted bipyridine ligand (Figure 3.4) 
that forms only Δ-M complexes diastereospecifically, with the L-valinate arms 
forming a chiral anion-binding pocket for chloride ions in the solid state. Tsang et 
al.38 demonstrated that the chiral pyridyl-thiazole ligand L (Figure 3.5) forms di-
cationic double stranded helicates with prevalence of P configuration.  
The interest in achieving enantiomerically pure helicates, avoiding complicated 
and not always successful procedures of enantiomers purification (mainly based on 
chromatographic or crystallographic methodologies), has led to the investigation of 
alternative strategies. Cozzi and Siegel developed a method in which achiral ligand 
strands can be anchored to a chiral template during the helicate assembly so that the 
enantiomericity of the helicate can be dictated by the configuration of the 
 
M (Fe(II), Co(II), Co(III)) 
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Figure 3.5. The chiral pyridyl thiazole ligand L by Tsang et al. yield 
diastereoselective formation of the P enantiomer of di copper(I) helicate figure 
taken from ref 38).  
 
 
 
     
 
 
 
Figure 3.6.  Raymond strategy: a) set of achiral bis-bidentate catecholate 
ligands and b) chiral cations (N-methyl-s-nicotinium (s-nic), N-methyl 
cinchoninium (cinc) and N-methyl quininium (quin)) investigated; c) crystal 
structure of the K(s-nic)5[Ga2L13] helicate (right) with the detail of the 
interaction between two catecholate rings and one s-nic ion (left and middle). 
Figure adapted from ref 39). 
 
 
[Cu(CH3CN)4PF6] 
c) 
a) 
b) 
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template.40,41 Raymond et al.39 studied how the chirality of negatively charged di-
gallium(III) triple helicates, based on achiral bis-bidentate catecholate ligands, is 
influenced by the presence of chiral cations (Figure 3.6). This influence depends on 
van der Waals and cation-π interactions between the helicate and the chiral cations. 
Chiral induction via interaction with asymmetric ion pairing has been reviewed by 
Lacour et al.42,43 Despite alternative methods, the covalent integration of chiral 
auxiliary on the ligand, to influence the chirality of the supramolecular assembly, is 
the most explored approach to achieve diasteroisomerically pure (completely or 
partially pure) assemblies.44-48  
In the same way the attachment of amino acids at the extremities of the parent bis 
pyridylimine ligands could not only influence the DNA binding activity of the 
cylinders, but also affect their chirality. The conjugation of serine and arginine in 
both their configurations (D and L) would allow this to be probed. 
 
3.4 Synthesis and characterisation of conjugated cylinders. 
 
The strategy applied for the synthesis of end-conjugated cylinders is showed in 
Figures 3.7 and 3.8. Compound (4) in Figure 3.7 represents a growing peptide chain 
on the resin of a standard solid phase peptide synthesis with Fmoc chemistry,49-51 
where R is any of the conjugating units designed (the tripeptide Gly-Gly-L-Ser or 
one of the amino acids D or L-Ser and D or L-Arg). 6-Dimethoxymethyl-nicotinic 
acid (3), synthesised according to previously reported procedures,52 presents a 
carboxylic group at the 5 position of the pyridine ring that can form an amide bond 
with the terminal amino group of the tripeptide (or amino acid) directly on the resin. 
In this way the desired conjugating unit was attached to the 5 position of the pyridine 
ring with high yield (a Kaiser Test53 was performed to verify the completeness of the 
coupling reaction) and avoiding complicated purification steps for the coupling 
reaction in solution. Following cleavage from the resin, deprotection and purification 
by RP-HPLC, 2-formyl-5-R-pyridine (7-a, b, c, d, e) proved a good precursor for the 
synthesis of end-functionalised pyridylimine based ligands as they can form Schiff 
bases with different diamine spacers. The carboxylic groups of the conjugating units 
were ‘protected’ by carboxy amidation both to avoid the eventual competition of 
carboxylic oxygen in metal coordination and because the presence of negative  
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2-formyl-5-R-pyridine  
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Scheme of synthesis of precursor 2-formyl-5-R-pyridine; (i) I2 
/DMSO, (ii) CH(OCH3)3, HCOOH, H2SO4, (iii) 1M NaOH in MeOH, (iv) 
HBTU, DIEA, (v) 95% TFA, 2.5% Water, 2.5% TIS, (vi) 1M HCl in THF, 6 
days.  
 
 
charges on the final hybrids would not have favourable influence on DNA binding. 
For the synthesis of the conjugated complexes two routes were possible (Figure 3.8). 
One way consisted in the synthesis of the end-conjugated ligands LR1 and LR2 by 
reaction of (7) with 4,4'-methylenedianiline (8) or 4,4'-methylenbis (2,6-
diethylaniline) (9) respectively (routes (vii) and (viii) plain black arrows), followed 
by reaction with the appropriate metal salt. Although the formation of ligands was 
always possible, only the Gly-Gly-Ser conjugated ligands La1 and La2 were 
achieved pure. This happened because pyridylimine based ligands, both parents and 
conjugates, are relatively unstable. It is not possible to purify them by standard
        
                                                                   R: 
 
      Gly-Gly-L-Ser  (a)                                  L-Ser (b)                         L-Arg (d)               
 
                                                                    
 
                                                                 D-Ser (c)                        D-Arg (e)                  
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Figure 3.8. Scheme of synthesis of conjugated cylinders. Starting from 
precursor (7) two routes were designed: synthesis of the Ligands LR1 and LR2 
((vii) and (viii), black plain arrows) from which the complexes are obtained by 
reaction with appropriate metal salts, and the ‘one pot’ synthesis ((ix) and (x), 
dashed red arrows) where the complexes are achieved directly by reaction of 
(7), the spacers ((8) or (9)) and the desired metal salt in the same mix. (vii) and 
(vii) reflux MeOH. (ix) and (x) nitrogen atmosphere and different solvents and 
temperature conditions depending on the metal ion. 
 
 
 
chromatographic techniques and the best way to obtain them pure is by precipitation 
and washing. Ligands La1 and La2 are soluble only in DMSO, thus they were 
purified by combining washings with methanol and water (in which the starting 
materials were soluble). This was not possible with the other conjugated ligands for 
which a combination of solvents able to wash off only the starting materials or either 
a procedure of re-crystallisation was not found. However, the synthesis of the ligands 
is important but not essential, and all the complexes could be achieved using the ‘one 
pot synthesis’ ((ix) and (x), red dashed lines in Figure 3.8) in which the precursor (7-
a, b, c, d, e), the chosen spacer ((8) or (9)) and the appropriate metal salt reacted in 
one mix to afford the desired complexes, skipping the ligand synthesis and 
purification step. It is known that sometimes, in metallo-supramolecular assembly, 
N
O
O
H
(7-a, b, c, d, e)
N
O
NN
N
O
NH-R-CONH2
NH2H2N
N
O
NN
N
O
NH2H2N
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(8)
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[Cu2LR22]
m+ X-
2+ Cl-
R = (a) Gly-Gly-L-Ser
(b) L-Ser, (c) D-Ser
(d) L-Arg, (e) D-Arg
M = Fe, Cu, Ag.
X = Cl, PF6
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NH2CO-R-NH
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NH2CO-R-NH NH-R-CONH2
n = 2 if M is Cu or Ag
3 if M is Fe
m = 2 if M is Cu or Ag and R is not Arg
4 if M is Fe and R is not Arg
10 if M is Fe and R is Arg
(ix) 
(x) 
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the presence of the metal “assists” the synthesis of the ligand in situ because it drives 
the equilibrium toward the formation of the final architecture. The complexes 
obtained were purified by washing and/or re-crystallisation.   
Figure 3.9 shows the list of conjugated cylinders that have been purified and 
characterised: 5 Fe(II) triple stranded cylinders conjugated with Gly-Gly-L-Ser, L-
Ser, D-Ser, L-Arg and D-Arg ([Fe2(La1)3]4+, [Fe2(Lb1)3]4+, [Fe2(Lc1)3]4+, 
[Fe2(Ld1)3]10+ and [Fe2(Le1)3]10+), 4 Cu(I) double stranded cylinders conjugated with 
Gly-Gly-L-Ser, L-Ser, D-Ser ([Cu2(La1)2]2+, [Cu2(La2)2]2+, [Cu2(Lb2)2]2+ and 
[Cu2(Lc2)2]2+) and 1 Ag(I) double stranded cylinder conjugated with Gly-Gly-L-Ser 
(Ag2(La1)2]2+). Several attempts of synthesis of the double stranded Cu(I) cylinder 
conjugated to arginine residues were unsuccessful most probably because other 
chelating units of the ligand competed with the bispyridylimine units in the 
coordination of the Cu(I) ions. Furthermore, the Ag(I) cylinder (Ag2(La1)2]2+) was 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. List of synthesised complexes (right) and the corresponding ligands 
(left). 
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Double stranded cylinders 
[Cu2(La1)2]2+ and  [Ag2(La1)2]2+ 
 
Triple stranded cylinder 
[Fe2(La1)3]4+ 
 
Double stranded cylinders 
[Cu2(La2)2]2+  
 
Triple stranded cylinders 
[Fe2(Lb1)3]4+, [Fe2(Lc1)3]4+, 
[Fe2(Ld1)3]10+ and [Fe2(Le1)3]10+ 
Double stranded cylinders 
[Cu2(Lb2)2]2+ and [Cu2(Lc2)2]2+ 
 
Ligands                                            Complexes 
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isolated only as PF6 salt which is not soluble in water so this complex was not 
employed in subsequent DNA binding studies. All the compounds were characterised 
by mass spectrometry and 1H NMR spectroscopy with the support of COSY 
experiments for the assignment of the resonances (see Appendix A). Despite many 
attempts of crystallisation no crystals big enough for X-ray characterisation were 
obtained. It was not possible to obtain accurate elemental analysis data because the 
compounds are very hygroscopic and molecules of water interfered with the 
interpretation of the results. In general the compounds are not very stable in water 
(see Chapter 4, section 4.1). Ser-conjugates are the more stable complexes, but by 
NMR in water there is always a very small amount of hydrolysis products observed. 
For this reason controls with starting materials were always carried out for all DNA 
binding studies and cytotoxicity tests, to ensure that the activity observed was not 
due to hydrolysis products. Mass spectrometry (both ESI-MS and MALDI) was 
unsuccessful for arginine conjugates because of their charge and instability, although 
NMR and UV-Vis spectroscopy were perfectly consistent with the expected 
compound. 
All the triple stranded Fe(II) conjugated cylinders in water present the same UV-
Vis profile both in the MLCT region and in the ligand region of the spectrum (Figure 
3.10). The MLCT band of the conjugates present a λmax at 599 nm in water whilst the 
λmax of the parent Fe(II) cylinder in the MLCT region is at 572 nm.  Analogously all 
the Cu(I) conjugates have the same profile in the visible region the MLCT band 
present a shift of 25 nm at higher wavelength compared to the uncojugated Cu(I) 
complex. This suggests that all the conjugated cylinders present the same central di-
metallic core (the helicate) and, compared to the corresponding parent cylinders, the 
presence of the amide group at the 5 position of the pyridine rings causes a shift at 
higher wavelengths of the λmax of both the MLCT band and the bands where the 
bispyridylimine ligands absorb.  
Further useful information was obtained from 1H NMR data. All the spectra of the 
conjugated cylinders exhibit one single set of signals, indicating that the conjugation 
did not disturb the symmetry that is typical for these metallo-supramolecular 
architectures. Table 3.1 reports the chemical shifts of the protons of the central 
cylinder core (the pyridine H6py, H3py and H4py, the imine H7 and the spacer methyl 
H11 protons) for the Fe(II) and Cu(I) conjugated cylinders in water and acetonitrile
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respectively. The corresponding resonances of the parent unconjugated cylinders and  
the ligand La1 are reported too. All the conjugated Fe(II) cylinders present the same 
values of chemical shifts for the protons indicated: the imine proton H7 at low fields 
(at 9.0 ppm), the two pyridine protons H4py and H3py almost overlapping each other, 
the pyridine proton H6py at 7.5 ppm and the proton of the spacer H11 at 4.0 ppm. This 
would indicate that all the conjugated Fe(II) cylinders keep the same architecture for 
the central helicate core, independently of the type or the length of the attached 
peptide. Comparing the chemical shifts of the protons of Fe(II) conjugates and Fe(II) 
parent cylinder, we cannot expect exactly the same set of signals for the pyridine 
regions, because of the presence of the amide groups in 5 position of the conjugated 
ligands. However, imine H7 and pyridine H6py protons, neighbouring the two 
coordinating nitrogens, have similar chemical shifts in conjugated and unconjugated 
complexes. Most importantly, comparing the NMR spectra of the free parent ligand 
L1 with the Fe(II) parent cylinder, a typical high field shift of the H6py proton 
occurred as consequence of the neighbour pyridine nitrogen coordination (see 
Chapter 2, section 2.3.2). An analogous effect occurs for the H6py proton of any 
Fe(II) conjugated cylinder. Finally, the signals corresponding to the phenyl protons 
of any Fe(II) conjugate are broad bands exactly as it has been described for the 
parent cylinder in Chapter 2. These results confirm that the conjugated complexes 
present a central helicate core with the same symmetry observed for the 
unconjugated helicates and imine and pyridine nitrogens are again responsible for the 
coordination of the Fe(II) centres. UV-Vis and NMR spectroscopy indicate that all 
the Fe(II) conjugated cylinders have a central cylinder core with the same 
architecture. Moreover, the presence of amino acids of opposite configuration (D or 
L) does not influence the 1H NMR spectrum, as [Fe2(Lb1)3]4+ and [Fe2(Lc1)3]4+ 
exhibit exactly the same set of signals, both for the protons of the cylinder core and 
the protons from the conjugated amino acids. Equally, [Fe2(Ld1)3]10+ and 
[Fe2(Le1)3]10+ have precisely the same 1H NMR  spectra. Analogous results were 
obtained for the Cu(I) complexes: they all present the same set of signals by 1H NMR 
for the central cylinder core and D and L-Ser conjugates exhibits identical spectra.  
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3.5 Chirality of conjugated cylinders. CD studies. 
 
CD scans of the conjugated cylinder were undertaken to explore whether the 
presence of the stereocenter Cα of the amino acids at the edges of the cylinder 
influenced the handedness of the central helicate, by promoting partial or total 
formation of one of the two possible diasteroisomers.  
The two opposite CD spectra of M and P enantiomer of parent Fe(II) cylinder 
([Fe2(L1)3]4+ ), whose characteristics are widely discussed in Chapter 2, are shown 
again in Figure 3.11.a) to be compared with the CD spectra of D and L-Arg 
conjugated Fe(II) cylinders ([Fe2(Ld1)3]10+  and [Fe2(Le1)3]10+ respectively) in Figure 
3.11.b). The CD signals of two solutions of the arginine-conjugates in water (Cl- as 
counter anion) are precisely the opposite of each other, and their shape correspond 
strictly to the signals of the enantiomers of the Fe(II) unconjugated cylinder, both in 
the MLCT and in the ligand region of the spectra. These CD signals in the visible 
region can only be due to the cylinder core of the conjugates and this suggests that 
the cylinder core of [Fe2(Ld1)3]10+ is a P triple helicate whilst the centre of 
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Figure 3.11. CD spectra of a) M and P enatiomers of parent Fe(II) cylinder in 
water ([Fe2(L1)3]4+) and b) L and D-Arg conjugated Fe(II) cylinders 
([Fe2(Ld1)3]10+ and [Fe2(Le1)3]10+ respectively) both PF6- salt in acetonitrile and 
Cl- salt in water. All the solutions of conjugated complexes have the same UV-
Vis absorbance magnitude at the MLCT band. 
 
a) 
b) 
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([Fe2(Le1)3]10+ is the opposite enantiomer, an M triple helicate. This result indicates 
that the conjugation of two arginine residues at the 5 positions of the pyridine rings 
of the bis-pyridylimine ligands, promotes the formation of one specific 
diasteroisomer of the resulting hybrid cylinder which depend on the configuration of 
the Cα of the arginine. Consequently the handedness of the central helicate core is 
also influenced and the CD spectra indicate that the conjugation with D-arginine 
induces formation of M helicate and the L-arginine promotes the P helicate.  
The CD signals of the PF6- complexes in acetonitrile (at the same concentrations) 
are also equal and opposite, as shown in Figure 3.11 b). The four solutions shown in 
CD graph had the same concentrations and they all presented the same value of 
absorbance at 599 nm (λmax of MLCT band) by UV-vis analysis, but the CD 
magnitude of each band is higher for the PF6- complexes in acetonitrile than the 
chloride complexes in water. This effect was not observed for the Fe(II) parent 
cylinder where CD bands of the separated enantiomers always keep the same 
magnitude, independent of the counter anion or the solvent that was used. This could 
suggest a possible role of the counter anion, rather than the solvent, in the induction 
of one specific helicate. The interactions that the PF6- anions form with the complex 
might stabilise the formation of one specific helicate better than the interactions of 
Cl-, so that the diasteroisomeric purity of PF6- complexes is superior. Since this effect 
depends on the configuration of the arginine residues conjugated at the extremities of 
the helicate, it is possible that these interactions involve either the amino acid 
backbones or the positively charged side chains of the arginine residues, as in the 
helicate reported by Telfer (Figure 3.4). 
The CD analysis of the Fe(II) serine conjugates was more ambiguous. The CD 
profile in acetonitrile of [Fe2(Lb1)3](PF6)4 and [Fe2(Lc1)3] (PF6)4  is comparable with 
the CD signal of the two arginine conjugates (Figure 3.12) although the connection 
with the Cα configuration of the linked amino acid is inverted: it seems that the L-
Ser induces M enantiomericity to the central helicate core whilst D-Ser promotes P. 
However, when the counter anion is exchanged to chloride and the analysis carried 
out in water, this typical profile is lost and CD signals are present but difficult to 
interpret. No CD signal was observed for the tripeptide Fe(II) cylinder conjugate 
([Fe2(La1)3]4+), possibly because the L-Serine residues are too distant from the 
helicate core to affect its handedness.  
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The tripeptide Cu(I) conjugate, [Cu2(La1)2]2+ did not exhibit any CD signal whilst 
the CD spectrum of [Cu2(La2)2]2+ presented very distinctive bands (Figure 3.13), 
both in the MLCT and in the ligand region. It is unclear why the later complex 
should be more sensitive to the presence of the serine groups. It is known that the 
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Figure 3.12. L and D-Ser conjugated Fe(II) cylinders ([Fe2(Lb1)3]4+ and 
[Fe2(Lc1)3]4+ respectively) both PF6- salt in acetonitrile and Cl- salt in water. All 
the solutions of conjugated complexes have the same UV-Vis absorbance 
magnitude at the MLCT band. 
 
-10
-5
0
5
10
15
200 300 400 500 600 700
5
7.5
10
15
20
30
40
C
D
/m
de
g
Wavelength (nm)  
Figure 3.13. CD spectra of different concentrations (in μM in the legend) of 
Gly-Gly-Ser Cu(I) double stranded conjugate [Cu2(La2)2]2+ in water. The 
MLCT region (750-350 nm) was analysed in 1 cm cuvette and the UV region 
(350-200 nm) in 0.1 cm cuvette. 
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unconjugated ligand L1 with Cu(I) forms a mix of helicate and box isomers (Chapter 
2, section 2.2.2), and this was proved by 1H NMR spectroscopy in which two types 
of signals corresponding to the methyl proton of the central spacer were present (a 
singlet for the helicate and a doublet for the box isomer). The analogous proton of 
the conjugate complexes could not be properly observed because the corresponding 
signal is usually overlapped with the signals of the peptide protons. Consequently it 
was not possible to establish whether the two isomers are present and eventually if 
this is related to the absence of CD signal for this complex. Furthermore, the two D 
and L-serine Cu(I) conjugates [Cu2(Lb2)2]2+ and [Cu2(Lc2)2]2+ do not have CD signal 
either, which made more complicated an interpretation about the role that the type of 
spacer or the length of the conjugating unit had in affecting the handedness of the 
central helicate of Cu(I) conjugates. 
 
3.6 NMR studies with Δ-TRISPHAT. Comparing D and L-Arg conjugated Fe(II) 
cylinders  with the parent Fe(II) cylinder. 
 
3.6.1 Fe(II) parent cylinder and Δ-TRISPHAT. 
 
CD studies revealed that only the conjugation with arginine residues produced an 
unambiguous effect on the chirality of the Fe(II) triple helicate. NMR studies of 
([Fe2(Ld1)3]10+ and [Fe2(Le1)3]10+ in the presence of a chiral NMR shift reagent for 
cationic coordination complexes could provide further information about the 
diasteroisomeric purity of the two complexes and the chirality of the helicate core. 
Lacour and co-workers proposed the use of the now popular chiral anion 
tris(tetrachlorobenzenediolato) phosphate(V) (TRISPHAT,) Figure 3.14) as a chiral 
NMR shift reagent after they were able to separate the Λ and Δ-TRISPHAT 
isomers.54-56 Now the tetrabutylammonium salt of Δ-TRISPHAT is commercially 
available and it has been demonstrated that one specific isomer of TRISPHAT can 
preferentially bind to specific isomers of mono and di-nuclear coordination 
complexes causing distinctive NMR chemical shifts of the protons involved in the 
interaction.57-59 Moreover, TRISPHAT can be used to resolve racemic mixture of 
complexes by selective extraction and crystallisation60,61 or as chiral component of 
eluents for chromatographic resolution.62  
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Figure 3.14. Δ-TRISPHAT, [Tetrabutylammonium][Δ-tris(tetrachloro-1,2-
benzenediolato) phosphate(V)] 
 
TRISPHAT showed to be particularly effective in interacting differently with 
opposite enantiomers of metallo-supramolecular helicates.60 For this reason NMR 
studies of Fe(II) parent cylinder in the presence of TRISPHAT were previously 
carried out in Hannon group by C.R. Pearmund as part of his PhD thesis project.63 
He demonstrated that the addition of Λ-TRISPHAT anion to an acetonitrile solution 
of racemic Fe(II) triple helicate cylinder ([Fe2(L1)3]4+) resulted in the splitting of 
some of the resonances to give two identical set of signals, suggesting that the anion 
interacts differently with each enantiomer. The splitting mainly involved the protons 
nearest the pyridyl and the imine coordinating nitrogens and the methyl proton of the 
central spacer, suggesting that these were the preferred area of interaction with the 
chiral anion.  
A similar experiment was herein repeated by using 2 equivalents of Δ-TRISPHAT 
added to a solution of racemic [Fe2(L1)3](PF6)4 in CD3CN (Figure 3.15).  To 
understand which of the two enantiomers interact with Δ-TRISPHAT, the same 
experiment was performed using an enantiomerically “impure” solution of the M 
enantiomer of [Fe2(L1)3](PF6)4; this solution contained mostly the M enantiomer, as 
revealed by its CD profile, but also a ~10% of P enantiomer as known impurity, so 
that the signals of each enantiomer could be identified in the NMR spectrum. The 
experiment (Figure 3.16) shows that the addition of Δ-TRISPHAT causes a shift of 
the methyl proton of the central spacer (H11) for the M enatiomer, whilst shifts of the 
imine and 6-pyridyl protons (H7 and H6 respectively) concern only the P enantiomer. 
This would suggest that both enantiomers interact with Δ-TRISPHAT, but while the 
contact with the P enantiomer concerns the coordination units of the helicate,
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Figure 3.15. 1H NMR (300 MHz, CD3CN, 298K) of (2) a racemic mixture of 
[Fe2(L1)3](PF6)4 and (1) the same complex solution to which 2 equivalents of Δ-
TRISPHAT were added. 
 
 
 
 
 
Figure 3.16. 1H NMR (300 MHz, CD3CN, 298K) of (2) a solution of the M 
enantiomer of   [Fe2(L1)3](PF6)4 containing  ~ 10% of the P enantiomer and (1) 
the same complex solution to which 2 equivalents of Δ-TRISPHAT were added. 
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Figure 3.18. a) CD scans in acetonitrile/methanol (8/1) of each precipitate and 
filtrate (P and F in the legend) collected and separated from each tube of the 
experiment in Figure 3.17. b) CD magnitudes (both filtrate and precipitate) at 
596 nm was divided by the corresponding value of UV-vis absorbance at 572 
nm and plotted in function of Δ-TRISPHAT/Fe2(L1)3](Cl)4 ratio 
 
 
whilst most of the P enantiomer stays in solution. However, adding more Δ-
TRISPHAT, the enantiomeric purity of the precipitate decreases, indicating that at 
some point also the P enantiomer-Δ-TRISPHAT adduct precipitates. The filtrate 
contains larger excess of P enantiomer when the addition of more Δ-TRISPHAT has 
promoted the precipitation of the M enantiomer. This study further confirms that the 
Δ-TRISPHAT binds differently to the two enantiomers in a way that the two adducts 
have different solubility in the solvent conditions investigated, and might form the 
basis for an alternative strategy to separate the two enantiomers (although the 
precipitation is not exclusively of one enantiomer and different conditions should be 
investigated). An initial experiment with a small amount of Λ-TRISPHAT that was 
available showed exactly the opposite result. 
 
3.6.2 Arginine conjugated Fe(II) cylinders and Δ-TRISPHAT. 
 
As the M and P enantiomer of the Fe(II) parent cylinder could be identified by 
NMR after their interaction with Δ-TRISPHAT, the same experiment was performed 
to study L and D-arginine  Fe(II) conjugated cylinders [Fe2(Ld1)3](PF6)10  and 
[Fe2(Le1)3](PF6)10. 1H NMR spectra of the two complexes in CD3CN are identical as 
a)            b) 
103 
 
shown in spectra (4) and (3) in Figure 3.19, where the signals corresponding to the 
protons of the arginine conjugating units are marked with red crosses. The addition 
of Δ-TRISPHAT (2 equivalents) causes shifts of the imine and 6-pyridyl protons (H7 
and H6) in the L-arginine conjugate [Fe2(Ld1)3](PF6)10 (Figure 3.19 (2)) and only the 
shift of the methyl proton of the central spacer H11 in the D-arginine conjugate 
[Fe2(Le1)3](PF6)10  (Figure 3.19 (1)). This is exactly the same effect observed for the 
two enantiomers of Fe(II) parent cylinder and confirms that the helicate centres of L 
and D arginine conjugates are respectively in P and M configuration, as suggested by  
 
 
 
 
Figure 3.19. 1H NMR (300 MHz, CD3CN, 298K) of (4) [Fe2(Ld1)3](PF6)10 (L-
Arg conjugate), (3) [Fe2(Le1)3](PF6)10 (D-Arg conjugate), (2) the same solution 
of [Fe2(Ld1)3](PF6)10 with 2 equivalents of Δ-TRISPHAT and (1) the same 
solution of [Fe2(Le1)3](PF6)10 with 2 equivalents of Δ-TRISPHAT. The signals 
marked with a red cross correspond to protons from the arginine conjugating 
units. 
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CD spectroscopy. The protons of the side conjugating units are not affected by the 
presence of Δ-TRISPHAT, despite the presence of the positive charged side chains of 
the arginine residues.  This could be because these protons are too distant to be 
affected in the NMR spectrum by the eventual interaction between the guanidinium 
group and the TRISPHAT, or this interaction simply does not occur, possibly 
because prevented by the presence of PF6- anions. But it is evident that the central 
helicate cores of the conjugates are free to interact with the Δ-TRISPHAT as the 
unconjugate enantiomers do. Interestingly, for each NMR spectrum of conjugate-Δ-
TRISPHAT there is only one set of signals which prove that the two conjugates in 
acetonitrile are diastereoisomerically pure.     
 
3.7 Conclusions. 
 
Synthetic routes to allow amino acids and short peptides to be conjugated onto the 
cylinder structure were established herein. The approach is flexible and based on 
amide bond formation between the conjugating unit and the 5 position of the pyridine 
rings of the parent bis-pyridylimine ligands (L1 or L5), so that the final complex 
hybrid of general formula M2Ln holds 2n conjugating units. The synthesised and 
characterised conjugates were: five Fe(II) triple stranded, one Cu(I) double stranded 
and one Ag(I) double stranded  based on the ligand L1 and three Cu(I) double 
stranded based on the ligand L5. 1H NMR and UV-Vis studies suggested that the 
anchored amino acid residues at the edge of the cylinder do not prevent the formation 
of the central cylinder core, in which imine and pyridine nitrogen are responsible for 
the coordination of the metal centres as in the unconjugated complexes. The chirality 
of the central helicate is, in some cases, influenced by the presence of the attached 
amino acids. This effect is uncertain in serine (both D and L) Fe(II) triple stranded 
conjugates and is absent in Gly-Gly-Ser Fe(II) triple stranded and serine (both D and 
L) Cu(I) L5-based conjugates. Only three hybrids exhibited very distinctive CD 
signals: the Gly-Gly-Ser Cu(I) double stranded L5-based and D and L-Arg Fe(II) 
triple stranded. CD analysis and 1H NMR experiments in the presence of Δ-
TRISPHAT as NMR shift reagent indicate that the conjugation of D-Arg induces the 
central helicate core to preserve the M configuration whilst the L-arginine promotes 
P helicate formation. The two PF6- arginine conjugates are diastereoisomerically pure 
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in acetonitrile whilst diastereoisomeric impurity of the corresponding Cl- complexes 
in water cannot be excluded.   
 
3.8 Experimental. 
 
3.8.1 Materials. 
 
All chemicals and solvents were purchased from Sigma–Aldrich, Fisher, Alfa 
Aesar, or Fluorochem and used as received. Deuterated solvents for NMR were 
supplied by Goss Scientific. Resins, amino acids and reagents for the peptide 
synthesis were Novabiochem products supplied by Merck Biosciences Ltd. Thin 
layer chromatography (TLC) was carried out on silica gel pre-coated aluminium 
sheets (Silica Gel 60 F254), supplied by MERCK KGaA. Visualisation used UV 
light (254/365). Column chromatography was performed using laboratory grade 
solvents on Silica Gel 60 (0.043–0.063 mm, supplied by Fluorochem, Glossop, UK) 
under gravity or with gentle pressure applied using nitrogen flow. All reverse phase 
high performance liquid chromatography (HPLC) analyses and purifications were 
performed on Dionex Summit HPLC systems with Chromoleon software, using 
HPLC grade solvents, supplied by Fisher. Analytical HPLC were acquired with the 
aid of a Summit P580 quaternary low pressure gradient pump with built in vacuum 
degasser while, for the preparative HPLC, a high pressure gradient pump was 
employed on the same machine. Phenomenex Luna 10l C18 (2) columns were used 
for analytical (250 x 4.6 mm, 1 ml/min flow) and preparative (250 x 21.2 mm, 21 
ml/min flow) RP-HPLC. 
NMR, UV-Vis and Circular Dichroism analyses were performed using the 
instruments described in section 2.5.4. Electrospray Ionisation (ESI) analyses, 
including accurate mass calculation (High Resolution Mass Spectrometry, HRMS) 
where possible, were carried out on a Micromass LCT Time of Flight Mass 
Spectrometer in positive ionisation mode and processed by MassLynx software. 
Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer 
as neat films and wavelengths (ν) are quoted in cm-1. 
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3.8.2 Synthesis of 6-formyl-nicotinic acid methyl ester (1).  
 
 
This compound was prepared by slight modifications of a reported procedure.52 
Methyl 6-methylnicotinate (5.54 g, 36.7 mmol) was mixed with iodine (9.31 g, 36.7 
mmol), and a small amount of DMSO was added to promote mixing. After 5 min of 
mixing, DMSO (20 ml) was added and this solution was added to a heated solution 
of DMSO (35 ml) at 130 °C. The temperature was slowly raised to 160 °C and the 
mixture was stirred at this temperature for 15 min. After cooling down the solution, a 
small amount of a saturated aqueous solution of Na2CO3 was added. The product was 
extracted with diethyl ether. Evaporation of the solvent gave the crude product, 
which was purified by column chromatography (CH2Cl2/EtOAc = 4:1). The product 
was obtained as an off-white solid in 2.06 g yield (33%). TLC with CH2Cl2/EtOAc = 
4:1 as eluent (Rf = 0.69). 1H NMR (400 MHz, CDCl3, 298 K) δ 10.14 (1H, s, H7), 
9.30 (1H, d, 4J = 1.8 Hz, H6py), 8.38 (1H, dd, 3J and 4J = 8.0, 1.8 Hz, H4py), 8.02 (1H, 
d, 3J = 8.0 Hz, H3py), 4.19 (3H, s, H8). EI mass analysis: m/z = 165.2 [M+H]+. 
 
3.8.3 Synthesis of 6-dimethoxymethyl-nicotinic acid methyl ester (2). 
 
6-Formyl-nicotinic acid methyl ester (1) (0.83 g, 5.03 mmol) was dissolved in 
trimethylorthoformate (20 ml), formic acid (2 ml) and sulphuric acid (2 drops). The 
mixture was heated to 50 °C and stirred at this temperature for 30 min, followed by 
stirring overnight at room temperature. Water (30 ml) and diethyl ether (30 ml) were 
added, the layers were separated and the aqueous layer extracted with diethyl ether 
(2x). The combined diethyl ether layers were washed with aqueous saturated Na2CO3 
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and dried with MgSO4. Evaporation of the solvent gave a light yellow solid in 0.75 g 
yield (71%). 1H NMR (400 MHz, CDCl3, 298 K) δ 9.28 (1H, d, 4J = 2.2 Hz, H6py), 
8.52 (1H, dd, 3J and 4J = 8.0, 2.2 Hz, H4py), 7.64 (1H, d, 3J = 8.0 Hz, H3py), 5.23 (1H, 
s, H7), 4.00 (3H, s, H8) 3.49 (6H, s, H9). EI mass analysis: m/z = 210.0 [M+H] +. 
 
3.8.4 Synthesis of 6-dimethoxymethyl-nicotinic acid (3). 
 
 
6-Dimethoxymethyl-nicotinic acid methyl ester (2) (0.95 g, 4.5 mmol) was 
dissolved in MeOH (6 ml) and 1 M NaOH (6 ml) was added. The resulting mixture 
was stirred overnight at room temperature. The methanol was evaporated and HCl (1 
M) was added until pH ~2-3. The compound was extracted with ethyl acetate (3x) 
and evaporation of the collected organic layers yielded 90% of pure yellow 
compound. 1H NMR (400 MHz, CDCl3, 298 K) δ 8.71 (1H, d, 4J = 2.0 Hz, H6py), 
8.12 (1H, dd, 3J and 4J = 8.0, 2.0 Hz, H4py), 7.53 (1H, d, J = 8.0 Hz, H3py), 5.38 (1H, 
s, H7), 3.44 (6H, s, H9). EI mass analysis: m/z = 196.0 [M+H] +. 
 
3.8.5 2-Dimethoxymethyl-5-(a)-pyridine (4-a to 6-a). 
 
 
Standard manual solid phase synthesis with fluorenylmethoxcarbonil (Fmoc) 
chemistry was applied.49-51 Rink Amide MHBA resin (loading grade 0.525 mmol/g) 
was used to obtain carboxamide peptide and a 2.8 mmol synthesis scale was applied. 
For the chain assembly, Fmoc-Gly-OH and Fmoc-Ser(t-Bu)-OH were used as Fmoc 
protected amino acids, and 6-dimethoxymethyl-nicotinic acid (3) was the last 
compound to be coupled at the N-terminal of the growing chain by amide bond 
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formation. For each Fmoc deprotection the resin was treated with a solution of 20% 
piperidine in dimethylformamide (DMF, 60 ml) and each coupling reaction was 
carried out by using amino acid/HBTU/ DIEA = 3:3:6 in relation to the synthesis 
scale, in DMF. A standard Kaiser test53 was used to verify that each coupling 
reaction was complete. After the solid phase synthesis was complete, the resin was 
treated with 50 ml of cleavage solution (trifluoroacetic acid 
(TFA)/H2O/triisopropylsilane = 9.5:0.25:0.25) for 3 h at room temperature. Then the 
mixture was filtrated, and the volume of the collected solution was reduced to few 
milliliters by evaporation. The crude compound was obtained by cold precipitation 
with diethyl ether and then analysed and purified by RP-HPLC. From 0 to 100% of 
acetonitrile 0.05% TFA in H2O 0.05% TFA in 40 min was the gradient used for this 
analysis. Pure (6) was achieved with 68% of yield (0.755 g). 1H NMR (400 MHz, 
D2O, 298 K) δ 8.97 (1H, d, 4J = 2.1 Hz, H6py), 8.49 (1H, dd, 3J and 4J = 8.1, 2.1 Hz, 
H4py), 7.84 (1H, d, 3J = 8.1 Hz, H3py), 5.60 (1H, s, H7), 4.38 (1H, t, 3J = 5.1 Hz, Hα3), 
4.14 (2H, s, H α1), 3.98 (2H, s, H α2), 3.82 (2H, t, 3J = 5.1 Hz, H β3), 3.43 (6H, s, H9). 
HRMS (ESI) analysis calcd. for C16H23N5O7Na 420.1495 [M+Na]+; found 420.1499. 
IR (ν) = 3232 (br m), 2982 (w), 1652 (vs), 1532 (s), 1489 (w), 1410 (w), 1333 (w), 
1255 (w), 1199 (m), 1180 (m), 1150 (w), 1070 (br m), 1021 (m), 973 (m), 799 (s), 
720 (s) cm-1. 
 
3.8.6 2-Dimethoxymethyl-5-(b, c, d, e)-pyridine (4-b, c, d,e to 6-b,c,d,e). 
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The same procedure described above for the synthesis of 2-dimethoxymethyl-5-(a)-
pyridine was applied to obtain the other four compounds 2-dimethoxymethyl-5-(R)-
pyridine where R is L-Ser (6-b), D-Ser (6-c), L-Arg (6-d) and D-Arg (6-e), using 
Fmoc-L-Ser(t-Bu)-OH, Fmoc-D-Ser(t-Bu)-OH, Fmoc-L-Arg(Pbf)-OH or , Fmoc-D-
Arg(Pbf)-OH respectively as protected amino acids for the attachment on the resin. 
Purifications by RP-HPLC (From 0 to 100% of acetonitrile 0.05% TFA in H2O 
0.05% TFA in 40 min) gave pure yellow compounds (Yields: 73% 6-b, 68% 6-c, 
38% 6-d, 69% 6-e). 
2-dimethoxymethyl-5-(b)-pyridine (6-b): 1H NMR (400 MHz, MeOD, 298 K) δ 
9.09 (1H, d,  4J = 2.2 H6py), 8.51 (1H, dd, 3J and 4J = 8.1, 2.2 Hz, H4py), 7.84 (1H, d, 
3J = 8.1 Hz, H3py), 5.50 (1H, s, H7), 4.68 (1H, t, 3J = 5.1, Hz, Hα), 3.94 (2H, d, 3J = 
5.1 Hz, Hβ) 3.30 (6H, s, H9). HRMS (ESI) analysis calcd. for C12H17N3O5Na, 
306.1066 [M+Na]+; found 306.1068. IR (ν) = 318 (br m), 2885 (w), 1649 (vs), 1531 
(s), 1420 (w), 1339 (m) 1102 (m), 1073 (br s) 909 (w), 836 (br m), 798 (w), 719 (m) 
cm-1. 
2-dimethoxymethyl-5-(c)-pyridine (6-c): 1H NMR (400 MHz, MeOD, 298 K) δ 
9.07 (1H, d,  4J = 2.2 H6py), 8.51 (1H, dd, 3J and 4J = 8.1, 2.2 Hz, H4py), 7.85 (1H, d, 
3J = 8.1 Hz, H3py), 5.55 (1H, s, H7), 4.61 (1H, t, 3J = 5.1, Hz, Hα), 3.94 (2H, d, 3J = 
5.1 Hz, Hβ) 3.35 (6H, s, H9). HRMS (ESI) analysis calcd. for C12H17N3O5Na, 
306.1066 [M+Na]+; found 306.1069. IR (ν) = 3181 (br m), 2892 (w), 1649 (vs), 1530 
(s), 1420 (w), 1292 (m) 1178 (m), 1073 (br s) 910 (w), 836 (br m) 719 (m) cm-1. 
2-dimethoxymethyl-5-(d)-pyridine (6-d): 1H NMR (400 MHz, MeOD, 298 K) δ 
9.01 (1H, d, 4J = 2.0 H6py), 8.37 (1H, dd, 3J and 4J  = 8.2, 2.0 Hz, H4py), 7.75 (1H, d, 
3J = 8.2 Hz, H3py), 5.45 (1H, s, H7), 4.59 (1H, dd, 3J = 5.3, 8.8 Hz, Hα), 3.32 (6H, s, 
H9) 3.24 (2H, td, 3J = 2.9, 7.0, Hz, Hδ), 1.99 (1H, m Hβ), 1.83 (1H, m Hβ), 1.72 (2H, 
m, Hγ). HRMS (ESI) analysis calcd. for C15H25N6O4, 353.1937 [M]+; found 
353.1931. IR (ν) = 3187 (br m), 2892 (w), 1648 (vs), 1533 (s), 1422 (w), 1293 (w), 
1198 (s), 1130 (vs), 914 (w), 839 ( m), 799 (w), 722 (m) cm-1. 
2-dimethoxymethyl-5-(e)-pyridine (6-e): 1H NMR (400 MHz, MeOD, 298 K) δ 
9.03 (1H, d, 4J = 2.0 H6py), 8.36 (1H, dd, 3J and 4J  = 8.2, 2.0 Hz, H4py), 7.75 (1H, d, 
3J = 8.2 Hz, H3py), 5.41 (1H, s, H7), 4.62 (1H, dd, 3J = 5.3, 8.8 Hz, Hα), 3.32 (6H, s, 
H9) 3.26 (2H, td, 3J = 2.9, 7.0, Hz, Hδ), 1.99 (1H, m Hβ), 1.83 (1H, m Hβ), 1.72 (2H, 
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m, Hγ). HRMS (ESI) analysis calcd. for C15H25N6O4, 353.1937 [M]+; found 
353.1933. IR (ν) = 3194 (br m), 2892 (w), 1651 (vs), 1532 (s), 1424 (w), 1321 (br 
w), 1179 (s), 1126 (vs), 914 (w), 836 ( m), 799 (w), 720 (m) cm-1. 
 
 3.8.7 2-formyl-5-(R)-pyridine (7-a, b, c, d, e). 
 
Deprotection of aldehyde group was achieved using the same procedure for all 2-
dimethoxymethyl-R-pyridine compounds where R is Gly-Gly-L-Ser (6-a), L-Ser (6-
b), D-Ser (6-c), L-Arg (6-d) and D-Arg (6-e). 2-Dimethoxymethyl-R-pyridine (1 
mmol) was partially dissolved in 18 ml of THF and 3 ml of 1M HCl were added in 1 
hour time at 0 °C. The mixture was stirred at room temperature and the reaction was 
monitored by analytical RP-HPLC every day (from 0 to 100% of methanol in water 
in 40 min for 7-a, b, c; from 0 to 100% of acetonitrile in water in 40 min for 7-d, e). 
The peak corresponding to the unprotected aldehyde (~ 3 min earlier than starting 
protected compound) was present in the chromatogram after 24 hours, but the 
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reaction was promoted by adding small quantities (~ 1 ml) of 1M HCl until the 
chromatogram showed the unprotected aldehyde as the main compound. 3-4 days 
were sufficient to have a complete reaction. The crude was purified by preparative 
RP-HPLC (from 0 to 100% of methanol in water in 70 min, 22 ml/min flow, 
acetonitrile instead of methanol was used only for 7-d, e) and freeze dried, obtaining 
pure compound (Yields: 59% 7-a, 54% 7-b, 57% 7-c, 38% 7-d, 31% 7-e). 
All the 1H NMR spectra, both in D2O and in MeOD, of 2-formyl-R-pyridine (7-a, b, 
c, d, e), shows two set of signals, because in solution the aldehyde group is in 
equilibrium with the hydrate form (as showed in the scheme above). Consequently 
the spectra present the resonances of the protons of the pyridine rings of both the 
species, the resonance of the aldehyde proton and that from the hydrate species. In 
the region of the signals due to the protons in the peptide chain, there is the 
contribution of both the species. 
2-formyl-5-(a)-pyridine (7-a): 1H NMR (400 MHz, D2O, 298 K) δ 9.98 (1H, s, H7), 
9.06 (1H, d, 4J = 2.0, H6py), 8.90 (3.2H, d, 4J = 2.0, H6'py), 8.41 (1H, dd, 3J and 4J = 
8.1, 2.0 Hz, H4py), 8.32 (3.2H, dd, 3J and 4J = 8.1, 2.0 Hz, H4'py), 8.08 (1H, d, 3J = 8.1 
Hz, H3py), 7.76 (3.2H, d, 3J = 8.1 Hz, H3'py), 6.04 (3H, s, H7'), 4.39 (4.7H, t, 3J = 4.8 
Hz, Hα3), 4.13 (9.2H, s, H α1), 3.98 (9.2H, m, H α2), 3.83 (9.2H, m, H β3). HRMS 
(ESI) analysis calcd. for C14H17N5O6Na, 374.1077 [M+Na]+; found 374.1074. IR (ν) 
= 3258 (br m), 2968 (w), 1643 (vs), 1529 (s), 1489 (w), 1411 (w), 1332 (w), 1250 
(w), 1199 (m), 1179 (m), 1150 (w), 1073 (br m), 1021 (m), 971 (m), 799 (s), 720 (s) 
cm-1. 
2-formyl-5-(b)-pyridine (7-b): 1H NMR (400 MHz, D2O, 298 K) δ 9.97 (1H, s, H7), 
9.05 (1H, d, 4J = 2.2 Hz, H6py), 8.86 (2.3H, d, 4J = 2.2, H6'py), 8.37 (1H, dd, 3J and 4J 
= 2.2, 8.1 Hz, H4py), 8.27 (2.3H, dd, 3J and 4J = 2.2, 8.1 Hz, H4'py), 8.07 (1H, d, 3J = 
8.1 Hz, H3py), 7.31(2.3 H, d, 3J = 8.1 Hz, H3'py), 6.01 (2.3H, s, H7'), 4.59 (3.3H, t, 3J = 
5.5 Hz, Hα), 3.92 (3.3 H, d, 3J = 5.5 Hz, Hβ). HRMS (ESI) analysis calcd. for 
C10H11N3O4Na, 260.0647 [M+Na]+; found 260.0649. IR (ν) = 3211 (br m), 2870 (w), 
1643 (vs), 1534 (s), 1415 (w), 1294 (m), 1190 (m), 1040 (br s) 908 (w), 852 (br m), 
799 (w), 720 (m) cm-1. 
2-formyl-5-(c)-pyridine (7-c): 1H NMR (400 MHz, D2O, 298 K) δ 10.0 (1H, s, H7), 
9.09 (1H, d, 4J = 2.2 Hz, H6py), 8.86 (4.8H, d, 4J = 2.2, H6'py), 8.31 (1H, dd, 3J and 4J 
= 2.2, 8.1 Hz, H4py), 8.27 (4.8 H, dd, 3J and 4J = 2.2, 8.1 Hz, H4'py), 8.00 (1H, d, 3J = 
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8.1 Hz, H3py), 7.31(4.8 H, d, 3J = 8.1 Hz, H3'py), 6.01 (4.8H, s, H7'), 4.58 (5.8H, t, 3J = 
5.5 Hz, Hα), 3.90 (5.8 H, d, 3J = 5.5 Hz, Hβ). HRMS (ESI) analysis calcd. for 
C10H11N3O4Na, 260.0647 [M+Na]+; found 260.0648. IR (ν) = 3198 (br m), 2892 (w), 
1643 (vs), 1532 (s), 1418 (w), 1290 (m), 1170 (m), 1042 (br s), 910 (w), 832 (br m), 
799 (w), 719 (m) cm-1. 
2-formyl-5-(d)-pyridine (7-d): 1H NMR (400 MHz, MeOD, 298 K) δ 9.00 (1H, d, 
4J=2.4 H6'py), 8.32 (1H, dd, 3J and 4J = 2.4, 8.3, Hz, H4'py), 7.75 (1H, d, 3J = 8.3 Hz, 
H3'py), 5.59 (1H, s, H7'), 4.62 (1H, dd, 3J = 5.3, 8.8 Hz, Hα), 3.27 (2H, dt, 3J = 2.3, 6.8, 
Hz, Hδ), 1.99 (1H, m Hβ), 1.83 (1H, m Hβ), 1.70 (2H, m Hγ). Only less than 10% of 
aldeyde form was present in the spectrum δ 10.07 (s, H7), 9.20 (d, 4J=2.4 H6'py), 8.42 
(dd, 3J and 4J = 2.4, 8.3, Hz, H4py), 8.06 (d, 3J = 8.3 Hz, H3'py). HRMS (ESI) analysis 
calcd. for C13H19N6O3, 307.1519 [M]+; found 307.1511. IR (ν) = 3163 (br m), 2952 
(w), 1643 (vs), 1530 (s), 1417 (w), 1291 (w), 1175 (m), 1040 (br s), 910 (m), 865 (br 
m) cm-1. 
2-formyl-5-(e)-pyridine (7-e): 1H NMR (400 MHz, MeOD, 298 K) δ 8.98 (1H, d, 
4J=2.4 H6'py), 8.33 (1H, dd, 3J and 4J = 2.4, 8.3, Hz, H4'py), 7.77 (1H, d, 3J = 8.3 Hz, 
H3'py), 5.57 (1H, s, H7'), 4.62 (1H, dd, 3J = 5.3, 8.8 Hz, Hα), 3.27 (2H, dt, 3J = 2.3, 6.8, 
Hz, Hδ), 1.99 (1H, m Hβ), 1.83 (1H, m Hβ), 1.70 (2H, m Hγ). Only less than 10% of 
aldeyde form was present in the spectrum  δ 10.08 (s, H7), 9.20 (d, 4J=2.4 H6'py), 8.43 
(dd, 3J and 4J = 2.4, 8.3, Hz, H4py), 8.07 (d, 3J = 8.3 Hz, H3'py). HRMS (ESI) analysis 
calcd. for C13H19N6O3, 307.1519 [M]+; found 307.1511. IR (ν) = 3186 (br m), 2892 
(w), 1640 (vs), 1536 (s), 1422 (w), 1292 (w) 1198 (s), 1127 (br s), 915 (m), 836 (br 
m) cm-1. 
 
3.8.8 Ligand La1.  
 
To 84.7 mg of 2-formyl-5-(a)-pyridine (7-a) (0.242 mmol), 6 ml of methanol were 
added and the suspension was sonicated and heated at 50–60 °C for 5 min. A 
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solution of 4,4'-methylenedianiline (8) (23.9 mg, 0.121 mmol) in 3 ml of methanol 
was added drop wise (over 10 min) to the mixture, the temperature raised to reflux 
and the mixture stirred at reflux for 6 h. The yellow precipitate that formed was 
isolated by filtration and abundantly washed with methanol and diethyl ether, dried 
under vacuum, washed again with water and finally washed with diethyl ether and 
dried to afford 85 mg of compound (10-a) (yield: 81%). Since the ligand La1 (10-a) 
is not soluble in methanol or in water, but it is partially soluble in a water/methanol 
mix, the drying between the two washing is very important to avoid a partial 
dissolution of the compound. 1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.16 (1H, t, 
3J = 5.8 Hz, H12), 9.11 (1H, d, 4J = 1.9 Hz, H6py), 8.64 (1H, s, H7), 8.32 (1H, dd, 3J 
and 4J = 8.3, 1.9 Hz, H4py), 8.25 (1H, t, 3J = 5.8 Hz, H13), 8.19 (1H, d, 3J = 8.3, H3py), 
7.81 (1H, d, 3J = 7.8 Hz, H14), 7.31 (4H, s, H9/10), 7.17 (1H, s, H15), 7.07 (1H, s, H15), 
4.81 (1H, t, 3J = 5.3 Hz, H16), 4.15 (1H, dt, 3J = 7.8, 5.3 Hz, Hα3) 3.99 (1H, s, H11), 
3.91 (2H, d, 3J = 5.8 Hz, H α1), 3.74 (2H, dd, 4J and 3J = 13.6, 5.8 Hz, H α2), 3.56 (2H, 
m, J = 16.1, 10.7, 5.8 Hz, H β3). HRMS (ESI) analysis calcd. for C41H44N12O10Na, 
887.3201 [M+Na]+; found 887.321. IR (ν) = 3286 (br m), 2893 (w), 1637 (vs), 1537 
(s), 1503 (w shoulder), 1412 (w), 1372 (w), 1326 (w), 1235 (m), 1199 (m), 1025 (w),  
993 (w), 916 (w), 8.54 (m), 784 (w) cm-1. 
 
3.8.9 Ligand La2. 
 
The procedure used for La1 was applied for the synthesis of ligand La2, but 4,4'-
methylenbis(2,6-diethylaniline) (9) was used instead of 4,4'-methylenedianiline. A 
yellow compound was achieved yielding 72 mg (61%). 1H NMR (400 MHz, DMSO-
d6, 298 K) δ 9.22 (1H, t, 3J = 5.5 Hz, H12), 9.13 (1H, d, 4J = 1.9 Hz, H6py), 8.41 (1H, 
dd, 3J and 4J = 8.3, 1.9 Hz, H4py), 8.32 (1H, s, H7), 8.25 and 8.23 (overlapped 1H, t, 3J 
= 5.3 Hz, H13 + 1H, d, 3J = 8.3, H3py), 7.81 (1H, d, J = 7.8 Hz, H14), 7.18 (1H, s, H15), 
7.07 (1H, s, H15), 6.99 (2H, s, H10), 4.81 (1H, t, 3J = 5.8 Hz, H16), 4.16 (1H, dt, 3J = 
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7.8, 5.3 Hz, Hα3) 3.97 (2H, d, 3J = 5.5 Hz, H α1), 3.86 (1H, s, H11), 3.77 (2H, dd, 3J 
and J4 = 13.6, 5.3 Hz, H α2), 3.56 (2H, m, J = 10.7, 5.3 Hz, Hβ3), 2.39 (4H, q, 3J = 7.8, 
7.3 Hz, H9a), 1.01 (6H, t, 3J = 7.3 Hz, H9b). HRMS (ESI) analysis calcd. for 
C49H60N12O10Na 999.4453 [M+Na]+; found 999.4465. IR (ν) = 3280 (br m), 2892 
(w), 1650 (vs), 1601 (m shoulder), 1532 (s), 1410 (w), 1290 (br m ), 1202 (w), 1168 
(w), 1047 (m), 1020 (m),  911 (w), 852 (w),  760 (w) cm-1. 
 
3.8.10 [Cu2(La1)2](Cl)2 
 
To a stirred nitrogen purged suspension of Ligand La1 (10-a) (26.0 mg, 0.030 mmol) 
in 3 ml of methanol, solid [Cu(CH3CN)4][PF6] (16.7 mg, 0.045 mmol) was added to 
give a red-brown mixture. The mixture was stirred overnight under nitrogen 
atmosphere and a red-brown precipitate was collected by filtration, abundantly 
washed with methanol, and dried with diethyl ether (yield: 54.1%). 1H NMR (500 
MHz, D2O/CD3CN = 1:2, 298 K) δ 9.42 (1H, br, H6py), 9.13 (1H, br, H7), 8.71 (1H, 
br, H3/4py), 8.36 (1H, br, H3/4py), 7.57 (2H, br, H9/10), 7.37 (2H, br, H9/10), 7.24 (1H, s, 
H15), 6.83 (1H, s, H15), 4.56 (1H, br, H α3), 4.37 (1H, s, H11),  4.29 (2H, br/m, Hα1), 
4.15 (2H, br/m, H α2), 4.01 (2H, m, H β1). ESI mass analysis m/z = 928.2 
[Cu2(La1)2]2+. IR (ν) = 3286 (br m), 2893 (w), 1650 (vs), 1537 (s), 1412 (w), 1328 
(w), 1079 (m), 1048 (m),  993 (w), 918 (w), 8.54 (m), 784 (w) cm-1. 
The complex was passed through ion-exchange resin (Dowex 1x8–100 mesh 
(Cl)), to exchange the counter anion to Cl-. ESI mass analysis confirmed that the ion 
exchange did not affect the complex. UV–Vis (water) λmax (nm) = 515, 344, 240, 
205. 
 
3.8.11 [Ag2(La1)2](PF6)2 
 
To a stirred nitrogen purged suspension of Ligand La1 (10-a) (30.0 mg, 0.034 
mmol) in 3 ml of methanol was added solid AgPF6 (12.8 mg, 0.051 mmol) to give a 
dark yellow mixture. The mixture was stirred overnight at room temperature under 
nitrogen atmosphere and the yellow precipitate was collected by filtration, 
abundantly washed with methanol and dried with diethyl ether (26.4 mg, yield: 
66%). 1H NMR (400 MHz, DMSO-d6, 298 K) δ 9.22 (1H, t, 3J =  5.8 Hz, H12), 9.18 
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(1H, d, 4J = 1.9 Hz, H6py), 8.97 (1H, s, H7), 8.47 (1H, dd, 3J and 4J = 8.3, 1.9 Hz, 
H4py), 8.28 (1H, t, 3J = 5.8 Hz, H13), 8,17 (1H, d, 3J = 8.3, H3py), 7.81 (1H, d, 3J = 8.3 
Hz, H14), 7.42 (2H, d, 3J = 8.3 Hz, H9/10), 7.32 (2H, d, 3J = 8.3 Hz, H9/10), 7.18 (1H, s, 
H15), 7.06 (1H, s, H15), 4.80 (1H, br, H16), 4.19 (1H, dt, 3J = 8.3, 5.3 Hz, Hα3) 4.0 
(1H, s, H11), 3.95 (2H, d, 3J = 5.8 Hz, H α1), 3.76 (2H, m, 3J and 4J = 12.2, 5.8 Hz, 
H α2), 3.55 (2H, m, 3J = 16.1, 8.3, 5.8 Hz, H β3). ESI mass analysis m/z = 973.21 
[Ag2La12]2+. 
 
3.8.12 [Fe2(La1)3](Cl)4 
 
To solid 2-formyl-5-(a)-pyridine (7-a) (25 mg, 0.071 mmol) and FeCl2 x 4H2O (4.7 
mg, 0.023 mmol), 4,4'-methylenedianiline (8) (7.1 mg, 0.035 mmol) pre-dissolved in 
methanol (3 ml) have added. The mixture was stirred overnight to give a blue-dark 
precipitate that was collected by filtration, abundantly washed with methanol and 
dried with diethyl ether (16.3 mg, yield: 50%). 1H NMR (500 MHz, D2O, 298 K) δ 
9.03 (1H, s, H7), 8.65 (2H, overlapped d, 3J = 8.1 Hz, H3py + d, 3J = 8.1 Hz, H4py), 
7.55 (1H, s, H6py), 7.00 (2H, br, H9/10), 5.95 (2H, br, H9/10), 4.56 (1H, br tr, Hα3), 4.32 
(2H, br d, Hα1), 4.11 (2H, m, H α2), 3.99 (1H, s, H11), 3.96 (2H, m, H β3). ESI mass 
analysis m/z = 677.29 [Fe2(La1)3]4+, 460.61 [Fe(La1)]2+. IR (ν) = 3254 (br m), 2892 
(w), 1645 (vs), 1532 (s), 1410 (w), 1372 (w), 1324 (w) 1260 (w), 1076 (w), 1018 
(w),  993 (w), 918 (w), 8.58 (m), 784 (w) cm-1. UV–Vis (water) λmax (nm) = 599 
(with a shoulder at 546), 338, 205. ε599 = 12,900 M-1 cm-1.  
 
3.8.13 [Cu2(La2)2](PF6)2 
 
To a stirred nitrogen purged suspension of ligand La2 (11-a) (55.0 mg, 0.056 mmol) 
in 4 ml of methanol was added solid [Cu(CH3CN)4] [PF6] (31.6 mg, 0.084 mmol) to 
give a red-brown mixture. The mixture was stirred overnight under nitrogen 
atmosphere and a red-brown precipitate was collected by filtration, washed with 
methanol and dried with diethyl ether (39.2 mg, yield: 62%). 1H NMR (500 MHz, 
D2O/CD3CN = 1:3, 298 K) δ 8.98 (1H, s, H6py), 8.74 (1H, s, H7), 8.60 (1H, br d, 3J = 
7.7 Hz, H4py), 8.19 (1H, d, 3J = 7.7 Hz, H3py), 7.08 (1H, br, H10), 6.53 (1H, br, H10), 
4.39 (1H, t, 3J = 5.0 Hz, Hα3), 4.14 (2H, s, Hα1), 3.97 (2H, d, 4J = 3.3 Hz, Hα2), 3.87 
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(1H, s, H11), 3.80 (2H, m, Hβ3), 0.98 (6H, br, H9b), 0.48 (4H, br, H9a). ESI mass 
analysis m/z = 1040.88 [Cu2(La2)2]2+. IR (ν) = 3278 (br m), 2892 (w), 1644 (vs), 
1601 (m shoulder), 1534 (s), 1414 (w), 1292 (m), 1202 (w), 1168 (w), 1047 (m), 
1026 (m),  909 (w), 852 (w),  760 (w) cm-1. 
 
 3.8.14 [Cu2(La2)2](Cl)2 
 
The same procedure used for the synthesis of [Cu2(La2)2](PF6)2 was applied, but 
[Cu(CH3CN)4] [PF6] was replaced with CuCl. The red-brown precipitate, collected 
by filtration, was dissolved in water, the impurity in suspension eliminated by 
filtration, and the resulting dark red solution was freeze dried to afford 25.3 mg 
(yield: 42%) of dark red compound.  1H NMR (500 MHz, D2O, 298 K) δ 9.52 (1H, 
br, H7), 9.27 (1H, br, H6py), 9.15 (1H, br, H4py), 8.70 (1H, br, H3py), 7.61 (1H, br, 
H10), 7.06 (1H, br, H10), 4.91 (1H, br, Hα3), 4.66 (2H, br, Hα1), 4.49 (2H, br, H α2), 
4.33 (3H, br, overlapped H11+ H β1), 3.145–2.910 (4H, br, H9a), 1.507 (3H, br, H9b), 
1.043 (3H, br, H9b). ESI mass analysis m/z = 1040.92 [Cu2(La2)2]2+. UV–Vis (water) 
λmax (nm) = 500, 255 (with shoulders at 328 and 286), 206. 
 
3.8.15 [Fe2(Lb1)3](Cl)4 
 
1 ml of 4,4'-methylenedianiline (8) (18.7 mg, 0.09 mmol) in methanol was added 
dropwise to a stirring solution of 2-formyl-5-(b)-pyridine (7-b) (45 mg, 0.189 mmol) 
in 2 ml of methanol at 50°C  in nitrogen atmosphere. In few minute an intense 
yellow mixture is formed. Temperature was raised to reflux and solid FeCl2 x 4H2O 
(12.5 mg, 0.063 mmol) was added to the mixture, causing immediate formation of 
dark blue mixture. The mixture was stirred in nitrogen atmosphere in reflux for 1 
hour and at room temperature overnight. Water was added to the mixture until all the 
crude was in solution and saturated methanolic solution of NH4PF6 was added drop 
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wise to obtain dark-blue precipitate [Fe2(Lb1)3](PF6)4, which was filtrated and 
washed with diethyl ether, cold methanol/ethanol (1/1) and diethyl ether (50 mg, 
61% yield). Counter anion was exchanged from PF6- to Cl- using ion exchange resin 
(Dowex 1x8–100 mesh (Cl), Sigma-Aldrich). 1H NMR (400 MHz, D2O, 298 K) δ 
9.05 (1H, s, H7), 8.68 (1H, d, 3J = 8.1 Hz, H4py), 8.63 (1H, d, 3J = 8.1 Hz, H3py), 7.50 
(1H, d, 4J = 1.9 Hz, H6py), 6.70 (2H, br, H10), 5.50 (2H, br, H9), 4.51(1H, br t, Hα), 
3.98 (1H, s, H11), 3.87 (2H, m, H β). ESI mass analysis m/z = 506.41 [Fe2(Lb1)3]4+, 
665.22 [Fe(Lb1)2]2+, 693.10 [Fe(Lb1)]+, 637.48 [(Lc1)+H]+, 660.48 [(Lc1)+Na]+. IR 
(ν) = 3288 (br m), 2892 (w), 1648 (vs), 1612 (m shoulder) 1541 (s), 1500 (m 
shoulder), 1411 (w), 1318 (w), 1292 (br, m) 1205 (w), 1168 (w), 1074 (m), 1018 (m), 
993 (w shoulder), 916 (w), 862 (w) cm-1. UV–Vis (water) λmax (nm) = 599 (with a 
shoulder at 546), 338, 286, 240. ε599 = 12,900 M-1 cm-1. 
 
3.8.16 [Fe2(Lc1)3](Cl)4 
 
The same procedure used for the synthesis of [Fe2(Lb1)3](Cl)4 was herein applied, 
but using 2-formyl-5-(c)-pyridine (7-c) (54mg, 66% yield). 1H NMR (400 MHz, 
D2O, 298 K) δ 9.04 (1H, s, H7), 8.69 (1H, d, 3J = 8.1 Hz, H4py), 8.64 (1H, d 3J = 8.1 
Hz, H3py), 7.54 (1H, d, 4J = 1.9 Hz, H6py), 6.85 (2H, br, H10), 5.68 (2H, br, H9), 4.51 
(1H, br t, Hα), 3.95 (1H, s, H11), 3.87 (2H, m, H β). ESI mass analysis m/z = 506.41 
[Fe2(Lc1)3]4+, 665.22 [Fe(Lc1)2]2+, 710.97 [Fe2(Lc1)2](Cl)2+, 637.48 [(Lc1)+H]+, 
660.42 [(Lc1)+Na]+. IR (ν) = 3250 (br m), 2893 (w), 1654 (vs), 1591 (m shoulder) 
1536 (s), 1500 (m shoulder), 1413 (w), 1317 (w), 1293 (br m), 1205 (w), 1168 (w), 
1050 (m), 1016 (m), 993 (w shoulder), 917 (w), 862 (w) cm-1. UV–Vis (water) λmax 
(nm) = 599 (with a shoulder at 546), 338, 286, 240. ε599 = 12,900 M-1 cm-1. 
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3.8.17 [Fe2(Ld1)3](Cl)10 
 
1 ml of 4,4'-methylenedianiline (8) (12.9 mg, 0.065 mmol) in methanol was added 
dropwise to a stirring solution of 2-formyl-5-(d)-pyridine (7-d) (40mg, 0.130 mmol) 
in 2 ml of methanol at 50°C  in nitrogen atmosphere. In few minute an intense 
yellow mixture is formed. Temperature was raised to reflux and solid FeCl2 x 4H2O 
(8.5 mg, 0.0043 mmol) was added to the mixture, causing immediate formation of 
dark blue solution. The solution was stirred in nitrogen atmosphere in reflux for 1 
hour and at room temperature overnight. Diethyl ether was added to the solution to 
afford the precipitation of a blue solid which was collected by filtration and washed 
with ethanol and diethyl ether, dried overnight on P2O5 to achieve 30.7 mg of 
chloride complex (51% yield) 1H NMR (400 MHz, D2O, 298 K) δ 9.04 (1H, s, H7), 
8.66-8.61 (overlapped 1H, dd 3J = 8.1 Hz, H4py+ 1H, d, 3J = 8.1 Hz, H3py), 7.57 (1H, 
s, H6py), 7.03 (2H, br, H10), 5.50 (2H, br, H9), 4.31 (1H, dd, 3J and 4J = 5.8, 8.0, Hα), 
3.93 (1H, s, H11), 3.14 (2H, t, 3J = 7.2 Hz, Hδ) 1.80 (2H, br m, Hβ), 1.58 (2H, br m, 
Hγ). UV–Vis (water) λmax (nm) = 599 (with a shoulder at 546), 340, 282 (shoulder), 
238. ε599 = 12,900 M-1 cm-1. 
Saturated methanolic solution of NH4PF6 was added drop wise to 20 mg of 
chloride complex dissolved in the minimum volume of methanol to obtain dark-blue 
precipitate [Fe2(Ld1)3](PF6)10, which was filtrated and washed with diethyl ether, 
cold methanol/ethanol (1/1) and diethyl ether (16 mg, 57% yield). 1H NMR (500 
MHz, CD3CN, 298 K) δ 9.33 (1H, d, 3J = 6.7 Hz, H12) 8.98 (1H, s, H7), 8.57 (1H, d 
3J = 8.0 Hz, H4py), 8.54 (1H, d 3J = 8.0 Hz, H3py), 8.01 (1H, s, H6py), 6.73 (1H, s, H13) 
6.61 (1H, br, Hε) 6.21(1H, s, H13) 6.07 (2H, br, H9/10), 5.44 (2H, br, H9/10), 4.13 (1H, 
br dt, Hα), 4.02 (1H, s, H11), 3.14 (2H, m, Hδ), 1.72 (2H, br, Hβ), 1.47 (2H, br Hγ). IR 
(ν) = 3160 (br m), 2912 (w), 1643 (vs), 1536 (m), 1500 (w shoulder), 1415 (w), 1318 
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(w), 1290 (w), 1200 (m), 1172 (m) 1129 (m), 1017 (w), 916 (w), 861 (w), 719 (w) 
cm-1. 
 
3.8.18 [Fe2(Le1)3](Cl)10 
 
The same procedure used for the synthesis of [Fe2(Ld1)3](Cl)4 was herein applied, 
but using 2-formyl-5-(e)-pyridine (7-e) (28.3 mg, 47% yield). 1H NMR (400 MHz, 
D2O, 298 K) δ 9.08 (1H, s, H7), 8.69-8.67 (overlapped 1H, dd, 3J = 8.1 Hz, H4py+ 1H, 
d, 3J = 8.1 Hz, H3py), 7.60 (1H, s, H6py), 7.03 (2H, br, H10), 5.50 (2H, br, H9), 4.36 
(1H, dd, 3J and 4J = 5.8, 8.0, Hα), 3.97 (1H, s, H11), 3.18 (2H, t, 3J = 7.2 Hz, Hδ) 1.85 
(2H, br m, Hβ), 1.61 (2H, br m, Hγ). UV–Vis (water) λmax (nm) = 599 (with a 
shoulder at 546), 340, 282 (shoulder), 238. ε599 = 12,900 M-1 cm-1. 
1H NMR (500 MHz, CD3CN, 298 K) δ 9.33 (1H, d, 3J =  6.7 Hz, H12) 8.95 (1H, s, 
H7), 8.60 (1H, d 3J = 8.0 Hz, H4py), 8.57 (1H, d, 3J = 8.0 Hz, H3py), 8.01 (1H, s, H6py), 
6.78 (1H, s, H13) 6.66 (1H, br, Hε) 6.20 (1H, s, H13) 6.19 (2H, br, H10), 5.44 (2H, br, 
H9/10), 4.17 (1H, br dt, Hα), 4.05 (1H, s, H11), 3.18 (2H, m, Hδ), 1.72 (2H, br, Hβ), 
1.47 (2H, br Hγ). IR (ν) = 3167 (br m), 2912 (w), 1646 (vs), 1536 (m), 1500 (w 
shoulder), 1478 (w), 1412 (w), 1319 (w), 1290 (w), 1203 (m), 1166 (m) 1112 (w), 
1017 (w), 918 (w), 862 (w), 719 (w) cm-1. 
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3.8.19 [Cu2(Lb2)2](Cl)2  
 
4 ml of dried methanol where added to 29 mg (0.12 mmol) of 2-formyl-5-(b)-
pyridine (7-b), 23 mg (0.06 mmol) of 4,4'-methylenbis(2,6-diethylaniline) (9) and 19 
mg (0.061mmol) of [Cu(CH3 CN)4] [PF6] in nitrogen atmosphere. The mixture was 
stirred at 60 °C for one hour and it turned to dark red-brown after 10 min, followed 
by overnight stirring at room temperature, in nitrogen atmosphere and protected in 
aluminium foil. Few drops of water were added to the mixture to dissolve it 
completely and precipitation with diethyl ether gave a red-brown compound that was 
washed with diethyl ether, ethanol, water, ethanol and dried with diethyl ether. 28 mg 
(47%) of pure compound were obtained.  1H NMR (500 MHz, CD3CN, 298 K) δ 
9.02 (1H, s, H6py), 8.68 (1H, br, H7), 8.56 (1H, br d, 3J = 8.0 Hz, H4py), 8.15 (1H, d, 3J 
= 8.0 Hz, H3py), 7.57 (1H, br d, 3J = 6.9 Hz, H12), 6.60 (2H, br, H10), 6.57 (1H, s, 
H13), 6.00 (1H, s, H13), 4.57 (1H, br m, Hα), 3.84 (3H, br d, overlapped H11+Hβ), 2.40 
(4H, br, H9a), 0.80 (6H, br, H9b). ESI mass analysis m/z =812.2 [Cu2(Lb2)2]2+. IR (ν) 
= 3200 (br m), 2892 (w), 1648 (vs), 1601 (m shoulder), 1532 (s), 1417 (w), 1292 (br 
m ), 1202 (w), 1168 (w), 1047 (m), 1020 (s),  911 (w), 852 (w),  760 (w) cm-1. 
Counter anion was exchanged from PF6- to Cl- using ion exchange resin (Dowex 
1x8–100 mesh (Cl), Sigma-Aldrich). 1H NMR signals were broadened because of the 
presence of paramagnetic impurities. ESI mass analysis confirmed m/z =812.2 
[Cu2(Lb2)2]2+. UV–Vis (water) λmax (nm) = 500, 337, 254  
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3.8.20 [Cu2(Lc2)2](Cl)2 
 
 
The same procedure described for [Cu2(Lb2)2](Cl)2 was used, but using 2-formyl-5-
(c)-pyridine (7-c) to obtain 22 mg (37% yield) of pure compound. 1H NMR (500 
MHz, CD3CN, 298 K) δ 9.02 (1H, s, H6py), 8.68 (1H, s, H7), 8.55 (1H, br d, H4py), 
8.16 (1H, d, 3J = 8.0 Hz, H3py), 7.57 (1H, br d, 3J = 6.9 Hz, H12), 6.83 (2H, br, H10), 
6.53 (1H, s, H13), 6.01 (1H, s, H13), 4.56 (1H, br  m, Hα), 3.88 (3H, m, overlapped 
H11+Hβ), 2.41 (4H, br, H9a), 1.00 (6H, br, H9b). ESI mass analysis m/z =812.2 
[Cu2(Lc2)2]2+. IR (ν) = 3198 (br m), 2892 (w), 1643 (vs), 1601 (m shoulder), 1532 
(s), 1415 (w), 1294 (br m ), 1202 (w), 1168 (w), 1047 (m), 1021 (s),  908 (w), 852 
(w),  760 (w) cm-1. Counter anion was exchanged from PF6- to Cl- using ion exchange 
resin (Dowex 1x8–100 mesh (Cl), Sigma-Aldrich). 1H NMR signals were broadened 
because of the presence of paramagnetic impurities. ESI mass analysis confirmed 
m/z =812.2 [Cu2(Lc2)2]2+. UV–Vis (water) λmax (nm) = 500, 337, 254. 
 
3.8.21 Circular dichroism, UV-Vis and NMR experiments with Δ-
TRISPHAT. 
 
CD scans of the conjugates were carried out in 10 or 1 mm path length cuvettes 
(depending on the concentration of the complex in each experiment) using a Jasco J-
715 spectropolarimeter. Each CD scan was always supported by a corresponding 
UV-Vis scan, carried out with a Varian Cary 5000 spectrophotometer. The chirality 
of the complexes was analysed by CD in acetonitrile for hexafluorophospate 
complexes and in water for chloride complexes. When CD signals of different 
complexes had to be compared, previous UV-vis analysis in the MLCT region was 
carried out to ensure that the complexes had the same concentrations.  
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1H NMR experiments with Δ-TRISPHAT (purchased from Sigma-Aldrich) were 
carried out as follows: NMR spectra of the complexes alone in CD3CN were run, 
then 2 equivalent of Δ-TRISPHAT were added directly to the complex solution in the 
NMR tube. NMR spectra were run 15 min after that Δ-TRISPHAT was completely 
dissolved.  
The experiment of precipitation of the chloride Fe(II) parent cylinder with Δ-
TRISPHAT was carried out dissolving 30 mg of complex in 15 ml of water. The 
solution was divided in five aliquots of 3 ml each in five test tubes, with 1.45 mM 
concentration of complex in each tube. Separately, five solutions with different 
concentrations of Δ-TRISPHAT in 3 ml of acetonitrile were prepared (0.725, 1.087, 
1.45, 2.175 and 2.9 mM) and each solution was added drop wise one complex 
solution. At the end each tube contained 0.725 mM of complex and Δ-
TRISPHAT/complex ratio of 0.5, 0.75, 1 and 2. The mixtures were left in the fridge 
overnight and the then filtered. The collected filtrates were freeze dried and the 
precipitates were accurately washed with water and then dried over P2O5. The 
filtrates and the precipitates were re-dissolved in acetonitrile/methanol (8/1) for the 
UV-vis and CD analysis. 
 
3.9 References 
 
(1) De Wolf, F. A.; Brett, G. M. Pharmacological Reviews 2000, 52, 207-
236. 
(2) Malafaya, P. B.; Silva, G. A.; Reis, R. L. Advanced Drug Delivery 
Reviews 2007, 59, 207-233. 
(3) Uherek, C.; Wels, W. Advanced Drug Delivery Reviews 2000, 44, 
153-166. 
(4) Lambert, D. M. European Journal of Pharmaceutical Sciences 2000, 
11, S15-S27. 
(5) Pooga, M.; Land, T.; Bartfai, T.; Langel, U. Biomolecular 
Engineering 2001, 17, 183-192. 
(6) Miyajima, Y.; Ishizuka, T.; Yamamoto, Y.; Sumaoka, J.; Komiyama, 
M. Journal of the American Chemical Society 2009, 131, 2657-2662. 
 (7) Esfand, R.; Tomalia, D. A. Drug Discovery Today 2001, 6, 427-436. 
(8) Medina, S. H.; El-Sayed, M. E. H. Chemical Reviews 2009, 109, 
3141-3157. 
(9) Peer, D.; Karp, J. M.; Hong, S.; FaroKhzad, O. C.; Margalit, R.; 
Langer, R. Nature Nanotechnology 2007, 2, 751-760. 
(10) Brigger, I.; Dubernet, C.; Couvreur, P. Advanced Drug Delivery 
Reviews 2002, 54, 631-651. 
123 
 
(11) Liu, Z.; Cai, W. B.; He, L. N.; Nakayama, N.; Chen, K.; Sun, X. M.; 
Chen, X. Y.; Dai, H. J. Nature Nanotechnology 2007, 2, 47-52. 
(12) Kam, N. W. S.; Jessop, T. C.; Wender, P. A.; Dai, H. J. Journal of the 
American Chemical Society 2004, 126, 6850-6851. 
 (13) Sadler, K.; Tam, J. P. J Biotechnol 2002, 90, 195-229. 
(14) Vo-Dinh, T.; Cullum, B. Fresenius Journal of Analytical Chemistry 
2000, 366, 540-551. 
(15) Kovar, J. L.; Simpson, M. A.; Schutz-Geschwender, A.; Olive, D. M. 
Analytical Biochemistry 2007, 367, 1-12. 
(16) Hannon, M. J.; Moreno, V.; Prieto, M. J.; Moldrheim, E.; Sletten, E.; 
Meistermann, I.; Isaac, C. J.; Sanders, K. J.; Rodger, A. Angewandte 
Chemie-International Edition 2001, 40, 880-884. 
(17) Meistermann, I.; Moreno, V.; Prieto, M. J.; Moldrheim, E.; Sletten, 
E.; Khalid, S.; Rodger, P. M.; Peberdy, J. C.; Isaac, C. J.; Rodger, A.; 
Hannon, M. J. Proceedings of the National Academy of Sciences of 
the United States of America 2002, 99, 5069-5074. 
(18) Oleksi, A.; Blanco, A. G.; Boer, R.; Uson, I.; Aymami, J.; Rodger, A.; 
Hannon, M. J.; Coll, M. Angewandte Chemie-International Edition 
2006, 45, 1227-1231. 
(19) Cerasino, L.; Hannon, M. J.; Sletten, E. Inorganic Chemistry 2007, 
46, 6245-6251. 
(20) Hotze, A. C. G.; Hodges, N. J.; Hayden, R. E.; Sanchez-Cano, C.; 
Paines, C.; Male, N.; Tse, M. K.; Bunce, C. M.; Chipman, J. K.; 
Hannon, M. J. Chemistry & Biology 2008, 15, 1258-1267. 
(21) Malina, J.; Hannon, M. J.; Brabec, V. Nucleic Acids Research 2008, 
36, 3630-3638. 
(22) Childs, L. J.; Malina, J.; Rolfsnes, B. E.; Pascu, M.; Prieto, M. L.; 
Broome, M. L.; Rodger, P. M.; Sletten, E.; Moreno, V.; Rodger, A.; 
Hannon, M. J. Chemistry-a European Journal 2006, 12, 4919-4927. 
(23) Vazquez, O.; Vazquez, M. E.; Blanco, J. B.; Castedo, L.; Mascarenas, 
J. L. Angewandte Chemie-International Edition 2007, 46, 6886-6890. 
(24) Fitzsimons, M. P.; Barton, J. K. Journal of the American Chemical 
Society 1997, 119, 3379-3380. 
(25) Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, 
K. R.; Lippard, S. J. Bioconjugate Chemistry 2008, 19, 39-49. 
 (26) Brunner, J.; Barton, J. K. Biochemistry 2006, 45, 12295-12302. 
(27) Nucleic Acid Structure and Recognition; Neidle, S., Ed.; Oxford 
University Press. Oxford 2002. 
(28) Supramolecular Chemistry; Steed, J. W., Atwood, J.L., Ed.; Wiley, 
2000. 
(29) Calnan, B. J.; Tidor, B.; Biancalana, S.; Hudson, D.; Frankel, A. D. 
Science 1991, 252, 1167-1171. 
(30) Tao, J. S.; Frankel, A. D. Proceedings of the National Academy of 
Sciences of the United States of America 1992, 89, 2723-2726. 
(31) Goun, E. A.; Pillow, T. H.; Jones, L. R.; Rothbard, J. B.; Wender, P. 
A. Chembiochem 2006, 7, 1497-1515. 
 (32) Futaki, S. Advanced Drug Delivery Reviews 2005, 57, 547-558. 
(33) Rothbard, J. B.; Kreider, E.; Vandeusen, C. L.; Wright, L.; Wylie, B. 
L.; Wender, P. A. Journal of Medicinal Chemistry 2002, 45, 3612-
3618. 
124 
 
(34) Wender, P. A.; Rothbard, J. B.; Jessop, T. C.; Kreider, E. L.; Wylie, 
B. L. Journal of the American Chemical Society 2002, 124, 13382-
13383. 
(35) Wright, L. R.; Rothbard, J. B.; Wender, P. A. Current Protein & 
Peptide Science 2003, 4, 105-124. 
(36) Vazquez, O.; Blanco-Canosa, J. B.; Vazquez, M. E.; Martinez-Costas, 
J.; Castedo, L.; Mascarenas, J. L. Chembiochem 2008, 9, 2822-2829. 
(37) Telfer, S. G.; Bernardinelli, G.; Williams, A. F. Chemical 
Communications 2001, 1498-1499. 
(38) Tsang, C. S.; Yeung, H. L.; Wong, W. T.; Kwong, H. L. Chemical 
Communications 2009, 1999-2001. 
(39) Yeh, R. M.; Raymond, K. N. Inorganic Chemistry 2006, 45, 1130-
1139. 
(40) Woods, C. R.; Benaglia, M.; Cozzi, F.; Siegel, J. S. Angewandte 
Chemie-International Edition 1996, 35, 1830-1833. 
(41) Annunziata, R.; Benaglia, M.; Cinquini, M.; Cozzi, F.; Woods, C. R.; 
Siegel, J. S. European Journal of Organic Chemistry 2001, 173-180. 
(42) Lacour, J.; Hebbe-Viton, V. Chemical Society Reviews 2003, 32, 373-
382. 
(43) Lacour, J.; Frantz, R. Organic & Biomolecular Chemistry 2005, 3, 15-
19. 
(44) Baret, P.; Gaude, D.; Gellon, G.; Pierre, J. L. New Journal of 
Chemistry 1997, 21, 1255-1257. 
(45) Baum, G.; Constable, E. C.; Fenske, D.; Housecroft, C. E.; Kulke, T. 
Chemistry-a European Journal 1999, 5, 1862-1873. 
(46) Reid, S. D.; Wilson, C.; De Matteis, C. I.; Love, J. B. European 
Journal of Inorganic Chemistry 2007, 5286-5293. 
(47) Prabaharan, R.; Fletcher, N. C.; Nieuwenhuyzen, M. Journal of the 
Chemical Society-Dalton Transactions 2002, 602-608. 
(48) Meyer, M.; Kersting, B.; Powers, R. E.; Raymond, K. N. Inorganic 
Chemistry 1997, 36, 5179-5191. 
 (49) Merrifield, B. Science 1986, 232, 341-347. 
(50) Solid Phase Peptide Synthesis a Pratical Approach; Atherton, E., 
Sheppard, R.C., Ed.; Oxford University Press, 1989. 
 (51) An Introduction to Peptide Synthesis; Bailey, P. D., Ed.; Wiley, 1990. 
 (52) Markovac, A.; Stevens, C. L.; Ash, A. B.; Hackley, B. E. 
Journal of Organic Chemistry 1970, 35, 841-&. 
(53) Kaiser, E. T.; Mihara, H.; Laforet, G. A.; Kelly, J. W.; Walters, L.; 
Findeis, M. A.; Sasaki, T. Science 1989, 243, 187-192. 
(54) Lacour, J.; Ginglinger, C.; Favarger, F.; TorcheHaldimann, S. 
Chemical Communications 1997, 2285-2286. 
(55) Lacour, J.; Ginglinger, C.; Grivet, C.; Bernardinelli, G. Angewandte 
Chemie-International Edition in English 1997, 36, 608-610. 
(56) Ginglinger, C.; Jeannerat, D.; Lacour, J.; Juge, S.; Uziel, J. 
Tetrahedron Letters 1998, 39, 7495-7498. 
(57) Monchaud, D.; Lacour, J.; Coudret, C.; Fraysse, S. Journal of 
Organometallic Chemistry 2001, 624, 388-391. 
(58) Ratni, H.; Jodry, J. J.; Lacour, J.; Kundig, E. P. Organometallics 
2000, 19, 3997-3999. 
125 
 
(59) Planas, J. G.; Prim, D.; Rose, E.; Rose-Munch, F.; Monchaud, D.; 
Lacour, J. Organometallics 2001, 20, 4107-4110. 
(60) Jodry, J. J.; Lacour, J. Chemistry-a European Journal 2000, 6, 4297-
4304. 
(61) Lacour, J.; Goujon-Ginglinger, C.; Torche-Haldimann, S.; Jodry, J. J. 
Angewandte Chemie-International Edition 2000, 39, 3695-3697. 
(62) Lacour, J.; Torche-Haldimann, S.; Jodry, J. J.; Ginglinger, C.; 
Favarger, F. Chemical Communications 1998, 1733-1734. 
 (63) PhD Thesis, University of Warwick; Pearmund, C. R., Ed., 2006. 
 
  
 
 
126 
 
CHAPTER 4  
 
DNA RECOGNITION AND CYTOTOXIC ACTIVITY OF 
CONJUGATED CYLINDERS 
 
4.1 Preliminary considerations about the stability of the complexes.   
 
In this chapter the DNA binding properties of the conjugated cylinders, prepared 
in Chapter 3, are explored using different spectroscopic and electrophoresis 
methodologies. In some cases it is possible to compare their properties with those 
exhibited by the corresponding unconjugated cylinders. Also investigated is whether 
the DNA nuclease activity of the conjugated Cu(I) complexes is preserved, if the 
conjugated Fe(II) cylinders are able to target DNA three way junctions and if they 
exhibit  cytotoxicity against cancer cell lines. 
Before describing these studies some general consideration of the stability of the 
conjugates is relevant. The Fe(II) conjugates in water are not as stable as the parent 
Fe(II) cylinder. Uv-Vis absorption scans of the chloride complexes in water were 
collected every half hour at room temperature for 30 hours and the chart in Figure 
3.1.a) shows that, for all the complexes, the absorbance at the max of the MLCT 
band decreases with time, indicating their degradation. The two arginine conjugates 
are the least stable (with half life of ~ 2.5 hours), followed by the tripeptide 
conjugate (4 hours half life). The two serine conjugates are more stable, since they 
do not completely degrade in the time scale of the experiment and 15 hours are 
needed to observe their decomposition by half, however the parent Fe(II) cylinder 
does not show significant degradation for the entire time of UV-vis detection. This 
suggests that the length and charge of the conjugated units influences the stability of 
the chloride Fe(II) cylinder in water. The stability of the complexes was also 
monitored in presence of calf thymus (ct) DNA. The chart in figure 4.1.b) shows the 
variation of absorbance at the same wavelengths of solutions of complexes 
containing ct-DNA at DNA:complex ratio of 6:1. The same complex concentrations 
of the experiment in absence of DNA were used, except for the two arginine 
conjugates, where more diluted solutions had to be used to avoid the precipitation of 
the DNA caused by the complex itself (see below). For all the complexes a
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Figure 4.1. Absorbance at max of the MLCT band versus time (h) at room 
temperature of a) Fe(II) complexes, conjugates and parent cylinder in water (35 
M complexes concentration) and b) Fe(II) complexes in water in presence of 
ct-DNA; in b) concentrations of 35 M and 200 M were used for the 
complexes and the DNA respectively, except for the two arginine conjugates 
where the same ratio DNA/complex was used but 2.5 times diluted solutions 
were used (see Figure 4.2). max was 599 nm for the conjugates and 573 nm for 
the parent cylinder. The conjugating units are used to indicate the corresponding 
conjugate in the legends.    
 
 
significant improvement of the stability in presence of DNA was observed. In 36 
hours the absorbance at max of the MLCT band decreases by 28% and 52% for the 
serine and the tripeptide conjugates respectively. The arginine conjugate/DNA 
adducts appear stable for the first 9 hours, but then their degradation begins and 10.5 
h are needed to observe degradation by half. However, a direct comparison between 
the arginine conjugates and the other complexes is not accurate in this case, since the 
different concentration conditions that had to be used may affect the percent of 
complex degradation in a certain time. In general, the enhanced stability of the 
complexes is evidence that they all bind to DNA in a way that the DNA “protects” 
the complexes from being decomposed. All the Cu(I) conjugated cylinders are as 
stable as the parent Cu(I) cylinders, as their UV-vis profile was completely unaltered 
during the time in which they were monitored (36 hours at room temperature). 
  Because of the instability of the conjugates, all the experiments described in this 
chapter were carried out preparing fresh stock solutions of the complexes. The 
concentrations of the prepared stock solutions were always checked by UV-Vis
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Figure 4.2. 300 M of ct-DNA with arginine conjugated cylinder. 
DNA:complex ratio is 20:1 but precipitation of blue strands is visible already at 
60:1 ratio. 
 
 
using the calculated molar extinction coefficient at 599 nm of 12,900 M-1 cm-1. The 
stock solutions were kept on ice for the time in which they were used, and their UV-
vis profiles were monitored at the end of the each experiment to check that 
degradation did not occur. Furthermore, control experiments were carried out 
separately using the compounds that can arise from the degradation of the 
complexes, such as the spacer, the peptide/amino acid-pyridine fragment and iron 
ions. In each experiment, none of these compounds exhibited any DNA binding 
activity, even at concentrations three times higher than those used for the complexes. 
Only the spacer showed a minor DNA intercalating effect detectable only by Linear 
Dichroism (LD, section 4.3), at DNA:spacer ratio of 3:1 which was considered 
irrelevant when compared to the major effect caused by the complexes. In this way, 
it could be assumed that any result observed was due to the action of the conjugates 
only.  
 A further important feature of the two arginine conjugates was observed: they are 
able to form aggregates with the DNA with consequent precipitation of the DNA as 
blue strands (Figure 4.2), most probably because of the high positive charge of these 
complexes.
1-5
 Different conditions of concentration were investigated, to find those 
in which precipitation of DNA-complex aggregates did not occur, since this would 
have affected the DNA recognition experiments in solutions. It was found that the 
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maximum concentration of DNA to use is 100 M (with 10 mM NaCl and 1mM of 
sodium cacodylate buffer, with a pH of 6.8). Above this concentration, even small 
additions of arginine conjugate caused precipitation of DNA (formation of 
aggregates is visible already at 60:1=DNA:complex).   
 
4.2 DNA binding studies by circular dichroism (CD). 
 
In Chapter 2 and 3, CD has been used to observe the chirality of helicates, but this 
is also one of the most common techniques to study the interaction of biomolecules 
(such as nucleic acids and protein) with other agents (either synthetic agents or other 
biomolecules). The chiral centres of the primary structure of DNA are the carbons of 
the ribose-phospate backbone, which do not produce any transitions in the UV-vis 
region that are easily detectable. But the single nucleotides have distinctive CD 
signals that are induced by the chiral ribose into the transitions of the neighbouring 
bases. The CD bands of any secondary structure of DNA originate from the 
transitions of the bases in the UV region, but depend also on the reciprocal 
orientation and distances of the bases and consequently the signal is strictly 
connected to the asymmetric orientation and conformation of the structure itself. 
Indeed, different forms of DNA exhibit different CD signals depending on their 
geometric parameters rather than their bases composition, so that the most common 
structures such as B-, A- or Z-DNA can be identified by their characteristic CD 
spectra.
6
 The CD spectrum of B-DNA extracted from calf thymus (ct) (shown in 
Figure 4.3) presents the characteristic B-DNA pattern below 300 nm, with a 
shortwave negative and a longwave positive band of nearly equal intensity, with an 
intersection point at the UV absorption maximum (260 nm). When DNA is analysed 
in presence of another molecule, such as a synthetic agent, if such molecule does not 
have a CD signal because it is not chiral or it is in the form of a racemic mixture, 
modifications in the CD spectrum of the DNA can arise from DNA-synthetic agent 
interactions and provide information about the type of binding.  
CD studies of B-DNA with racemic Fe(II) parent cylinder [Fe2(L1)3](Cl)4 have 
already been reported
7,8
 and a typical CD titration with this complex is shown in 
Figure 4.4. The racemic mixture of [Fe2(L1)3](Cl)4 does not have a CD signal, but, 
when it binds to the asymmetric DNA, CD is induced by the DNA into complex 
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transitions and an induced CD signal (ICD) is formed with bands in the visible 
region, where the complex absorbs. The ICD signal of [Fe2(L1)3](Cl)4 in the presence 
of ct-DNA presents characteristic bands at 315 and 375 nm (transitions from the 
ligand) and at 541 and 615 nm (MLCT bands), whose magnitude increases on 
increasing the concentration of the complex up to a DNA(bp):complex=8:1 ratio.  
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Figure 4.3 CD signal of 300 M (in base pairs) B-DNA from calf thymus (ct).  
 
 
 
 
              
 
 
Figure 4.4 Example of titration of 500 M (in bases) ct-DNA in 20 mM NaCl 
and 1 mM Na(CH2)2AsO2 · 3H2O buffer (pH 6.8) with increasing concentrations 
of parent [Fe2(L1)3]
4+. The DNA base:[Fe2(L1)3]
4+ ratios are for smallest 
magnitude spectra to largest: 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 7.5:1, 10:1, 15:1, 
25:1, and 50:1. Insert shows CD at key wavelengths as a function of complex 
concentration. Insert wavelengths are: x CD at 315 nm, □ CD at 375 nm ♦ CD at 
541 nm (Figure taken from reference 7).  
 
 
 
 
Induced CD signal 
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This behaviour indicates that, up to these concentrations, the complex binds to 
DNA in one single mode (consistently with the binding in the major groove 
explained in Chapter 2). Different binding modalities cannot be excluded at higher 
complex concentrations. Further information that can be obtained from CD studies 
concerns the effect of the cylinder binding on the structure of the DNA: although the 
CD signal of the DNA in the UV region is slightly perturbed, it still retains the same 
profile of the B-DNA in absence of the complex, suggesting that the binding of the 
complex to the DNA does not affect its secondary structure.  
Analogous CD titrations were performed with the Fe(II) conjugates cylinders. Figure 
4.5 shows the CD of 300 M of ct-DNA with increasing concentrations of the 
tripeptide conjugate [Fe2(La1)3]Cl4. Using the same stock solution of complex, two 
equal titrations were performed, one analysed with a 0.1 cm cuvette (to avoid 
saturation of the signal in the UV region that occurs at these concentrations of DNA 
and complex, Figure 4.5.a)) and the other was analysed in 1 cm cuvette, to better 
visualise the less intense signal in the MLCT region (Figure 4.5.b)). In the UV 
region, the CD signal of the B-DNA is perturbed by the addition of the complex, 
with small decreases in the magnitudes of all the bands and at higher complex 
loading the maxof the positive band of the DNA (275 nm) shifts 5 nm to higher 
wavelengths. An induced CD shows as a shoulder at 300 nm. In the ligand and 
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Figure 4.5. CD of 300 M of ct-DNA in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2·3H2O (pH 6.8)  with increasing concentration of the Gly-Gly-
Ser conjugate ([Fe2(La1)3]Cl4). The legends show ct-DNA/complex ratios. a) 
Uv region (200-350 nm) was analysed in 0.1 cm cuvette and b) the visible 
region (750-280 m) in 1 cm cuvette. 
a) b) 
132 
 
MLCT regions of the complex spectroscopy (Figure 4.5.b)), ICD bands are evident at 
high complex loading only. These ICD signals prove that the Fe(II) tripeptide 
conjugate binds to the DNA and it does not cause modification of the B-DNA 
conformation. The produced ICD signal in the visible region appears weaker than 
that seen with the parent cylinders; however a direct comparison would be difficult 
as the two complexes have different value of .  
Similar titrations were performed using the Fe(II) D-Ser conjugate [Fe2(Lc1)3]Cl4 
(Figure 4.6.a) and b)) and the L-Ser conjugate [Fe2(Lb1)3]Cl4 (Figure 4.6.c) and d)).  
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Figure 4.6. CD of 300 M of ct-DNA in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2·3H2O (pH 6.8)  with increasing concentration of D-Ser 
conjugate [Fe2(Lc1)3]Cl4 a) Uv region (200-350 nm) in 0.1 cm cuvette and b) 
visible region (750-280 m) in 1 cm cuvette). Same titration with the L-Ser 
conjugate [Fe2(Lb1)3]Cl4. (c) Uv region (200-350 nm) in 0.1 cm cuvette and d) 
visible region (750-280 m) in 1 cm cuvette).  The signals of the complex alone 
were subtracted from the signals of the complex/DNA adducts at the 
corresponding complex concentrations. 
a) 
d) c) 
b) 
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These two complexes have their own CD signals (Chapter 3) and for this reason the 
signal of the complex alone was subtracted from each signal of complex-DNA 
adduct at the corresponding concentration, to eliminate contribution of the CD 
absorbance of the complex. As observed for the tripeptide conjugate, these two 
complexes also produce a very little perturbation of the DNA signal suggesting that 
binding occurs without modification of the B-DNA conformation and only at 5:1 
ratio (DNA:complex) the shifts of the bands at 275 nm become relevant. Observing 
the two MLCT regions only the L-Ser conjugate exhibits ICD bands that are visible 
from 10:1. This could initially suggest a different affinity and/or different binding 
mode for the two complexes toDNA, but all the successive analysis of these two 
complexes with different techniques, did not reveal important difference in their 
activity. Rather, this difference might originate from a different level of chirality of 
the two complexes that produce DNA-complex adducts with different ICD signals in 
the visible region. 
CD titrations were also performed with the two arginine conjugates, but using 100 
M of starting ct-DNA solution (Figure 4.7 a) to d)). Also in this case, the CD 
signals of the complexes alone were subtracted from the signals of the DNA-
complex adducts. In both titrations, ICD signals are observed with relatively intense 
induced bands at 300, 335, 534 and 614 nm and the two complexes present opposite 
profiles. This confirms that the two arginine conjugates also bind the DNA, although 
a direct comparison with the other Fe(II) conjugates it is not possible because all the 
complexes have different intrinsic CD profiles in water. In Figure 4.7. e) the two ICD 
signals of the DNA/complex adducts at 8:1 are compared and in this case the signal 
of the DNA alone was also subtracted from the adducts. It seems that the bands of 
the ICD signal of the D-Arg conjugate/DNA adduct have higher intensity, both the 
bands in the visible region and, more evidently, the band at 300 nm. This might 
indicate a different DNA binding affinity and/or mode between the two complexes. 
A difference in DNA binding between L and D-Arg conjugates is indeed expected, 
since the central helicates of these two complexes are in P and M conformation 
respectively and it was demonstrate that the unsubstituted P and M isomers bind the 
DNA differently.
8
 However, this needs to be confirmed by other techniques, because 
a small difference in the CD profile of the complex alone could affect the accuracy of 
the analysis of DNA-complex adducts. 
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Figure 4.7. CD of 100 M of ct-DNA in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2·3H2O (pH 6.8)  with increasing concentration of a) and b) L-Arg 
conjugate [Fe2(Ld1)3]Cl4 and c) and d) D-Arg conjugate [Fe2(Le1)3]Cl4 (in b) 
and d) the enlargement of the UV regions). The legends show decreasing ratio 
of DNA:complex. The signals of the complex alone were subtracted from the 
signals of the complex/DNA adducts at the corresponding complex 
concentrations. e) ICD signals of ct-DNA/L-Arg and ct-DNA/D-Arg both at 8:1 
ratio where the signals of both complexes alone and ct-DNA alone were 
subtracted from the DNA-complex adducts.  
a) 
d) c) 
b) 
e) 
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D and L-Arg conjugated cylinders in presence of poly[G-C] and poly[A-T] DNA 
were also analysed by CD, to verify whether the complexes exhibits any binding 
preference between these polymers. Figure 4.8.a) shows how the CD signals of these 
two types of DNAs are slightly different (as a consequence of their different at 260 
nm) and the CD of poly[G-C] and poly[A-T] mixed at 1:1 ratio is also shown. The 
ICD signals of the D-Arg conjugate with poly[G-C], poly[A-T] and the mix poly[G-
C]/poly[A-T](1/1) at DNA:complex concentration of 10:1 are shown in Figure 
4.8.b). The signals of the complex alone and the corresponding DNAs alone were 
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Figure 4.8. CD of 100 M of poly[G-C], poly[A-T] and a mix (1/1) of poly[G-
C] and poly[A-T] in 10 mM NaCl and 1  mM Na(CH2)2AsO2·3H2O (pH 6.8)  a) 
only DNAs b) with D-Arg conjugate [Fe2(Le1)3]Cl4 at ratio 10:1 of D-
Arg/DNAs and c) with L-Arg conjugate [Fe2(Ld1)3]Cl4 at ratio 10:1 of L-
Arg/DNAs. The signals of the complex alone and DNAs alone were subtracted 
from the signals of the complex/DNA adducts. 
 
a) 
c) b) 
136 
 
 
subtracted to the signal of the DNA-complex adducts. The resulting ICD signals 
between 200 and 300 nm are different for the poly[G-C]-complex and poly[A-T]-
complex adducts. The intensity of the ICD band at 300 nm (where the ligand 
absorbs) of the D-Arg complex/poly[G-C] is higher than the intensity of the same 
band of D-Arg complex/poly[A-T]. The intensity of the band relative to the complex 
with the mix of the two DNAs is an average between the other two. The same 
experiment was carried out with the L-Arg conjugate (Figure 4.8.c)) and an 
analogous behaviour was observed at 300 nm. It is difficult to extract any 
unambiguous information at lower wavelength, as too many CD signals are 
overlapped in the UV region. In the visible region the complexes exhibit the same 
behaviour in the presence of different DNA sequences. Thus, these experiments 
suggest that the two complexes might bind differently the two different DNA 
polymers analysed, but this has to be further proved with the use of methodologies 
that are more appropriate to study the DNA binding selectivity of chiral complexes. 
This will object of future work (see Chapter 5).   
 
4.3 Linear dichroism studies.  
 
The Linear Dichroism (LD) technique is based on the principle that electronic 
transitions in molecules are fixed in a specific orientation and that if the molecules 
themselves are aligned in a specific orientation then the polarization of the transition 
may be probed by the differential absorption of oriented linearly polarized light. In 
practice two linearly polarized light beams that are parallel or perpendicular to the 
direction of the orientation of the molecules are used and the difference in 
absorbance can be recorded as LD signal.
9-11
 
There are several methods to provide orientation to long and small molecules. The 
technique used herein is known as flow orientation and is based on the use of the 
Couette flow cell that is represented in Figure 4.9.a). The cell is made of two coaxial 
cylinders, one internal to the other, and the solution to analyse is placed into the 
narrow gap between the two cylinders. The rotation of the internal cylinder causes 
the orientation of the molecules by viscous drag and this orientation can be probed 
with  linearly polarised light. With the flow orientation method, only long molecules, 
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Figure 4.9. a) Representation of a Couette flow cell. The incident radiation is 
perpendicular to the rotation axis of the internal cylinder. Strands of long DNA 
(more than 1000 base pairs) are oriented upon the rotation of the internal 
cylinder. b) LD spectrum of B-DNA from calf thymus. 
 
 
such as DNA with more than 1000 base pairs, present significant and detectable 
orientation and in Figure 4.9.b) the typical LD spectrum of B-DNA from calf thymus 
is showed. With this method, small molecules do not orient and do not show any LD 
signal. However, if a small molecule, such as a synthetic agent, binds to the oriented 
DNA (or in general to a long molecule with LD signal), then the resulting LD 
spectrum changes in relation to both the contribution of newly oriented electronic 
transitions from the small molecule attached and to possible variations of the DNA 
orientation occurring upon its interaction with the agent.   
LD titration of 100 M of ct-DNA with all the Fe(II) conjugated cylinders were 
performed and compared with the parent unconjugated cylinder. In Figure 4.10 a) to 
f) all the titrations with the Fe(II) complexes are shown: in a) the parent 
[Fe2(L1)3]Cl4, in b) the tripeptide conjugated [Fe2(La1)3]Cl4, in c) and d) the L and 
D-Ser conjugated [Fe2(Lb1)3]Cl4 and [Fe2(Lc1)3]Cl4, in e) and f) the L and D-Arg 
conjugated [Fe2(Ld1)3]Cl10 and [Fe2(Le1)3]Cl10). For the parent Fe(II) cylinder, the 
gradual loss of signal at 260 nm, as increasing concentrations of complex are added, 
is a consequence of the loss of the initial orientation of the DNA strands resulting 
from either an increase in DNA flexibility or a shortening of the DNA by kinking, 
a)                                                       b) 
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bending, compaction, or aggregation of DNA. Moreover the complex itself acquires 
an induced orientation as a consequence of its binding to the DNA, and, since the 
binding is not random, a systematic increasing of induced LD signal occurred in the 
MLCT region of the complex.
7
 Analogous results are obtained with the conjugated 
Fe(II) complexes. In all the titrations carried out, there is a significant loss of signal 
at 260 nm as a consequence of changes in the orientation of the DNA caused by the 
binding of the complexes. The three conjugates [Fe2(La1)3]Cl4, [Fe2(Lb1)3]Cl4 and 
[Fe2(Lc1)3]Cl4 also exhibit induced LD signals in the MLCT region which confirms 
that their binding to the DNA is not random but in an oriented fashion. However, no 
induced LD signal in the visible region is observed when the DNA is titrated with the 
two arginine conjugates [Fe2(Ld1)3]Cl10 and [Fe2(Le1)3]Cl10. In some cases the 
absence of induced LD bands in the visible region is due to the ability of the agent to 
cause condensation/aggregation of the DNA with consequent precipitation of strands 
of DNA-agent adducts. As explained in section 4.1, the arginine conjugate are indeed 
able to precipitate the DNA but this does not occur at the concentration conditions 
selected for these titrations. The absence of bands in the MLCT region of the 
complexes is a little surprising given the response of the parent cylinder and the other 
three conjugates but it does not per se mean that the complexes do not bind in a 
specific manner. Nature and shape of the induced LD in complex spectroscopy is the 
same for parent as for L and D-Ser and tripeptide conjugates, implying a similar 
mode of binding. However, the presence of six guanidinium groups at the edges of 
the arginine conjugate cylinders could offer different possibilities of interaction with 
the DNA, including contacts with the phosphate groups, in addition to the binding at 
the major groove through the helicate core. 
The analysis of the decrease of the LD adsorbance at 260 nm is useful to compare the 
behaviour of different complexes on the DNA orientation. In this case, the behaviour 
of the two arginine conjugated has to be discussed separately from all the other 
complexes, because of the absence of induced LD signal. In fact, all the other 
complexes present induced LD bands not only in the MLCT region, but also in the 
UV region and these bands overlap with that originating from the DNA, contributing 
to the value of absorbance at 260 nm especially at low DNA:complex ratio. In 
contrast, when the DNA is titrated with the two arginine conjugates, the absorbance 
at 260 nm originates from the DNA only. 
139 
 
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
ct-DNA
100-1
60-1
30-1
20-1
15-1
10-1
8-1
5-1
L
D
Wavelength (nm)
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
ct-DNA
100:1 
60:1
50:1
40:1
30:1
20:1
15:1
10:1
8:1
5:1
L
D
 
Wavelength (nm)  
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
ct-DNA
100-1
60-1
30-1
20-1
15-1
10-1
8-1
5-1
L
D
Wavelength (nm)  
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
DNA
100-1
60-1
30-1
20-1
15-1
10-1
8-1
5-1
L
D
Wavelength (nm)  
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
ct-DNA
100-1
60-1
30-1
20-1
15-1
10-1
8-1
5-1
L
D
Wavelength (nm)  
-0.014
-0.012
-0.01
-0.008
-0.006
-0.004
-0.002
0
0.002
200 300 400 500 600 700
ct-DNA
100-1
60-1
30-1
20-1
15-1
10-1
8-1
5-1
L
D
Wavelength (nm)  
 
Figure 4.10. LD of 100 M of ct-DNA in 10 mM NaCl and 1 mM 
Na(CH2)2AsO2·3H2O (pH 6.8)  with increasing concentration of a) 
[Fe2(L1)3]Cl4, b) [Fe2(La1)3]Cl4, c) [Fe2(Lb1)3]Cl4, d) [Fe2(Lc1)3]Cl4, e) 
[Fe2(Ld1)3]Cl10 and f) [Fe2(Le1)3]Cl10. The legends show decreasing ratios of 
DNA:complex and, where necessary, inserts show the enlargement of the 
corresponding MLCT regions.  
a)                                                  b) 
c)                                                    d) 
e)                                                      f) 
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Figure 4.11. a) Plotting of LD absorbance at 260 nm vs complex 
concentration extracted from the titrations with [Fe2(L1)3]Cl4, [Fe2(La1)3]Cl4, 
[Fe2(Lb1)3]Cl4 and Fe2(Lc1)3]Cl4. b) From the same titrations, plotting of LD 
absorbance at the max of the MLCT band vs complex concentration (max is 574 
nm for parent [Fe2(L1)3]Cl4 and 600 nm for [Fe2(La1)3]Cl4, [Fe2(Lb1)3]Cl4 and 
[Fe2(Lc1)3]Cl4). LD=LD-LDDNA where LD is the value of LD absorbance at 
max and LDDNA is the LD absorbance of the DNA at the same wavelength. In 
the legends the complexes are indicated with their conjugating units. 
 
 
The chart in Figure 4.11 a) shows the variation of the LD absorbance at 260 nm 
as a function of the complex concentrations, extracted from the titrations with the 
parent [Fe2(L1)3]Cl4, the tripeptide conjugate [Fe2(La1)3]Cl4, the  L and the D-Ser 
conjugates [Fe2(Lb1)3]Cl4 and Fe2(Lc1)3]Cl4 shown in Figure 4.10 a), b), c) and d). 
LD is the difference between the absorbance at 260 nm after each addition of 
complex and the absorbance of DNA alone (100 M) at the same wavelength. The 
chart in figure 4.11.b) shows the analogous plotting, but using LD values at the max 
of the induced bands in the MLCT region (max is 574 nm for parent [Fe2(L1)3]Cl4 
and 600 nm for [Fe2(La1)3]Cl4, [Fe2(Lb1)3]Cl4 and [Fe2(Lc1)3]Cl4). From these data, 
the parent Fe(II) cylinder and the two serine conjugated Fe(II) cylinders exhibit 
similar activity in affecting the orientation of the DNA, whilst the tripeptide 
conjugated Fe(II) cylinder is the least effective complex.  
Separately, the chart in Figure 4.12 shows the variation of LD at 260 nm versus 
complex concentration corresponding to the titration with the two arginine 
conjugates (from Figure 4.10 e) and f)). The D-Arg conjugate emerges as the more 
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Figure 4.12. Plotting of LD absorbance at 260 nm vs complex concentration 
extracted from the titrations with [Fe2(Ld1)3]Cl10 and [Fe2(Le1)3]Cl10. In the 
legend the complexes are indicated with their conjugating units. 
 
 
 
DNA/complex 
ratio 
% of loss of LD signal at 260 nm upon interaction with 
increasing concentrations of cylinders 
L-Arg 
conjugate 
D-Arg 
conjugate 
Parent 
Cylinder 
GGS 
conjugate 
D-Ser 
conjugate 
L-Ser 
conjugate 
100.0 8.6 18.3 7.3 5.6 17.1 6.4 
60.0 13.7 27.1 11.8 12 24.3 12.8 
30.0 27.4 46.1 21.5 19.2 23.7 23.6 
20.0 42.4 61.4 29.4 25.2 43.3 37.4 
15.0 58.5 72.8 36.7 28.2 53 47.1 
10.0 72.9 92.9 53.1 36.6 67.5 63.6 
8.0 85.6 100 62.9 42.2 72.1 72.6 
5.0 98.9 100 81.8 55.1 92.3 92 
 
Table 4.1. The percent of loss of LD signal at 260 nm caused by addition of 
increasing concentrations of different complexes was calculated using the 
titrations shown in Figure 4.10. 
 
 
active in causing modification to the DNA and this supports the CD results and is 
consistent with the fact that the D-Arg conjugation induces the central helicate core 
in M configuration (see Chapter 3) and with the demonstrated
8
 higher ability of this  
enantiomer in coiling the DNA.  
Table 4.1 offers a complementary vision of the effect of these conjugated 
cylinders from LD titration, by comparing the % of loss of LD signal at 260 nm upon 
adding increasing concentrations of complexes. At low concentration of D-Arg 
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conjugate already 18.3% of the initial LD signal at 260 nm is lost, against the only 
8.6% caused by the L-Arg conjugate. The LD signal decreases by half at 30:1 
(DNA:complex ratio) and a complete loss of the signal occurs at 8:1 ratio. Slightly 
higher concentrations of L-Arg conjugate are needed to produce the same effect. By 
contrast, the tripeptide conjugate causes only 55% of the DNA LD signal lost at 260 
nm even at high complex concentrations (5:1 ratio), whilst the two serine conjugate 
and the parent cylinder present similar behaviour with the parent cylinder slightly 
less effective. However, at very low complex concentration (100:1 and 60:1 ratios) 
the D-Ser conjugate provokes a remarkable higher loss of LD signal, compared to L-
Ser and parent cylinder. The reason for this is unclear, since it was not possible to 
establish the actual conformation of the helicate core of the serine conjugates 
(Chapter 3) and whether this, eventually, influences the DNA binding. 
Analogous titrations were performed with the Cu(I) complexes, the parent 
[Cu2(L5)2]Cl2, the two tripeptide conjugates [Cu2(La1)2]Cl2 and [Cu2(La2)2]Cl2, and 
the two L and D-Ser conjugates [Cu2(Lb2)2]Cl2 and [Cu2(Lc2)2]Cl2 (Figure 4.13 a) to 
e)). All the complexes exhibit DNA binding and coiling, but they are less effective 
than the Fe(II) cylinders. This is the expected consequence of the smaller positive 
charge of the complexes, and also the absence of one ligand strand offer less 
possibility of hydrophobic interactions with the DNA. The magnitude of induced LD 
bands in the MLCT region increases in all the titrations, except that with 
[Cu2(La1)2]Cl2. This is not surprising since the nature of the ligand of this Cu(I) 
complex does not ensure the exclusive formation of the helicate conformation (box 
conformation cannot be excluded),
12
 so that more binding mode are possible for this 
complex.  
The chart in Figure 4.13.f) reports the variation of LD at 260 nm in function of 
complex concentration. All the conjugates exhibits comparable activity by LD. The 
L-Ser conjugate seems slightly more effective than the D-Ser conjugate, but all the 
conjugated complexes are unequivocally less active than their unconjugated 
equivalent.   
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Figure 4.13. LD of 300 M of ct-DNA in 20 mM NaCl and 1 mM 
Na(CH2)2AsO2·3H2O (pH 6.8)  with increasing concentration of a) parent 
[Cu2(L5)2]Cl2, b) Gly-Gly-Ser conjugate [Cu2(La1)2]Cl2, c) Gly-Gly-Ser 
conjugate [Cu2(La2)2]Cl2, d) L-Ser conjugate [Cu2(Lb2)2]Cl2 and e) D-Ser 
conjugate [Cu2(Lc2)2]Cl2. The legends show decreasing ratios of DNA:complex 
and, where necessary, inserts show zoom of the corresponding MLCT region. In 
f) the plotting of the LD at 260 nm in function of complex concentration. 
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4.4 Gel Electrophoresis studies. 
 
Gel electrophoresis is one of the most common techniques used for the separation 
of bio-molecules such as DNA, RNA and proteins. It is based on the principle that 
these molecules have a specific net charge that can be used to cause their migration 
along an appropriate gel matrix under the effect of an electric field applied to the gel. 
The electric field drives the molecules toward the electrode with the opposite charge 
and the velocity of the migration (v) depends on the strength of the electric field (E) 
applied, the net charge of the molecule (z) and the frictional coefficient (f): 
       
The frictional coefficient f depends on the shape and mass of the migrating molecule 
and on the viscosity of the medium that contrast the mobility of the molecules 
throughout the pores of the matrix. Usually, the matrix is a cross linked polymer, that 
assumes the consistence of a gel, whose composition and porosity is chosen 
according with the molecule to analyse. Generally, polyacrylamide gels are used to 
analyse short sequences of nucleic acids (DNA or RNA) and proteins (this method is  
also known as PAGE electrophoresis), whilst agarose gels are used for bigger 
molecules such as plasmid DNA. The scheme in Figure 4.14 represents a typical 
agarose gel used to analyse a big molecule of DNA such as plasmid DNA. This is a 
type of double stranded circular DNA that occurs naturally in bacteria. The main 
 
  
 
Figure 4.14. Representation of three different conformations of plasmid DNA 
that migrate with different rate on an agarose gel. 
145 
 
conformations that plasmid DNA can assume are: the supercoiled conformation, 
where the DNA is compact with a twist built up; the circular conformation, which 
can be obtained upon enzymatic or artificial cut of one of the strands of the 
supercoiled plasmid causing the opening of the supercoiling to a relaxed circular 
structure; the linear conformation, deriving from a double cut of both strands of 
supercoiled or circular DNA. Solutions containing a mix of these three 
conformations of plasmid can be loaded in wells on the surface of the gel and, when 
the electric current is applied at the two sides of the gel, the DNA migrates toward 
the positive electrode, but the different conformations of DNA migrate with a 
different rate according with their shapes. In this case the supercoiled plasmid runs 
faster than circular plasmid and the linear conformation has an intermediate rate.  
There are different methods to visualise the bands on the gel after the 
electrophoresis run is complete. For DNA run on agarose gel, the gel can be stained 
by luminescent compounds that interact with the DNA. For example the gel can be 
treated with ethidium bromide which intercalates between the DNA bases and can be 
detected upon exposing of the gel to light. When shorter sequences of DNA are 
analysed on polyacrylamide  gel (and at lower concentrations), then a more sensitive 
technique of visualisation is necessary and in this case the DNA is labelled with 
radioactive isotopes and an autoradiogram of the gel can be recorded.  
Herein, both agarose and polyacrylamide gel techniques were employed. The 
first to explore the nuclease activity of the conjugated Cu(I) cylinders in presence of 
an oxidising agent, and the second to verify whether the conjugated Fe(II) cylinders 
bind into the DNA three way junction as the unconjugated cylinder does.  
 
4.4.1 Agarose gel to test nuclease activity of Cu(I) complexes. 
 
The copper complexes of some di-imine ligands, (for example copper(I/II) bis-
phenanthroline) are known to exhibit oxidative DNA cleavage properties.
13-15
 The 
unsubstituted cylinder [Cu2(L5)2]Cl2 has been shown to cleave DNA in presence of 
hydrogen peroxide. Interestingly it displays some double strand cleavage activity 
which may reflect its di-nuclear nature with two linked sites capable of cleaving two 
strands
16
. To verify that the conjugated Cu(I) cylinders ([Cu2(La1)2]Cl2, 
[Cu2(La2)2]Cl2, [Cu2(Lb2)2]Cl2 and [Cu2(Lc2)2]Cl2) retain the same DNA cleavage 
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capacity, gel electrophoresis (1% agarose) experiments using supercoiled plasmid 
pBR322 DNA were performed. Solutions of 90 M of plasmid were incubated with 
each Cu(I) complex at different concentrations (different DNA:complex ratios) in 
presence of  hydrogen peroxide (HP) as oxidising agent. Solutions containing only 
DNA-complex adducts without HP were also analysed and all the resulting gels are 
shown in Figure 4.15. Although the nuclease activity of parent [Cu2(L5)2]Cl2 has 
already been reported, the experiment was performed also with this complex (gel a)) 
to provide a standard for comparison. In each gel lanes 1 and 2 are DNA (plasmid 
pBR322, 90 M) and DNA with 25 mM of HP respectively, to confirm that HP 
alone does not affect the DNA. The DNA is mainly present in the supercoiled 
conformation (band C in gel a)), but the circular conformation is also visible (band A 
in gel a)). Gel a) shows that using parent [Cu2(L5)2]Cl2, the supercoiled 
conformation disappears already at 30:1(DNA:complex ratio).
16
 The circular and the 
linear (band B) conformations are both visible at 30:1 and they gradually disappear 
as the concentration of complex is increased, whilst formation of a broad smear 
(band D) becomes visible to indicate that the DNA is chopped in fragments of 
different length that run in the gel with different rates. Nuclease activity was 
observed for all the conjugates, although the complete absence of the supercoiled 
conformation occurs at higher concentrations of complex. The tripeptide conjugate 
([Cu2(La2)2]Cl2, gel b)
17
) and the L-Ser conjugate ([Cu2(Lb2)2]Cl2, gel c)) cause 
rupture of the supercoiled DNA at 10:1 and 15:1 respectively, with successive 
formation of ladder at higher complex concentrations, so that the L-Ser conjugates 
seems slightly more effective. The D-Ser conjugate (gel d)) provokes the break of the 
supercoiled conformation at 15:1 but for unclear reasons, the chopping is not 
complete at higher complex concentrations as it occurs for the other two conjugates. 
The artificial nuclease activity of the tripeptide conjugated [Cu2(La1)2]Cl2 (gel e)), is 
not so efficient as the former complexes (supercoiled DNA is still present at high 
complex loading, although visibly less abundant). In all the gels, the concurrent 
presence of supercoiled, circular and linear DNA is consistent with the possibility of 
the simultaneous double strand cleavage due the action of both metal centres, that 
was already hypothesised for the parent [Cu2(L5)2]Cl2. Lanes 10 to 13 of gels b), d) 
and e) are relative to the complexes incubated with the DNA without HP and it is 
evident that they do not affect the DNA in these conditions, as it was already
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Figure 4.15. The ethidium bromide stained gels of pBR322 plasmide and a) 
parent [Cu2(L5)2]Cl2, b) [Cu2(La2)2]Cl2, c) [Cu2(Lb2)2]Cl2 d) 
([Cu2(Lc2)2]Cl2and e) [Cu2(La1)2]Cl2. The lanes are numbered in black at the 
bottom of each gel. For each gel: Lane 1: DNA of reference (90 M); Lane 2: 
DNA with HP (25 mM, after 1 hour of incubation). The red values on the top of 
the gels are referred to the DNA/complex ratios of samples that were incubated 
with 25 mM of HP. The blue values correspond to DNA/complex ratios of 
samples incubated without HP. For gel d) only, lane 10 to 13 are: 
DNA:[Cu2(Lb2)2]Cl2=15:1 (10), DNA:[Cu2(Lb2)2]Cl2=8:1 (11), 
DNA:[Cu2(Lc2)2]Cl2=15:1 (12) and DNA:[Cu2(Lb2)2]Cl2=8:1 (13), without HP.  
             30  20   15  10   8    5        30  25  20  15  10   8   5    25  15    8   5 
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D  
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observed for the parent [Cu2(L5)2]Cl2. 
In conclusion, all the conjugates exhibit the ability of chopping plasmid DNA in 
the presence of HP, but with different efficiency. However they are all less effective 
than the parent Cu(I) complex and this is consistent with the better DNA binding that 
the parent complex showed by LD experiments. 
 
4.4.2 PAGE electrophoresis to test the DNA three way junction binding of 
Fe(II) complexes. 
 
In Chapter 2 it has been explained that one of the most exciting qualities of parent 
Fe(II) cylinders is their ability to bind  at the heart of a DNA three way junctions 
(3WJ). This was observed for the first time when the crystal structure of the complex 
in presence of the palidromic hexanucleotide 5’-d(CGTACG)-3’ was obtained.18 
Successively, it was of interest to verify that this was not an artefact of 
crystallisation, but a type of action that could also occur in solution. J. Malina et al.
19
 
carried out PAGE electrophoresis experiments using three different strands of 14-
mer non palindromic oligonucleotide that can potentially form a three way junction 
of seven base pairs per arm.
20
 Those experiments demonstrated that the Fe(II) parent 
cylinder promotes the formation of the three way junction between the three strands 
and, moreover, stabilises such structure even when temperature conditions are not 
favourable for the formation of the junction in absence of the complex. Those results 
also highlighted the importance of the shape of the cylinder in stabilising the three 
way junction (bulky cylinders were not successful), and that the M enantiomer of the 
parent cylinder is slightly more effective than the P enantiomer.  An analogous 
PAGE electrophoresis experiment was carried out by Siriporn Phongtongpasuk, from 
the Hannon group, using the facilities of the Functional Genomics and Proteomics 
Unit of the school of Bioscience at the University of Birmingham. In this experiment 
all the conjugated Fe(II) cylinders were incubated with the same three strands of 
oligonucleotide used by Malina (Figure 4.16.a)) and analysed by polyacrylamide gel. 
Figure 4.16. b) shows the autoradiogram of the gel run at room temperature in which 
Lanes 1, 2 and 3 contain strands S3*, S3*+S2 and S3*+S2+S1 respectively where 
S3* is the strands labelled with 
32
P at the 5' extremity. These strands are relatively 
short and in these conditions of buffer and temperature they do not interact to form 
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Figure 4.16. a) The three sequences of oligonuctleotide used to assembly the 
three way junction are indicated as S1, S2 and S3* where S3* is the 32P 
labelled strand. b) Polyacrylamide gel (autoradiogram) at room temperature 
of the three strands incubated with the conjugated Fe(II) cylinders. Lane 1 to 
3 are the controls S3*, S3*+S2, S3*+S2+S1 respectively; Lane 4 to 9: 
S3*+S2+S1 (0.4 M for each strand, 1.2 M total concentration of DNA) in 
presence of parent [Fe2(L1)3]Cl4 (4), [Fe2(Lc1)3]Cl4 (5), [Fe2(Lb1)3]Cl4 (6), 
[Fe2(Le1)3]Cl10 (7), [Fe2(Ld1)3]Cl10 (8) and [Fe2(La1)3]Cl4 (9). Lane 4' to 9': 
the same solutions, separately prepared, were loaded in the same order for a 
more accurate analysis. All the loaded samples contained 0.4 M of complex 
to have a theoretical 3WJ:complex ratio of 1:1.   
 
 
either the three way junction or a double strand (only at ~5 °C a partial formation of 
3WJ could occur
19,20
) and for this reason they run as single bands with the same rate 
in the gel. However, incubation of the three strands with any conjugated Fe(II) 
cylinder leads to the formation of a three way junction. Lanes 4 to 9 contain 
S3*+S2+S1 in the presence of the parent cylinder [Fe2(L1)3]Cl4 as control (Lane 4), 
the D and L-Ser conjugated [Fe2(Lc1)3]Cl4 and [Fe2(Lb1)3]Cl4 (Lane 5 and 6), the D 
and L-Arg conjugated [Fe2(Le1)3]Cl10 and [Fe2(Ld1)3]Cl10 (Lane 7 and 8) and the 
tripeptide conjugated [Fe2(La1)3]Cl4 (Lane 9). Lanes 4' to 9' contain the same 
samples in the same order, loaded a second time for a better accurateness of the 
analysis. All the complexes exhibit a similar ability to promoting the formation of the 
three way junction. As expected, the rate of migration of the 3WJ-complex adduct is 
slightly different depending on the charge and the dimension of the complexes: the 
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Figure 4.17. Quantification of the intensity of the bands (by Quantity one) from 
the gel in Figure 4.16. % of three way junction formed in presence of each 
complex a) absolute considering the precipitation of the DNA in the wells and 
b) only relative to the bands of single strand. The labels indicate the complexes 
according with their conjugating units. 
 
 
arginine conjugates have a higher positive charge so that they form adducts with the 
DNA that run more slowly toward the positive electrode. The tripeptide conjugate-
3WJ is slower than any serine conjugate-3WJ, most probably because the first 
complex is more extended. The 3WJ-serine conjugates have nearly the same ratethan 
the 3WJ-parent cylinder adduct. From the gel, it is visible that the lanes relative  
to the 3WJ-arginine conjugates adducts are those with fewer amounts of single 
strands, although formation of precipitate DNA-complex is also evident in the 
corresponding wells. The bands of the gel have been quantified to calculate the 
percent of three way junction that was formed for each complex. In the chart in 
Figure 4.17.a) the effective % of 3WJ has been calculated as follows: 
 
 % 3WJ = [I3WJ/(Iss+I3WJ+Ippt)]*100 
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where I3WJ, Iss, and Ippt are the measured intensities of the bands relative to the three 
way junctions, the single strands and the precipitates in the wells for each lane. This 
is the reasonable method to quantify the real percent of 3WJ that is formed for each 
complex, but in this case the Ippt is zero for all the complexes except the arginine 
conjugates. However, it is not possible to estimate how that precipitate would have 
contribute if it was free to run in the gel, and all the DNA that run in those lanes is 
entirely involved in the formation of the 3WJ. For this reason the percent of 3WJ 
relatively to the single strands only was calculated as follows: 
 
% 3WJ = [I3WJ/(Iss+I3WJ)]*100 
 
and the values reported in the chart of Figure 4.17.b). This shows that the arginine 
conjugates promote a relative higher formation of 3WJ with the D-Arg the most 
effective. The parent cylinder and the serine conjugates exhibit comparable activity 
and the tripeptide conjugate is, also in this experiment, the less effective. 
 
4.5 Cytotoxic activity by MTT assay. 
 
Triple stranded parent cylinders, both Fe(II) and Ru(II) exhibited a significant 
toxicity in cancer cell lines
21
 and herein it was investigated whether the conjugated 
Fe(II) cylinders preserve this characteristic. One common method to verify the 
toxicity of candidate drugs is to calculate their half maximal inhibitory concentration 
(IC50) values, which indicate the concentration of drug that is needed to inhibit a 
given biological process by half. In this case the IC50 is the concentration of complex 
that is needed to inhibit by 50% the viability of cancer cells thus that the lower is this 
value, the higher is the cytotoxic activity of the complex. IC50 values of the Fe(II) 
conjugated cylinders were measured in collaboration with Victoria Sadovnikova, 
from the Hannon group, and using the facilities kindly made available by Prof. Kevin 
Chipman, Dr. Chris Bunce and Dr. Nicholas Hodges from the School of Bioscience 
of the University of Birmingham. 
Two human cancer cell lines (ovarian A2780 and breast MDA-MB-231) were 
treated with all the conjugated Fe(II) cylinders (the tripeptide conjugated 
[Fe2(La1)3]Cl4, the L and D-Ser conjugated [Fe2(Lb1)3]Cl4 and [Fe2(Lc1)3]Cl4, L and 
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D-Arg conjugated [Fe2(Ld1)3]Cl10 and [Fe2(Le1)3]Cl10) and the same cell lines were 
also treated with the parent [Fe2(L1)3]Cl4 and with the known anticancer agent 
cisplatin as a control and standard for comparison. Each cell line was incubated in 
medium with six different concentrations of each compound (200, 100, 50, 25, 12.5 
and 6 M) for 72 hours and IC50 values were calculated by performing the 
colorimetric test known as MTT assays. Yellow MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a tetrazole) is reduced to purple formazan by the 
mitochondrial reductase in living cells (Figure 4.18), thus the amount of living cells 
after the incubation with the synthetic complexes can be estimated by treating them 
with MTT, incubating for two hours, and measuring (by UV-Vis spectroscopy) the 
amount of formazan that is formed, which is proportional to the amount of living 
cells after the treatment.  The table and the chart shown in Figure 4.19 report the 
calculated IC50 values in M. The first important result is that all the conjugated 
compounds present a remarkable cytotoxic activity in the tested cell lines. The 
cytotoxicity of the conjugated cylinders in A2780 varies between 5 and 9 M, which 
is comparable with the cytotoxicity of the cisplatin and they appear more active than 
the parent cylinder. In MDA-MB-231 all the compounds present a comparable 
cytotoxicity. [Fe2(La1)3]Cl4 and [Fe2(Ld1)3]Cl10 tend to be slightly less active among 
the conjugates. The lower activity of the first complex is expected, since it showed 
slightly less affinity in binding the DNA in the spectroscopic experiments. The result 
concerning the L-Arg conjugates [Fe2(Ld1)3]Cl10 is unclear, although the fact that  
 
 
 
 
Figure 4.18. Reduction of MTT to formazan by mitochondrial reductase in 
living cells.  
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Table 4.2. IC50 values (M) 
 
Compound A2780 MDA-MB-231 
Gly-Gly-Ser conj. 9±2 34±6 
L-Ser conj. 7±3 23±1 
D-Ser conj. 5±2 29±3 
L-Arg conj. 9±2 35±7 
D-Arg conj. 6±3 26±1 
Parent [Fe2(L1)3]Cl4 14±2 27±3 
cisplatin 4±2 27±3 
 
 
Figure 4.19. Table and chart indicating the IC50 values (M) of the conjugated 
Fe(II) cylinders, parent Fe(II) cylinders and cisplatin for A7280 and MDA-MB-
231 cell lines. The conjugates are labelled indicating their conjugating units. 
 
 
this conjugation induces the helicate core in P conformation, which is the less active 
in binding the DNA, might also influence the cytoxicity of the complex. In section 
4.1 it was explained that the conjugated complexes are less stable than the parent 
cylinder and, particularly, the two arginine conjugates are the complexes that degrade 
more rapidly. Although this could have negatively influenced the cytotoxicity of the 
conjugates, they exhibit significant IC50 values and in the future it will be interesting 
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to verify if the presence of the conjugating units, especially the arginine residues, 
improve the cell uptake of the cylinders. The same cell lines were treated with all the 
possible fragments that can be obtained by complex degradation (the spacer and the 
aldehyde components) and all the MTT assays revealed IC50 values higher than 100 
M, confirming that those cytotoxic activities are only due to the complexes. 
 
4.6 Conclusions. 
 
In this Chapter several techniques were used to study the DNA recognition and 
the cytotoxicity of the conjugated cylinders. The stability of the conjugates in water 
was monitored by UV-vis spectroscopy at room temperature for 36 hours and it was 
observed that none of the Fe(II) conjugates is as stable as the Fe(II) parent cylinder. 
D and L serine complexes are the most stable among the conjugates, followed by the 
tripeptide conjugate. The two arginine conjugates degrade faster. This would suggest 
that the anchoring of units at the edges of the triple stranded Fe(II) cylinders reduces 
the stability of the complexes in water, at least for the conjugating units explored 
herein. The effect is not so dramatic with the conjugation of a neutral and relatively 
small amino acid such as the serine, but the instability increases with the attachment 
of the larger tripeptide. For the arginine conjugates the higher instability might be 
due both to the size of the amino acid and the presence of the high positive charge at 
the sides of the cylinders. However, the stability of the complexes in water improves 
drastically in presence of DNA, to indicate that the complexes interact with the DNA 
and such interaction “protects” in part the complexes from their degradation. In 
contrast all the Cu(I) conjugates in water are as stable as the unconjugated Cu(I) 
complexes. CD titrations with ct-DNA and the Fe(II) conjugates were performed. 
Each conjugate exhibits ability in binding the DNA, possibly in one single mode and 
without affecting the B-DNA conformation. CD spectroscopy is not the most suitable 
technique for a comparison of the DNA binding affinity between the conjugates, 
since the different inherent chirality of the conjugates themselves may differently 
influence the ICD signals. However D and L-arginine have equal and opposite CD 
signals so that a comparison between these two complexes could be examined. The 
D-Arg conjugate/ct-DNA adduct exhibits more intense ICD bands than the L-Arg 
conjugate/ct-DNA at the same complex concentrations. This might indicate higher 
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binding affinity for the D-Arg conjugate. ICD signals of D and L-Arg in presence of 
poly[A-T] and poly[G-C] were also analysed. The resulting ICD profiles are 
different in the region where the ligand absorbs and this might signify that the 
complexes bind differently poly[A-T] and poly[G-C]. A deeper investigation of a 
possible DNA binding selectivity of these two complexes with more specific 
techniques could be object of future investigation (see Chapter 5).  
LD titrations of the Fe(II) conjugates with the ct-DNA confirmed that these 
complexes are able to bend/coil the DNA. The DNA coiling ability of the two serine 
conjugates is comparable with that observed for the Fe(II) parent cylinder. At higher 
complex loading any remarkable difference was observed between D and L-serine 
whilst at lower complex concentrations (up to 60:1) the D-Ser induces twice higher 
change of DNA orientation than the L-Ser cylinder. The tripeptide conjugate seems 
slightly less effective in coiling the DNA than the serine conjugates and the parent 
cylinder, indicating that the presence of a longer conjugating chain may negatively 
affect the binding activity of the cylinder. An increase of the induced LD signal upon 
increasing the complex concentration was observed for the serine and the tripeptide 
conjugates and this confirms that these complexes bind the DNA in an oriented 
fashion. The two arginine conjugates also cause remarkable DNA coiling. At high 
loading complexes (DNA:complex=5:1) the LD signal of the oriented DNA is 
completely lost. The D-Arg is more effective than the L-Arg conjugate in coiling the 
DNA. This would confirm the CD result and, more interestingly, the fact that the M 
enantiomer conformation of the triple stranded helicate, here induced by the 
anchored D-arginine, is more effective in DNA recognition than the P enantiomer. 
Surprisingly, the two arginine conjugates do not exhibit induced LD signal in the 
complex spectroscopy. This does not exclude that the complexes bind in the major 
groove (through the helicate core) in an oriented fashion as the other cylinders do. 
But different kind of interactions between the guanidinum groups of the arginine 
residues and the DNA are theoretically possible and, given the response of the LD 
experiments, cannot be excluded. LD titrations were also performed with the Cu(I) 
conjugates. All the Cu(I) complexes present DNA coiling/bending  activity, although 
less remarkable than that exhibited by the Fe(II) complexes. This might be due to 
their lower positive charge. No remarkable differences between the Cu(I) conjugates 
were observed and only the D-Ser complex appeared slightly less effective. However, 
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all the conjugates exhibit lower DNA coiling properties than their unconjugated 
analogous. Most importantly, agarose gel electrophoresis experiments confirm that 
the Cu(I) conjugates retain a remarkable artificial nuclease activity, which was the 
main feature of the parent Cu(I) cylinders.  
Polyacrylamide gel electrophoresis experiments demonstrate that all the Fe(II) 
conjugated complexes recognise the DNA three way junctions, so that this important 
characteristic of the triple stranded cylinders was not affected by the end-
conjugation. The conjugates and the parent cylinder show similar ability in binding 
the three way junction, although the D-Arg conjugate seems to be the complex that 
better stabilises this structure of DNA. This would be consistent with the M 
conformation of the helicate core (induced by the D-arginine residues), which is 
known to bind more efficiently to 3WJ. 
Finally, all the Fe(II) conjugates present cytotoxicity against cancer cell lines that 
is comparable with and, for one cell line, even higher than that observed for the 
parent cylinder. Also in this study the D-Arg cylinder was the most effective. Since 
the conjugates did not show remarkable higher DNA binding than the parent cylinder 
at molecular level, an improved cell uptake could be the reason of the higher 
cytotoxicity of the conjugates and this will be object of future investigations. 
 
4.7 Experimental. 
 
4.7.1 Materials. 
 
Ultrapure water (18.2 Mby Fisher) was used in all Circular and Linear dichroism 
experiments and for the solutions to analyse by electrophoresis gel. The ct-DNA, 
(highly polymerised), poly[d(G-C)2] and poly[d(A-T)2] were purchased from Sigma-
Aldrich and they were dissolved in water without any further purification. Stock 
solutions of DNAs were kept frozen until the day of use. The DNA concentrations of 
those stocks were determined by UV-Vis measurements using the known molar-
extinction coefficient of 258=6600 mol
-1
dm
3
cm
-1
 per DNA base for ct-DNA and 
poly[d(A-T)2] and 256=8400 mol
-1
dm
3
cm
-1
 per DNA base for poly[d(G-C)2]. Also 
stock solutions of 1M NaCl and 100 mM sodium cacodylate buffer (pH 6.8) were 
prepared and, together with DNA stocks, were used to obtain the final solutions to 
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analyse. Commercially available tris-acetate-EDTA (TAE, from Fisher) working 
buffer was used for gel electrophoresis of pBR322 pllasmid DNA (New England 
Biolabs).  
 
4.7.2 Circular Dichroism. 
 
Spectra were collected in cuvettes of 1 cm pathlength or 2 mm pathlength 
(depending on the concentration to use in a specific region of the spectrum) using a 
Jasco J-715 spectropolarimeter. Spectroscopic titrations were performed from which 
CD absorption spectra were recorded. For each titration three solutions were 
prepared: solution A of DNA (300 or 100 M for Cu(I) or Fe(II) complex 
respectively), NaCl (20 or 10 mM for Cu(I) or Fe(II) complex respectively) and 
sodium cacodylate buffer (10 mM); stock solution B of complex in water (500 or 165 
M for Cu(I) or Fe(II) complex respectively); Stock solution C of DNA (600 or 300 
M for Cu(I) or Fe(II) complex respectively), NaCl (40 or 20 mM for Cu(I) or Fe(II) 
complex respectively) and sodium cacodylate buffer (20 mM).  First solution A was 
recorded to have the CD spectrum of DNA without complex. Then the titration was 
performed decreasing the DNA:complex ratio from 60:1 to 8:1 by adding aliquots of 
solution B. For each volume of solution B, the same volume of solution C was added 
to ensure that the concentration of ct-DNA, NaCl and sodium cacodylate remained 
unaltered.
9
  
 
4.7.3 Linear Dichroism. 
 
Flow LD spectra were collected by using a flow Couette cell (Krometek) in a 
Jasco J-715 spectropolarimeter adapted for LD measurements. Long molecules, such 
as DNA can be orientated in a flow Couette cell. The flow cell consists of a fixed 
outer cylinder and a rotating solid quartz inner cylinder, separated by a gap of 0.5 
mm, giving a total pathlength of 1 mm. The titrations performed with ct-DNA were 
identical to those described for the CD experiments. 
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4.7.4 Agarose gel electrophoresis. 
 
The electrophoresis experiments were carried out by using gel trays of 210x150 
mm with an 11-toothed comb to produce the sample wells. A Electrophoresis Power 
Supply-EPS 301 system was used as a constant voltage supply set to 180 V and 125 
mA. The gel was prepared warming up 2 gr of agarose (from USB corporation) in 1 
x Tris acetate buffer (1 x TAE, which was obtained by dilution of 100 ml of 10 x 
TAE, supplied by SIGMA, in 1 L of water). The same 1 x TEA buffer was used as 
working buffer. The solutions to analyse were prepared in 16 l of volume 
containing: 96.3 M pBR322 plasmid DNA, 25 M hydrogen peroxide (from a fresh 
250 M stock solution) where required and different concentrations of complexes 
(from 50M stock solution in water) to obtain solution with different 
plasmid/complex ratio. The solutions were incubated for 1 h at 37 °C and then 4 l 
of loading buffer (30% glycerol and 0.25% bromophenol blue in ultra pure water) 
were added. 16 l of each solution were loaded and the samples ran for 2 h. After 
electrophoresis the gel was stained in 100 ml of 1 x TEA buffer containing 1 ml of 
ethidium bromide solution (0.5 mg ml
-1
) for 15-20 min followed by a washing with 
MgCl2 100 mM for 5 min. The gel was visualized using a UVtec-uvipro platinum 
system. 
 
4.7.5 Polyacrylamide gel electrophoresis.   
 
This procedure was kindly provided by Siriporn Phongtongpasuk (from M.J. 
Hannon group), who performed the PAGE experiments. The formations of DNA 
three way junction by the complexes were probed using 15% native polyacrylamide 
gel electrophoresis run in TB buffer pH 8.3 comprising of 89 mM 
tris(hydroxymethy) amino methane, 89 mM boric acid. The oligonucleotides were 
purchased from MWG Eurosin, which provided the three sequences purified by 
PAGE. One strand of DNA (S3) was labelled with 
32
P at 5’ terminus by using T4 
polynucleotide kinase (by New England BioLab) and [-32P] adenosine 5'-
triphosphate (by Perkin Elmer). The labelled strand was purified by QIA quick 
nucleotide removal kit. Briefly, 10 volumes of Buffer PN were added to 1 volume of 
the reaction sample. Then the mixture was transferred onto spin column and 
159 
 
centrifuged column at 6000 rpm for 1 minute.  The supernatant was discarded. The 
column was transferred into a new elution tube and buffer PE was added (500 l). 
Then discard the flow-through and repeat wash with another 500 l of Buffer PE. 
The column was centrifuged again at 13,000 rpm for 1 minute to get rid of the buffer 
residual. The column was transferred into 1.5 ml eppendorf. Then 30 l of milliQ 
water was added to the column and allowed to stand for 5 minute before centrifuged 
at 13,000 rpm for 2 minutes to obtain 8 M of stock radiolabeled DNA. 
Stechiometric amounts of oligonucleotide were mixed with complexes to have final 
concentrations to load on the gel of 0.4 M of each single strand (1.2 M total 
concentration of DNA) and 0.4 M of complex (so that the theoretical 3 way 
junction: complex is 1:1) in the TBN buffer containing mM tris(hydroxymethy) 
amino methane, 89 mM boric acid and 100 M NaCl. The solutions were incubated 
at room temperature for 1 hour and followed on ice for 15 minutes. The samples 
were analyzed by 15% polyacrylamide gel electrophoresis for 3.50 hours at 5 W at 
room temperature. Then the gel was exposed on phosphor plate for an hour. The 
image was obtained from Molecular imager FX (Bio-Rad). The images were 
quantified by Quantity one. 
 
4.7.6 Cell culture and MTT assay. 
 
This procedure has been written in collaboration with Victoria Sadovnikova (from 
the Hannon group) who carried out part of the assays. DMEM medium and FBS 
were obtained from Invitrogen. Antibiotic antimycotic solution, L-glutamine, 
trypsin-EDTA, HEPES buffer solution, sodium pyruvate, MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and DMSO were purchased 
from Sigma, UK. Tissue culture flasks, 96 well microtiter plates were obtained from 
Appleton Woods, UK. 
Two human cell lines were used (A2780-ovarian and MDA-MB-231 – breast 
cancer cell lines) in assessing the cytotoxicity of the synthesized compounds. All cell 
lines grew as monolayers in DMEM medium supplemented with 10% FBS, 1% L-
glutamine, 1% HEPES buffer, 1% sodium piruvate and 1% antibiotic. Cells were 
maintained in the incubator at 37 C° and humidified atmosphere and regularly 
checked for absence of contamination. Cells were collected from the tissue culture 
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flaks using 10% trypsin-PBS solution. Single cell suspensions were prepared, cells 
counted using cell counting chamber and placed in 96 microtiter plates at the 
concentration of 10.000 cells/well MDA-MB-231 and 4000 cells/well A2780 to a 
total volume 100µL per well. Plates were maintained at 37C° and humidified 
atmosphere in the incubator for 24 hours to allow cells to attach to the surface.
22 
Cells were treated with 6 different concentrations of the synthesized complexes 
dissolved in fresh medium (200, 100, 50, 25, 12.5, 6 M), and incubated for 72 
hours. 
MTT solution was prepared by dissolving yellow 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) 0.25g  in 50 mL of phosphate-buffered 
saline. The solution was stored at 4 °C in a dark place. 20 μL of MTT solution was 
added in each well of the 96 well plates, except 3 wells of the control. Cells were 
further incubated for 2 hours. The medium was carefully removed and 200 μL of 
DMSO was added in each well to dissolve the formed purple crystals of formazan.  
Absorbance was measured in 15-20 minutes after the addition of DMSO using a 96-
well plate reader (BioRad) set at 590 nm.
23
 All experiments were repeated at least 
two or three times for more accurate results. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE WORK. 
 
5.1 Conclusions. 
 
The work presented in this thesis has concerned two main themes: i) the study of 
the behaviour of the di-nuclear Fe(II) supramolecular cylinder at different 
temperature conditions  and in two different solvents (water and acetonitrile), and ii) 
the synthesis, characterisation and biological activity of cylinders conjugated to short 
peptides and amino acids. 
The NMR, CD and UV-vis thermal experiments described in Chapter 2 
demonstrate that a fluxional process occurs in the di-nuclear Fe(II) triple helicate in 
acetonitrile when the temperature is increased. The complex in acetonitrile is stable 
at high temperatures and the fluxional process is possibly related to a mechanism of 
intramolecular racemisation that involves the two metal centres. In other words, the 
increase of the temperature causes racemisation of the two metal-complex units 
which lose their initial configuration. The racemisation occurs most probably by 
Bailar twist mechanism, and it seems that the process becomes significant from ~40 
°C. Since the Fe(II) cylinder binds strongly DNA and has interesting cytotoxic 
activity against cancer cell lines, it is currently object of different biological studies 
to verify the potential of this complex as an effective drug. For this reason CD and 
UV-vis thermal experiments were carried out also in water showing that similar 
racemisation effect occurs, but the complex exhibits also a concentration dependent 
instability in water at higher temperatures (over 70 °C). However, the binding of the 
complex with the DNA prevents both racemisation and part of the degradation of the 
M enantiomer of the cylinder, whilst this “protection” by the DNA is not so effective 
for the P enatiomer, confirming that the two complexes bind the DNA with different 
affinity and/or modality. The information rising from these studies should be useful 
for the planning of biological experiments with the cylinder where temperature is 
involved (such as PCR or incubation of the cylinder with biomolecules or after cell 
treatment). It should always be taken into account that M and P enantiomers are 
unstable and labile in water when temperature is increased, but the presence of the 
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DNA has a different influence on their lability and stability depending on the 
enantiomer with which it is interacting.  
In Chapter 3 a versatile protocol for the conjugation of amino acids and short 
peptides at the edges of bis-pyridylimine ligand based cylinders has been established. 
The method allows the anchoring of 2 conjugating units at the edges of the ligands, 
thus the final peptide-cylinder hybrids of general formula M2Ln bear 2n conjugated 
peptides. 5 Fe(II) triple stranded, 4 Cu(I) double stranded and 1 Ag(I) double 
stranded conjugated cylinders were synthesised and characterised. The L1 based 
Fe(II) triple stranded cylinders were conjugated with the tripeptide GGS and with the 
amino acids D and L-Arg, D and L-Ser. Their characterisation suggests that all the 
conjugates present a central di-Fe(II) helicate core whose NMR and UV-Vis 
spectroscopy is independent from the conjugated unit. Similarly, the Cu(I) 
conjugates (ligand L5 and L1 based) and the Ag(I) conjugate (ligand L5 based) 
present a central di-metal cylinder core that is not affected by the conjugating units at 
the edges. Interestingly, the appended peptides influence the chirality of the central 
helicates. For most of the complexes this influence is not easily explicable, although 
it seems to depend on the counter anion and/or the solvent that is used. Less 
ambiguous is the effect of the arginine conjugation: both NMR and CD experiments 
indicates that the D-Arg induces the M conformation of the central helicate, whilst 
the L-Arg induces the P conformation. 
In Chapter 4 the DNA binding properties of the conjugates with ct-DNA were 
investigated by CD and LD spectroscopy. A direct comparison between the different 
conjugates and the corresponding unconjugated cylinders was not always possible 
because of the different CD profiles and the different induced CD and LD signals 
relative to the complexes. However all the conjugates exhibits DNA binding features 
comparable to those previously observed for the parent cylinder:
1
 the binding occurs 
but it does not affect the B-DNA conformation, most probably one single binding 
mode occurs and all the complexes cause bending/coiling of the DNA. For the two 
triple stranded arginine conjugates the possibility of more binding modes cannot be 
excluded. In addition, all the Cu(I) complexes retain the artificial DNA nuclease 
activity that was previously observed for the unconjugated Cu(I) cylinder,
2
 although 
the activity seems slightly lower. 
All the Fe(II) conjugates are cytotoxic against cancer cell lines and the calculated  
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values of IC50 are comparable with and in some cases lower than those relative to the 
parent cylinder. In addition, the Fe(II) conjugates retain the ability to bind and 
stabilise the DNA three way junctions as the parent Fe(II) cylinder does. In all these 
studies, especially LD, gel electrophoresis and cytotoxicity tests, D and L-arginine 
conjugates display a difference in activity that is equivalent to that showed by the M 
and P enantiomers of the parent cylinder.
3,4
 This suggests that a rational design of the 
conjugated biomolecules could affect the biological activity of the resulting 
conjugated cylinder by influencing its chirality. 
 
5.2 Future work. 
 
In this work the conjugation of cylinders with biomolecules was achieved for the 
first time and several features concerning the effect of the conjugation on the 
stability, chirality and biological activity of the conjugates were established. One of 
the main aims of the conjugation strategy is to verify whether the presence of amino 
acids and peptides can provide the cylinders with sequence selectivity binding. 
Preliminary CD studies of the arginine conjugates in presence of poly(dA-dT) and 
poly(dG-dC) suggest that a binding preference toward poly(dG-dC) might occur but 
the intrinsic CD signal of the complexes prevents an unambiguous interpretation of 
the results. DNA footprinting
5
 is one of the most common methods to investigate the 
sequence specificity of DNA-binding agents, thus both the DNA binding of the 
Fe(II) conjugates and the possible specificity of the artificial nuclease activity of the 
Cu(I) conjugates should be analysed with this technique in the future. Furthermore, 
despite the low stability of the Fe(II) conjugates in water, they exhibits a cytotoxicity 
against cancer cell lines that is comparable with and in same case more efficient than 
that exhibited by the parent cylinder. It is possible that a better cell uptake, caused by 
the presence of the amino acids (especially for the arginine conjugates), is involved 
and a comparison between the cell uptake of the parent cylinder and its conjugates 
should be a topic for future studies. 
The design of different end-functionalised cylinders, with different type of 
conjugations is currently under investigation. Using the synthetic approach described 
herein, Fe(II) parent cylinders bear 6 conjugating units. These units have to be 
designed in a way that the stability of the final hybrids is not significantly affected. 
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Figure 5.1 Representation of a hypothetical triple stranded cylinder conjugated 
to peptides triple helixes (collagen like).  
 
 
A rather challenging strategy would consist in the attachment of longer peptide 
sequences that could interact each other at the edges of the cylinder, for example 
promoting the formation of peptide triple helixes or -sheets motifs once that they 
are anchored (see model in Figure 5.1). This might contribute to the stabilisation of 
the entire hybrid and insertion of secondary structure motifs might promote the 
interaction with the DNA.  
However, if the conjugating units do not present the right pattern of interactions, 
they can cause destabilisation of the structure of the final hybrids. This occurs in part 
with the conjugation of the arginine residues: although these complexes exhibit 
remarkable binding properties and cytotoxicity, they are not particularly stable, 
probably because the long positive charged side chains of the arginine residues are to 
close each other. A mono or di-conjugation (one conjugation per edge) of the 
cylinder, rather than the 6 conjugation achieved so far, could help to resolve issues 
related to the presence of inconvenient interactions between conjugating units that 
are anchored at the same edge of the helicate. This could be achieved by the 
assembly of “capping” units at the edges of the cylinder as in the model in Figure 
5.2. Particularly suitable might be a tripodal structure, whose arms could be linked to 
the three strands of the ligands, and it should bear a further active group that allow 
the attachment of biomolecules or any other group with a desired function.  The 
tripodal compound cyclotriveratrylene (CTV) showed in Figure 5.2 has already been 
used to promote the formation of Fe(II) based triple stranded complexes
6
 and the 
induction of triple helixes formation of collagen peptides.
7
 It presents amino groups 
suitable for the formation of amide bonds with the carboxylic groups at the 5 
positions of the bis-pyridylimine ligands and a synthetic strategy to achieve
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Figure 5.2 Representation of mono-capped Fe(II) cylinder (left) and the 
structure of cyclotriveratrylene (CTV, right) 
 
 
cylinders capped with CTV units is currently under investigation.  
 
5.2.1 Dansylcadaverine-Fe(II) cylinder conjuagate. 
 
The studies carried out with amino acids conjugates indicated that the stability of 
the hybrids is not dramatically affected with the conjugation of short and neutral 
units anchored at the 5 position of the pyridine ring. Thus, the conjugation with other 
type of functionalities can be planned. Particularly, the labelling of the Fe(II) 
cylinder with fluorescent groups might offer the possibility of probing the agent 
inside cells. In this prospect, the conjugation of the Fe(II) cylinder with 
dansylcadaverine
8
 groups has been designed and achieved via amide bond formation, 
using a similar synthetic approach that was used for the peptide-conjugates (Figure 
5.3). All the intermediate compounds shown in Figure 5.3 and the final complex 
[Fe2(Ld)3](BF4)4 were characterised by mass spectrometry and 
1
H NMR (see 
Appendix A). Preliminary NMR analysis of the complex in acetonitrile shows that 
the signals of the protons of the central helicate (the pyridine, the phenyl and the 
imine protons) have the same chemical shift values that were observed for the 
peptide-Fe(II) cylinder conjugates (see Chapter 3 and Figure 5.4.a)). In addition, the 
UV-Vis spectrum of [Fe2(Ld)3](BF4)4 in acetonitrile retains (in the visible region) the 
same profile of the other Fe(II) cylinder conjugates described in Chapter 3. These 
first data suggest that also in this case the conjugation at the position 5 of the 
pyridine rings of the bispyridylimine ligand does not affect the symmetry of the 
central helicate core, once that the dansylcadaverine-cylinder conjugate is formed. 
Further characterisation of the complex is currently ongoing and DNA binding 
studies and fluorescence experiments have to be planned in the nearest future.  
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Figure 5.3 Scheme of synthesis of dansylcadaverine-Fe(II) cylinder conjugate; 
(i) EEDQ in MeOH, N2 atmosphere for 3 days,  (ii) 1 M HCl in THF for 3 days, 
(iii) overnight in EtOH, (iv) reflux in MeOH. 
 
 
 
 
 
   
 
Figure 5.4.a) 1H NMR of [Fe2(Ld)3](BF4)4 in CD3CN (298 K). Only the signals 
of the central cylinder core are assigned (see section 5.3.4 and Appendix A for 
the complete characterisation). b) UV-Vis spectrum of [Fe2(Ld)3](BF4)4 in 
acetonitrile showing the characteristic MLCT and ligand bands of the central 
helicate core (see section 3.4 for a comparison). 
 
 
H          
H3+H4 
H1 
H        
          
H     
          
H         
          
Ligand Ld 
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5.3 Experimental 
 
Materials and methods described in section 3.8.1 were employed also for the two 
syntheses below. Dansylcadaverine was purchased from Sigma-Aldrich. 
 
5.3.1 Synthesis of 2-Dimethoxymethyl-5-(dansylcadaverine)-pyridine. 
 
 
250 mg (1.2 mmol, 1) of 6-dimethoxymethyl-nicotinic acid (whose synthesis has 
been described in section 3.8.4 (3)) were dissolved in 15 ml of methanol together 
with 5 equivalents of EEDQ. 200 mg (0.6 mmol) of dansylcadaverine (previously 
dissolved in 3-5 ml of methanol) were added and the mixture was stirred for 3 days 
at room temperature and in N2 atmosphere. The reaction was monitored by analytical 
RP-HPLC (from 0 to 100% of acetonitrile 0.05% TFA in H2O 0.05% TFA in 40 min) 
to confirm that the dansylcadaverine was completely consumed and the crude was 
purified by preparative RP-HPLC (from 0 to 100% of acetonitrile 0.05% TFA in 
H2O 0.05% TFA in 70 min, 22 ml/min flow) affording 108 mg of yellow pure (by 
analytical HPLC) compound (52% yield). 
1
H NMR (400 MHz, MeOD, 298 K)  8.96 (1H, br s, H5), 8.58 (1H, d, 
3
J = 8.8 Hz 
H13/14/15), 8.54 (1H, d, 
3
J = 8.8, H13/14/15), 8.34 (1H, dd, 
3
J and 
4
J = 8.3, 2.4 Hz, H4py), 
8.27 (1H, dd, 
3
J and 
4
J = 7.3, 1.0 Hz, H16), 7.78 (1H, d, 
3
J = 8.3 Hz, H3py), 7.70 (1H, 
dd, 
3
J = 7.3, 2.0 Hz, H17), 7.66 (1H, dd, 
3
J and 
4
J = 8.8, 2.4 Hz, H13/14/15), 7.56 (1H, d, 
3
J = 7.3 Hz, H18),  5.47 (1H, s, H2), 3.41 (6H, s, H1), 3.21 (2H, tr, 
3
J = 7.3 H7/11), 3.10 
(6H, s, H19), 2.89 (2H, tr, 3J = 6.8, H7/11), 1.42 (4H, m, H8/10). 1.24 (2H, m, H9).  ESI 
mass analysis m/z = 537.2 [M+Na]
 +
. 
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5.3.2 Synthesis of 2-formyl-5-(dansylcadaverine)-pyridine. 
 
 
2-Dimethoxymethyl-5-(dansylcadaverine)-pyridine (0.5 mmol) was partially 
dissolved in 7 ml of THF and 3 ml of 1M HCl were added in 1 hour time at 0 °C. 
The mixture was stirred at room temperature and the reaction was monitored by 
analytical RP-HPLC every 18-22 h (from 0 to 100% of methanol in water in 40 min). 
The peak corresponding to the unprotected aldehyde (~ 2.5 min earlier than starting 
protected compound) appeared in the chromatogram after 24 hours, but the reaction 
was promoted by adding small quantities (~ 1 ml) of 1M HCl until the chromatogram 
showed the unprotected aldehyde as the main compound. 3 days were sufficient to 
have a complete reaction. The crude was purified by preparative RP-HPLC (from 0 
to 100% of methanol in water in 70 min, 22 ml/min flow) obtaining pure compound 
with 73% yield. 
1
H NMR (300 MHz, MeOD, 298 K)  8.89 (1H, d, 4J = 2.2 Hz, H5py), 8.53 (1H, d, 
3
J 
= 8.8 Hz H13/14/15), 8.36 (1H, d, 
3
J = 8.8, H13/14/15), 8.22 (1H, dd, 
3
J and 
4
J = 8.1, 2.2 
Hz, H4py), 8.19 (1H, dd, 
3
J and 
4
J = 7.3, 1.0 Hz, H16), 7.71 (1H, d, 
3
J = 8.1 Hz, H3py), 
7.56 (1H, dd, 
3
J = 7.3, 1.1 Hz, H17), overlapped 7.53 (1H, d, 
3
J = 8.8, Hz, H13/14/15), 
7.26 (1H, d, 
3
J = 7.3 Hz, H18),  5.55 (1H, s, H2), 3.18 (2H, m, H7/11), 2.86 (6H, s, 
H19), overlapped 2.83 (2H, tr, 3J = 6.8, H7/11), 1.37 (4H, m, H8/10). 1.22 (2H, m, H9).  
ESI mass analysis m/z = 491.2 [M+Na]
 +
.  
5.3.3 Synthesis of Ligand Ld. 
 
16.5 mg (0.08 mmol) of 4,4'-methylenedianiline were dissolved in 3 ml of ethanol 
and added drop wise (over 10 min time) to a stirring solution of 78 mg (0.16 mmol) 
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of 2-formyl-5-(dansylcadaverine)-pyridine in 5 ml of ethanol. Formation of yellow 
precipitate was immediately observed and the mixture was stirred overnight at room 
temperature. The yellow precipitate was collected by filtration, abundantly washed 
with ethanol and diethyl ether and dried under vacuum overnight, affording 58 mg of 
pure ligand (66% yield).  
1
H NMR (400 MHz, d6-DMSO, 298 K)  9.07 (1H, d, 4J = 2.4 Hz, H5py), 8.68 (1H, t,
 
3
J = 5.9 Hz H6), 8.66 (1H, s, H2) 8.41 (1H, d, 
3
J = 8.3 Hz, H13/14/15), 8.32-8.28 
(overlapped 1H, d, 
3
J = 8.8, H4py+ 1H, dd, 
3
J and 
4
J = 8.3, 2.2 Hz, H16), 8.17 (1H, d, 
4
J = 8.8 Hz, H3py), 8.04 (1H, dd, 
3
J = 8.3, 1.4 Hz, H13/14/15), 7.83 (1H, t, 
3
J = 5.9 Hz, 
H12), 7.64-7.55 (2H, m, overlapped H13/14/15+H17), 7.31 (4H, s, H20/21), 7.19 (1H, d, 
3
J 
= 7.3 Hz, H18),  3.98 (1H, s, H1), 3.09 (2H, m, H7), 2.77-2.75 (overlapped 6H, s, H19 
+ 2H, tr, 
3
J = 6.8, H11), 1.34 (4H, m, H8/10). 1.17 (2H, m, H9).  ESI mass analysis m/z 
= 1121.7 [M+Na]
 +
. 
 
5.3.4 Synthesis of dansylcadaverine-cylinder complex [Fe2(Ld)3](BF4)4. 
 
32 mg (0.03 mmol) of Ligand Ld and 7 mg of Fe(BF4)2 were dissolved in 5 ml of 
methanol in N2 atmosphere. Dark blue precipitate was observed within the first 5 min 
of reaction. The mixture was stirred (in N2 atmosphere) in reflux for the first hour 
and at room temperature over night. The blue precipitate was collected by filtration, 
abundantly washed with methanol, ethanol and ether and dried overnight, affording 
24 mg of pure complex (65% yield).  
1
H NMR (400 MHz, CD3CN, 298 K)  9.02 (1H, d, 
4
J = 2.4 Hz, H2), 8.63 (2H, 
overlapped H3py + H4py,
 3
J = 8.0 Hz), 8.53 (1H, d, 
3
J = 8.3 Hz, H13/14/15), 8.27 (1H, d, 
3
J = 7.3, H16), 8.17 (1H, d, 
4
J = 8.3 Hz, H13/14/15), 7.74 (1H, br s, H5py), 7.57 (2H, m, 
overlapped H13/14/15+H17), 7.24 (4H, d, 
3
J = 7.5 Hz, H18), 6.93 (1H, br, H20), 5.86 (1H, 
t, 
3
J = 7.3 Hz, H12), 5.52 (1H, br, H21),  4.02 (1H, s, H1), 3.14 (2H, br m, H7), 2.86 
(6H, s, H19), 2.78 (2H, br m, H11), 1.33 (4H, m, H8/10). 1.14 (2H, m, H9).  ESI mass 
analysis m/z = 852.2 [Fe2(Ld)3]
4+
, 1165.3 [Fe2(Ld)3(BF4)]
3+
. UV-Vis (acetonitrile) 
max(nm) = 595 (with a shoulder at 540), 334, 286, 247. 
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APPENDIX A 
1
H-NMR spectra and 2D-COSY. 
 
 
 
*Note: 
1
H NMR spectrum of 2-Dimethoxymethyl-5-(c)-pyridine (compound 6-c) is identical 
to the spectrum of 6-b. 
H6        H4        H3 
 
 
H           
H7 
H           
H H  
          
H9 
water 
2-Dimethoxymethyl-5-(a)-pyridine  
6-a 
400 MHz, D2O, 298K 
 
H          
H7 
H          
H9 
water 
2-Dimethoxymethyl-5-(b)-pyridine  
6-b* 
400 MHz, MeOD, 298K 
 
H6        H4        H3 
 
 
methanol 
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*Note: 
1
H NMR spectrum of 2-Dimethoxymethyl-5-(e)-pyridine (compound 6-e) is identical 
to the spectrum of 6-d. 
  
 
 
H6   H4   H3                     H7  H        H9H     HH       
 water  
 
 *                †                2-Dimethoxymethyl-5-(d)-pyridine  
6-d* 
400 MHz, MeOD, 298K 
 
H6      H4    H3                     H7’    
      H7’       H6’    H4’   H3’                          
H H       
H       
H        
2-formyl-5-(a)-pyridine  
7-a 
400 MHz, D2O, 298K 
 
* water  
† methanol                                 
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*Note: 
1
H NMR spectrum of 2-formyl-5-(c)-pyridine (compound 7-c) is identical to the 
spectrum of 7-b. 
                                      
 
*Note: 
1
H NMR spectrum of 2-formyl-5-(e)-pyridine (compound 7-e) is identical to the 
spectrum of 7-d. 
H6  H4 H3                 H7 H         H    HH       
  H7’     H6’   H4’H3’                          
† methanol                                 
†                2-formyl-5-(d)-pyridine  
7-d* 
400 MHz, MeOD, 298K 
 
H6        H4    H3                     H7               H      H   
         H6’    H4’   H3’                          
†                
† water                                 
2-formyl-5-(b)-pyridine  
7-b* 
400 MHz, D2O, 298K 
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H           
H12 
H6 
H7 
H4 H13 H3 
 
 
H14 
H9/10 
H15/16 
H16 
H11 
H           
H H           
          
* water  
† dmso                                 
 *        †                
H           H12 H6 
overlapped 
H7 H4 H13 H3 
 
 H14 
H10 
H15/16 H16 
H11 
H           
H H           
          
 *       †                
H9a H9b 
* water  
† dmso                                 
Ligand La1 
10-a 
400 MHz, dmso-d6, 298K 
 
Ligand La2 
11-a 
400 MHz, dmso-d6, 298K 
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*Note: small paramagnetic impurities, most probably due to the presence of traces of Cu(II), 
might be the cause of the broadness of the signals. For this reason a 2D-COSY spectrum 
could not be registered for this complex and peaks were assigned upon comparison with the 
signals of the Ag(I) analogous complex ([Ag2(La1)2](PF6)2, see 2D-COSY spectrum below) 
 
 
 
 
 
 
 
H           
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H11 
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H12 
H6 H7 
H13 H3 
 
 
H14 
H9/10 
H15/16 
H16 
    †*                   
H
4  
 
* water  
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H6 
H7 H3 
 
 
H9/10 
H11 
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H        
          
H
4  
 
H15/16 
H           
          
 water  
 
Complex [Cu2(La1)2](PF6)2* 
 
500 MHz, D2O:CD3CN = 1:2, 298K 
 
Complex [Ag2(La1)2](PF6)2 
 
500 MHz, dmso-d6, 298K 
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H6 
H7 
overlapped 
H4 H3 
 
 
 
H10 
H11 H           H 
          
H9 
H           
H           
          
 water  
 H9 
Complex [Fe2(La1)3](Cl)4 
 
500 MHz, D2O, 298K 
 
Complex [Cu2(La2)2](PF6)2 
 
500 MHz, D2O:CD3CN = 1:3,  
298K 
 
Downfield enlargement  
 
H6 
H7 
H3 
 
 
H10 
H
4  
 
H10 
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Complex [Cu2(La2)2](PF6)2 
 
500 MHz, D2O:CD3CN = 1:3, 
 298K 
 
Upfield enlargement  
 
H           H11 
H           H  
          
H9a 
H9b H           
          
  *                                               
†                   
* water  
† acetonitrile                                 
Complex [Cu2(Lb2)2](PF6)2 
 
500 MHz, CD3CN, 298K 
 
H           
H6 
H7 H3 
 
 
H9a 
H9b H           
H
4  
 
H          
          
H11 / H 
overlapped 
* water  
† acetonitrile                                 
  * †                   
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*Note: 
1
H NMR spectrum of complex [Fe2(Lc1)3](Cl)4 (the analogous D-Ser conjugated 
cylinder) is identical to the spectrum of [Fe2(Lb1)3](Cl)4 above. 
 
                                              
 
 
H           H12 
H6 
H7  H3/4 
 
 
H13 
H10 H9 
H11 
H          H           
          
H13 
Complex [Fe2(Lb1)3](Cl)4* 
 
400 MHz, D2O, 298K 
 
H6 
H7 
overlapped 
H4 H3 
 
 
 
H          
H           
 water  
 
H10 H9 
H11 
Complex [Fe2(Ld1)3](PF6)10** 
 
400 MHz, CD3CN, 298K 
 
Downfield enlargement 
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**Note: 
1
H NMR spectra of complex [Fe2(Le1)3]
10+
 (the analogous D-Arg conjugated 
cylinder), both in CD3CN and D2O, are identical to the spectra of [Fe2(Ld1)3]
10+
 above. 
 
 
 
 
 
* water  
† acetonitrile                                
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          Complex [Fe2(Ld1)3](PF6)10** 
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2-Dimethoxymethyl-5-
(dansylcadaverine)-pyridine 
 
400 MHz, MeOD, 298K 
 
Downfield enlargement 
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2H13/14/15 
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1H13/14/15 +1H17 
water 
H          
H           
          
H16 
2-Dimethoxymethyl-5-
(dansylcadaverine)-pyridine 
 
400 MHz, MeOD, 298K 
 
Upfield enlargement 
 
 
H           
H7/11 
H          
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H19     †                  
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water 
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0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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H 
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2-formyl-5-(dansylcadaverine)-
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300 MHz, MeOD, 298K 
 
 
 
Ligand Ld 
 
400 MHz, d6-dmso, 298K 
 
Downfield enlargement 
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Ligand Ld 
 
400 MHz, d6-dmso, 298K 
 
Upfield enlargement 
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